SEARCH:      Monitor Keywords |  Custom RSS

Drug, bio-affecting and body treating compositions July cataloged USPTO category listing 07/07

20070172424 - Enabling drug adherence through closed loop monitoring & communication: A method is described for measuring the blood concentration of a medicament through the introduction of a tracer compound. The measurement of the blood concentration of the tracer will yield a result that will enable a prediction of the blood concentration of the medicament. The method further describes ways to... Agent: Janus Medical Instruments, Inc.

20070172432 - Biodegradable hemostatic compositions: Biodegradable hemostatic compositions are provided including nucleic acids. The nucleic acids may be obtained from plant sources, animal sources, or combinations thereof, or they may be synthetic. The hemostatic compositions of the present disclosure are non-inflammatory, and are degraded in an animal's body after successfully re-establishing hemostasis of a tissue... Agent: United States Surgical, A Division Of Tyco Healthcare Group Lp

20070172431 - Methods, systems and compositions for skin care: The present invention describes systems, methods, and compositions for treatment and maintenance of skin. The invention includes a skin care system that addresses the problems of skin aging and inflammation. The invention further includes skin care systems, methods and compositions containing active ingredients that may inhibit matrix metalloproteniases (MMPs) or... Agent: Troutman Sanders LLP

20070172422 - Exponential pattern recognition based cellular targeting compositions, methods and anticancer applications: The present invention relates to the compositions, methods, and applications of a new approach to pattern recognition based targeting by which an exponential amplification of effector response can be specifically obtained at a targeted cells. The purpose of this invention is to enable the selective delivery of large quantities of... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070172420 - Ligands: and pharmaceutically-acceptable salts thereof, wherein R1 and Ar are as defined in the specification, enantiomers, in vivo-hydrolysable precursors, pharmaceutical compositions and formulations containing them, methods of using them to treat diseases and conditions either alone or in combination with other therapeutically-active compounds or substances, processes and intermediates used to prepare... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20070172421 - Substituted pyrrolidine-2-ones: d

20070172423 - Composition and method for modulating vasculogenesis for angiogenesis: A method for modulating vasculogenesis or arteriogenesis or angiogenesis, especially for treating heart and limb ischemia, using the core domain protein of PDGF-C, a new member of the PDGF/VEGF family of growth factors, or a homodimer or a heterodimer comprising the core domain. Also disclosed are pharmaceutical compositions comprising the... Agent: Crowell & Moring LLP Intellectual Property Group

20070172425 - Testing cell cycle regulation effect of a compound using a hollow fibre cell implant: The invention includes an in vivo pharmacodynamic method for testing a compound for cell cycle regulation.... Agent: Astrazeneca R&d Boston

20070172426 - Polymer coated microparticles: Methods for preparing uniformly sized microparticles, with an optional polymeric coating generally include: 1) providing nanoparticles, preferably having a size of between 1 nm and 100 nm; 2) adding a hydrophobic surface layer to the nanoparticles; 3) making a suspension of the hydrophobic nanoparticles and a polymerization initiator in an... Agent: Woodard, Emhardt, Moriarty, Mcnett & Henry LLP

20070172427 - Biofunctionalized quantum dots for biological imaging: Novel biofunctionalized quantum dots include a mercaptoalkanoic acid linked to the surface of a nanocrystalline core and a bio-functional group linked to the surface. Biofunctionalized quantum dots are made by a novel synthesis method. Biofunctionalized quantum dots can be used in imaging or therapy applications.... Agent: Venable LLP

20070172428 - Multivalent constructs for therapeutic and diagnostic applications: The invention provides compositions and methods for therapeutic and diagnostic applications.... Agent: Kramer Levin Naftalis & Frankel LLP

20070172429 - Labeling compositions and methods of use for deterrent trackability: Compositions and methods for controlling and tracking items are provided. More particularly, labeling compositions useful as a coding system to deter diversion of items of medication or other valued items are provided, wherein the labeling compositions comprise at least 25 unique identifiers, wherein the at least 25 unique identifiers are... Agent: Sutherland Asbill & Brennan LLP

20070172430 - Dry powder compositions for rna influenza therapeutics: A dry powder formulation for mucosal, intranasal, inhalation or pulmonary delivery which may include one or more siRNAs or dicer-active precursors thereof targeted to a transcript involved in infection by, or replication or production of an influenza virus.... Agent: Nastech Pharmaceutical Company Inc

20070172434 - Antimicrobial dental materials, restorations, and prostheses: The present invention relates to compositions and methods for antimicrobial dental materials in the restoration of the sequelae of oral infections including replacement of oral tissues lost to disease and prevention of additional infections.... Agent: Merchant & Gould PC

20070172433 - Biometic compounds containing hydroxyapatites substituted with magnesium and carbonate, and the processes used to obtain them: Carbonate hydroxyapatites containing magnesium, composite materials consisting of said hydroxyapatites and natural polymers are described; processes for the preparation of said materials and their use in orthopaedics and dentistry fields are also described.... Agent: Jay S. Cinamon Abelman, Frayne And Schwab

20070172435 - Medicament for internal application, in particular against cancerous diseases: The invention relates to a medicament for internal application, in particular against cancerous diseases. The medicament comprises polydimethylsiloxane and surfactants, whereby the proportion of polydimethylsiloxane is greater than the proportion of surfactants.... Agent: Mccarter & English Basam E Nabulsi

20070172436 - Nonaqueous ascorbic acid compositions and methods for preparing same: A method for preparing a nonaqueous ascorbic acid composition in an alcohol solvent comprising ascorbic acid, a solubilization enhancer, and an oleaginous skin protectant is described. The amount of ascorbic acid dissolved in the nonaqueous composition in the presence of the solubilization enhancer is greater than the amount of ascorbic... Agent: Jerry Zhang

20070172437 - Solubilizing agents for active or functional organic compounds: An active or functional organic compound is solubilized by an ester of an aryl alcohol, e.g., phenethyl, benzyl or substituted benzyl alcohol, and an alkyl or cycloalkyl carboxylic acid, or by a carbonate of said aryl alcohol and an alkyl or cycloalkyl carbonic acid.... Agent: Attn: William J. Davis, Esq. International Specialty Products

20070172438 - Comestic preparation containing a metallic pigment: The invention relates to a cosmetic preparation containing a metallic effect pigment which consists of a metal substrate having a layer enclosing the substrate. Said layer is produced in a sol/gel method, has a barrier effect against sweat and saliva and prevents a direct contact between skin and metallic substrate,... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070172439 - Method of chemiluminescence-utilizing makeup and beautification, luminant for skin irradiation beautification and makeup/beautification equipment: Presentation of the methods for makeup and beauty treatment by chemical luminescence, luminous bodies for beauty treatment by exposure to skin, and tools for makeup and beauty treatment... Agent: Knobbe Martens Olson & Bear LLP

20070172440 - Transparent cosmetic microemulsion-based formulation containing an alpha-hydroxy-carboxylic acid: The invention relates to a clear, microemulsion-based cosmetic formulation with reduced stickiness, comprising at least one antiperspirant active ingredient and/or deodorant active ingredient and α-hydroxycarboxylic acid.... Agent: Greenblum & Bernstein, P.L.C

20070172441 - Cation-modified purified galactomannan polysaccharide and cosmetic composition containing the substance: (where R1 and R2 each independently represent an alkyl group having 1 to 3 carbon atoms; R3 represents an alkyl group having 1 to 24 carbon atoms; X− represents an anion; n is either 0 or 1 to 30; and, when n is 1 to 30, (R4O)n represents a polymer... Agent: Oliff & Berridge, PLC

20070172442 - Topical compositions associating sodium hyaluronate fragments and retinoid useful for cosmetic and medical dermatology: The inventive compositions for topical application are characterised in that they comprises one or several hyaluronate fragments in the form of a main principle whose molecular weight ranges from 50 000 and 750 000 Da and a retinoid if necessary.... Agent: Birch Stewart Kolasch & Birch

20070172443 - Anti-chlorine shampoo composition: Retention of chlorine and hypochlorite in hair is reduced by treating the hair with a defined composition, allowing the composition to remain on the hair for at least 10 seconds, and then rinsing off the composition with water. The composition comprises at least 1% by total weight of the composition... Agent: Mark A. Litman & Associates, P.A. York Business Center

20070172444 - Hair tonics and method of screening the same: There is provided a hair tonic comprising at least two of an inhibitor against 5α reductase type 2, an inhibitor against transforming growth factor β2, and an inhibitor against caspase-3; a method comprising screening for at least two of inhibition against 5α reductase type 2, inhibition against transforming growth factor... Agent: Snider & Associates

20070172445 - Chronic articular inflammation-modulating composition based on collagen-polyvinylpyrrolidone: The invention relates to a chronic articular inflammation-modulating composition which uses collagen-polyvinylpyrrolidone. Collagen turnover is modulated using collagen-PVP in patients with rheumatoid arthritis and osteoarthritis, since the biocomplex negatively regulates collagenolytic activity and increases the content of type III collagen and TIMP-1 to levels similar to those observed in normal... Agent: Jones Day

20070172448 - method for detecting the specificity of activated lymphocyte: A method for detecting the specificity of activated lymphocytes is provided. The present method can be used to detect the specificity of activated lymphocytes in recipients or patients after organ transplantation or being infected by pathogenic microorganism or vaccination. The establishment of the present invention can not only timely diagnose... Agent: Knobbe Martens Olson & Bear LLP

20070172447 - Agent for preventing and/or treating tissue disruption-accompanied diseases: The present invention relates to an agent for preventing and/or treating diseases accompanied by tissue disruption, which comprises a polypeptide having granulocyte colony-stimulating factor activity as an active ingredient, and a medicament for mobilizing a multipotent stem cell from a tissue into peripheral blood, which comprises a polypeptide having granulocyte... Agent: Fitzpatrick Cella Harper & Scinto

20070172450 - Modulation of immune response and methods based thereon: The present invention relates to methods for the prevention and/or treatment of cardiovascular and allergic diseases and disorders, methods for inhibiting the growth of, or reducing the volume of, a solid tumor, as well as methods for preventing progression to AIDS in an HIV-infected human, by administering a peptide derived... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070172446 - Synthetic chemokine receptor ligands and methods of use thereof: e

20070172449 - Tnf-alpha variant formulations for the treatment of tnf-alpha related disorders: Combination therapies comprising novel TNF-α proteins for the treatment of TNF-α related disorders are provided herein.... Agent: Morgan, Lewis & Bockius, LLP

20070172455 - Chimeric interleukin-6 soluble receptor/ligand protein, analogs thereof and uses thereof: Chimeric proteins constructed from the fusion of the naturally occurring form of the soluble IL-6 receptor and IL-6 which are useful for treatment of cancer and liver disorders, enhancement of bone marrow transplantation, and treatment of other IL-6 related conditions are provided.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070172456 - Il-1 zeta, il-1 zeta splice variants and xrec2 dnas and polypeptides: The invention is directed to novel, purified and isolated IL-1 zeta and Xrec2 polypeptides and fragments thereof, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and uses thereof.... Agent: Immunex Corporation Law Department

20070172458 - Il-6/il-6r fusion protein: The present invention relates to a fusion protein comprising a functional IL-6 molecule and a functional DS-sIL-6R molecule. The present invention also relates to a nucleic acid encoding the fusion protein, methods for producing the fusion protein and the use of the fusion protein in the treatment of infectious diseases... Agent: Banner & Witcoff, Ltd.

20070172457 - Interleukins-21 and 22: The present invention relates to novel human proteins designated Interleukin-21 (IL-21) and Interleukin-22 (IL-22), and isolated polynucleotides encoding these proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing these human proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, and/or preventing... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070172451 - Methods for treating viral infection using il-28 and il-29: IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof... Agent: Zymogenetics, Inc. Intellectual Property Department

20070172452 - Methods for treating viral infection using il-28 and il-29: IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof... Agent: Zymogenetics, Inc. Intellectual Property Department

20070172453 - Tolerogenic approach for type 1 diabetes: The present invention provides compositions and methods for the treatment and prevention of type I diabetes.... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20070172454 - Use of il-6/il-6 chimera in huntington's disease: The invention relates to the use of an IL-6R/IL-6 chimera, a mutein, isoform, fused protein, functional derivative, active fraction or circularly permutated derivative or a salt thereof, for the manufacture of a medicament for the treatment and/or prevention of Huntington's disease.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070172459 - Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules: Compositions of modified cytokines and uses thereof generated using processes and systems for the high throughput directed evolution of peptides and proteins, particularly cytokines that act in complex biological settings, are provided. Also provided are modified cytokines formulated for oral delivery and uses thereof to treat diseases and conditions mediated... Agent: Fish & Richardson, PC

20070172461 - Polyepitope vaccines: The present invention relates to a recombinant polyepitope cytotoxic T lymphocyte vaccine. The vaccine comprises at least one recombinant protein including a plurality of cytotoxic T lymphocyte epitopes from one or more pathogens, wherein the at least one recombinant protein is substantially free of sequences naturally found to flank the... Agent: Steven L. Highlander, Esq. Fulbright & Jaworski L.L.P.

20070172460 - Random peptide library displayed on aav vectors: Described is a method of producing a repertoire of random peptides on the surface of AAV particles wherein said random peptides are expressed as a fusion with an AAV capsid protein of an AAV particle which displays at its surface said random polypeptides. Also described is a peptide library obtainable... Agent: Howrey LLP

20070172462 - Sirna-mediated gene silencing of synuclein: The present invention is directed to small interfering RNAs that down regulate expression of a synuclein gene and methods of using the small interfering RNAs.... Agent: Brinks Hofer Gilson & Lione

20070172466 - Method of replenishing cells damaged by treatment for cancer: A method of replenishing cells damaged by treatment for cancer comprising removing a sample of peripheral blood containing CD34+ pluripotent adult stem cells from a primate mammal, controllably expanding the cells without differentiation at a rate which produces an expansion factor of at least seven times within seven days while... Agent: Ladas & Parry LLP

20070172467 - Regeneration of endogenous myocardial tissue by induction of neovascularization: This invention provides a method of treating a disorder of a subject's heart involving loss of cardiomyocytes which comprises administering to the subject an amount of an agent effective to cause cardiomyocyte proliferation within the subject's heart so as to thereby treat the disorder. This invention further provides the instant... Agent: Cooper & Dunham LLP

20070172463 - Chromobacterium subtsugae sp.nov.and use for control of insect pests: Chromobacterium subtsugae sp. nov., a new species of the genus Chromobacterium which possesses insecticidal activity, is described. The invention also relates to insecticidally-active metabolites obtained from the strain and to insecticidal compositions comprising cultures of the strain and/or supernatants, filtrates, and extracts obtained from the strain, and use thereof to... Agent: Usda-ars-office Of Technology Transfer Patent Advisors Office

20070172464 - Stem cells having increased sensitivity to a chemoattractant and methods of generating and using same: The present invention relates to stem cells which exhibit increased sensitivity to a chemoattractant and, more particularly, to methods of generating and using them such as in clinical applications involving stem cell transplantation.... Agent: Marshall, Gerstein & Borun LLP

20070172465 - Use of umbilical cord blood stem cells to treat ischemic event: The invention relates generally to methods for isolation and culture of umbilical cord blood stem cells, cells isolated by the methods, and therapeutic uses for those cells.... Agent: Viksnins Harris & Padys Pllp

20070172468 - Dietary supplements for reducing cholesterol levels: The disclosure is generally directed to methods and compositions for reducing blood cholesterol levels, and more particularly to dietary supplements for reducing blood cholesterol levels. The dietary supplements for reducing cholesterol typically comprise at least one phytosterol source, at least one soluble fiber source, at least one guggulsterone source, and... Agent: Marshall, Gerstein & Borun LLP

20070172469 - Methods for inhibiting viral replication in vivo: The present invention is directed to methods of modulating viral replication in vivo comprising administering to an individual a therapeutically or prophylactically effective amount of a composition comprising arginine deiminase modified with polyethylene glycol, to methods of concurrently modulating viral replication and treating cancer, and to methods of modulating nitric... Agent: Woodcock Washburn LLP

20070172470 - Phosphatase regulation of nucleic acid transcription: Nucleic acids, polypeptides and methods are provided for regulating the phosphorylation state of the C-terminal domain (CTD) of RNA polymerase II (RNAP II). Also provided are methods for regulating cell differentiation.... Agent: Buchanan, Ingersoll & Rooney LLP

20070172471 - Method for identifying an anti- streptococcal agent and its use for treating streptococcal infections: A method for identifying an anti-streptococcal agent, comprises: (a) providing, as a first component, an isolated streptococcal M protein or a functional variant thereof; (b) providing, as a second component, isolated fibrinogen or a functional variant thereof; (b) providing, as a third component, an isolated β2 integrin or a functional... Agent: Foley And Lardner LLP Suite 500

20070172472 - Methods and systems for treating injured cardiac tissue: Methods and systems are disclosed for treating cardiac tissue by delivering a platelet composition which induces neovascularization in the cardiac tissue. The platelet composition can additionally contain structural materials and/or bioactive agents.... Agent: Medtronic Vascular, Inc.IPLegal Department

20070172473 - Corrosion inhibiting mildew remover kit: The corrosion inhibiting mildew remover kit includes a premeasured amount of sodium perborate, a premeasured amount of a liquid inhibitor and a premeasured amount of a liquid blend. The premeasured amount of sodium perborate, the premeasured amount of liquid inhibitor, the premeasured amount of liquid blend and water combine to... Agent: Naval Air Warfare Center Aircraft Division Office Of Counsel Bldg 435

20070172474 - Dairy components effective for fat loss: The present invention relates to methods comprising administering to an individual regulating body weight calcium-containing whey products in an amount effective to maintain muscle mass, induce weight and/or fat loss, prevent weight and/or fat gain, and/or increase the metabolic consumption of adipose tissue in the individuals.... Agent: Venable LLP

20070172475 - Highly concentrated, liquid formulations of anti-egfr antibodies: The invention relates to processes for the preparation of highly concentrated, liquid formulations comprising at least one anti-EGFR antibody and/or one of its variants and/or fragments, in particular monoclonal antibodies against the EGF receptor, particularly preferably of Mab C225 (cetuximab) and Mab h425 (EMD 72000), by ultrafiltration. The invention furthermore... Agent: Millen, White, Zelano & Branigan, P.C.

20070172476 - Method of treating b-cell neoplasms or hodgkin's lymphoma: The present invention relates to a method for injuring or depleting a B-cell neoplasm cell or a Hodgkin's lymphoma cell and a method for treating B-cell neoplasm or Hodgkin's lymphoma, wherein each method comprises administering to a patient a monoclonal antibody which specifically binds to a human CC chemokine receptor... Agent: Fitzpatrick Cella Harper & Scinto

20070172478 - Methods of treating skin disorders: Methods of treating skin disorders are provided.... Agent: Leydig Voit & Mayer, Ltd

20070172477 - Use of soluble cd14 for treatment of diseases: Use of soluble CD14 (sCD14) for the manufacture of a medicament for therapeutic or preventive treatment of a disease involving a chronic inflammation condition and a clinical disorder associated with insulin resistance in an animal or a human. Examples of diseases include type 2 diabetes mellitus, obesity, metabolic syndrome, arteriosclerotic... Agent: Hensley Kim & Edgington, LLC

20070172481 - Gdf3 propeptides and related methods: In certain aspects, the present invention provides compositions and methods for regulating body weight, in particular, for treating obesity and obesity-associate disorders. The present invention also provides methods of screening compounds that modulate activity of GDF3. The compositions and methods provided herein are also useful in treating diseases associated with... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070172479 - Protein formulations with reduced viscosity and uses thereof: Protein formulations and methods for reducing the viscosity of a protein formulation are provided. The method for reducing the viscosity of a protein formulation comprises adding a viscosity reducing agent, such as calcium chloride or magnesium chloride to the protein formulation.... Agent: Wilmerhale/wyeth

20070172480 - Recombinant platelet collagen receptor glycoprotein vi and its pharmaceutical use: The invention relates to Glycoprotein VI (GPVI), its isolation, purfication, and methods for recombinant production. Especially, the invention relates to the use of GPVI, preferably recombinant GPVI, in the treatment of disorders and pathological events correlated directly or indirectly to blood coagulation disorders such as thrombotic and cardiovascular diseases, The... Agent: Millen, White, Zelano & Branigan, P.C.

20070172482 - Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins: A method of producing a metalloprotein inhibitor, the method comprising generating antibodies directed at a composition including a metal ion-bound chelator, wherein the composition is selected having structural and electronic properties similar to a functional domain of the metalloprotein, thereby producing the metalloprotein inhibitor.... Agent: Martin Moynihan Prtsi Inc

20070172484 - Immunizing compostion and method for inducing an immune response against the beta-secretase cleavage site of amyloid precursor protein: The present invention is directed to an immunizing composition containing an antigenic product such as a multiple antigen peptide system (MAPS) or a filamentous bacteriophage displaying an AβPP epitope spanning the β-secretase cleavage site of AβPP and a method for inducing an immune response against the β-secretase cleavage site of... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070172483 - Methods for treating conditions associated with masp-2 dependent complement activation: In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2... Agent: Christensen, O'connor, Johnson, Kindness, PLLC

20070172487 - Alpha-enolase specific antibody and method of use: This invention relates to a method of monitoring cancer development by determining the abundance of alpha-enolase protein wherein increased abundance is an indication of the severity of cancer. In another embodiment, the invention relates to a method of detecting cancer malignancy by determining the abundance of alpha-enolase antibodies in a... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070172488 - Cell growth inhibitors containing anti-glypican 3 antibody: Provided is a cell growth inhibitor that can be used for treating diseases based on abnormal cell proliferation, and in particular cancer. The cell growth inhibitor contains an anti-glypican 3 antibody as an active ingredient.... Agent: Davidson, Davidson & Kappel, LLC

20070172486 - Expression of cyclin g1 in tumors: A method of treating a tumor (in particular osteosarcoma or Ewing's sarcoma) in a host by administering to a host or to the tumor cells an agent which inhibits cyclin G1 protein in an amount effective to inhibit cyclin G1 protein in tumor cells of the host. The agent may... Agent: Wilson Sonsini Goodrich & Rosati

20070172485 - Glycopeptides derived from pancreatic structures, antibodies and applications thereof in diagnostics and therapeutics: The invention relates to a glycopeptide comprising between 1 and 40 repeated C-terminal polypeptides, with 11 amino acids, of BSDL or FAPP, whereby the aforementioned polypeptides are glycosylated and bear glycosylated epitopes giving rise to a specific immunological reaction with induced antibodies in a patient suffering from type 1 diabetes,... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070172489 - Caspase inhibitors, especially caspase 3 inhibitors, for the treatment of influenza: The invention relates to the use of at least one caspase inhibitor, in particular a caspase-3 inhibitor, for preparing a pharmaceutical composition for the prophylaxis and/or therapy of a viral infection, in particular an infection with an RNA negative-strand virus, preferably an influenza infection, and to a test system for... Agent: Mayer & Williams PC

20070172490 - Leukocyte stimulation matrix: The present invention relates to a leukocyte stimulation matrix for the simulation of leukocytes and/or the induction of an immunological tolerance comprising a) at least one carrier, b) a soluble matrix for embedding at least one component for generating a leukocyte stimulation and/or the induction of an immunological tolerance, and... Agent: Mh2 Technology Law Group

20070172491 - Vaccine composition comprising an immunoadjuvant compound consisting of a rho gtpase family activator: This invention is based on the experimental finding that activators of Rho GTPases, namely the cytotoxic necrotizing factor 1 (CNF1), and DNT bear immunostimulatory properties towards the systemic response to orally administered ovalbumine. This invention concerns a vaccine composition including an immunoadjuvant compound, wherein the immunoadjuvant compound consists of a... Agent: Young & Thompson

20070172492 - Method for fermentation and cultivation, fermented plant extract, fermented plant extract powder, and composition containing the extract of fermented plant: For the purpose of providing a method of safely and inexpensively producing a fermented plant extract containing an immunopotentiator at a high concentration, the method for fermentation and culture of the present invention ferments a plant component such as wheat flour using Pantoea agglomerans which is a gram negative bacterium... Agent: Armstrong, Kratz, Quintos, Hanson & Brooks, LLP

20070172493 - 12832, a novel human kinase-like molecule and uses thereof: Novel human kinase-like polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length kinase-like proteins, the invention further provides isolated kinase-like fusion proteins, antigenic peptides, and anti-kinase-like antibodies. The invention also provides kinase-like nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention,... Agent: Millennium Pharmaceuticals, Inc.

20070172494 - Cold-adapted equine influenza viruses: The present invention provides experimentally-generated cold-adapted equine influenza viruses, and reassortant influenza A viruses comprising at least one genome segment of such an equine influenza virus, wherein the equine influenza virus genome segment confers at least one identifying phenotype of the cold-adapted equine influenza virus, such as cold-adaptation, temperature sensitivity,... Agent: Heska Corporation Intellectual Property Dept.

20070172495 - Lactobacillus acidophilus nucleic acid sequences encoding cell surface protein homologues and uses therefore: Cell wall, cell surface and secreted protein nucleic acid molecules and polypeptides and fragments and variants thereof are disclosed in the current invention. In addition, cell wall, cell surface and secreted fusion proteins, antigenic peptides, and anti-cell wall, cell surface and secreted antibodies are encompassed. The invention also provides recombinant... Agent: Alston & Bird LLP

20070172497 - Bont/a peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy: The present invention provides BoNT/A peptides as well as methods of predicting or determining immunoresistance to botulinum toxin therapy in an individual using BoNT/A peptides.... Agent: Mcdermott, Will & Emery

20070172496 - Conjugates of amyloid proteins as vaccines for amyloid-related diseases: New conjugates comprising fragments of amyloid proteins, which may be used in vaccines for the treatment, prevention and/or amelioration of diseases associated with deposition of amyloid proteins, such as, e.g. Alzheimers disease. Methods for treating, preventing and/or ameliorating amyloid-related diseases, by administering a conjugate comprising fragments of an amyloid protein... Agent: Thorpe North & Western, LLP.

20070172499 - Immunotherapy for humans: An immunotherapy useful for treating a cancer and/or treating and preventing a microbial infection is provided. A pharmaceutical composition which comprises a bacterial component as an effective ingredient is disclosed, which is used for immunotherapy in a patient suffering from a cancer or microbial infection, wherein the immunotherapy comprises eradicating... Agent: Birch Stewart Kolasch & Birch

20070172498 - Polypeptides for inducing a protective immune response against staphyloococcus aureus: The present invention features polypeptides comprising an amino acid sequence structurally related to SEQ ID NO: 1 and uses of such polypeptides. SEQ ID NO: 1 is a truncated derivative of a full length S. aureus polypeptide. The full-length polypeptide is referred to herein as full length “ORF0594”. A His-tagged... Agent: Merck And Co., Inc

20070172500 - Anthrax antitoxins: The present invention provides compositions useful in preparing and/or serving as antitoxins against Bacillus anthracis, the causative agent of anthrax. The present invention also provides polypeptides and polynucleotides relating to the capillary morphogenisis gene 2 (CMG-2), vectors containing the polynucleotides and polypeptides, and host cells containing related polynucleotide molecules, all... Agent: Fulbright & Jaworski L.L.P.

20070172501 - Method of immunizing humans against salmonella typhi using a vi-repa conjugate vaccine: This invention relates to conjugates of the Vi polysaccharide of S. typhi with the carrier Pseudomonas aeruginosa recombinant exoprotein A (rEPA), and compositions thereof, and to methods of using of these conjugates and/or compositions thereof for eliciting an immunogenic response in humans, including responses which provide protection against, or reduce... Agent: Klarquist Sparkman, LLP

20070172502 - Compositions and methods for treatment of toxoplasma gondii and other apicomplexans: Pyrimidine auxotroph mutants of apicomplexans are provided which are mutated in one of six enzymes of the de novo pyrimidine biosynthesis pathway. Also provided are methods of protecting an animal against infection by apicomplexans by administering a pyrimidine auxotroph mutant and methods for screening for inhibitors of pyrimidine salvage enzymes... Agent: Licata & Tyrrell P.C.

20070172503 - Compositions and methods to elicit immune responses against pathogenic organisms using yeast based vaccines: Embodiments of the present invention illustrate methods of treating and preventing infection due to a pathogen such as a fungal pathogen. In particular, the present invention relates to compositions and methods for vaccinations against or treatment for a fungal organism in a non-immunocompromised or immunocompromised subject.... Agent: Faegre & Benson LLP Patent Docketing

20070172504 - In vivo cell surface engineering: The present invention provides methods and compositions for the in vivo engineering of cell surfaces, such as tumor cell surfaces, with one or more immune co-stimulatory polypeptides. The methods, compositions and engineered cells are useful, for example, to stimulate an immune response against the cells. When the engineered cell surfaces... Agent: Foley And Lardner LLP Suite 500

20070172505 - Cosmetic composition comprising at least one specific block copolymer: The present invention relates to a cosmetic composition comprising, in a physiologically acceptable medium: at least one aqueous phase, at least one preservative, and at least one block copolymer of rod-coil type comprising at least one coil polymeric block structure with a variable conformation covalently bonded to at least one... Agent: Oliff & Berridge, PLC

20070172506 - Osteochondral implant procedure: A surgical procedure for preparing a damaged area of a human knee to receive at least one graft, according to which a moldable material is positioned over the damaged area and removed after it hardens. The mold is used as a template to determine the number and/or a dimension of... Agent: Haynes And Boone, LLP

20070172508 - Transluminal drug delivery methods and devices: Transluminal drug delivery method and device embodiments can include a urethral suppository formulated to prevent or treat diseases of the urethra and surrounding organs, such as interstitial cystitis or urethritis, by enhancing the absorption of a therapeutic agent of the suppository into body tissues without adversely affecting the natural defense... Agent: Catalyst Law Group, Apc

20070172507 - Transluminal drug delivery methods and devices: Transluminal drug delivery method and device embodiments may include a urethral suppository formulated to treat diseases of the urethra and surrounding organs by enhancing the absorption of a therapeutic agent of the suppository into body tissues without adversely affecting the natural defense mechanisms of these tissues. Adverse affects on the... Agent: Catalyst Law Group, Apc

20070172509 - Drug delivery system for retarding release of water soluble drugs: An implantable drug delivery system uses a hydrophobic compound as an outer layer or barrier for retarding release of water soluble drugs from the implantable system. The system includes an inner portion of a water soluble drug in a drug matrix material which stabilizes the drug. An outer portion of... Agent: Cindy A. Lynch Conor Medsystems, Inc.

20070172511 - Food products comprising a slowly digestible or digestion resistant carbohydrate composition: A food product comprises an oligosaccharide composition that is digestion resistant or slowly digestible. The oligosaccharide composition can be produced by a process that comprises producing an aqueous composition that comprises at least one oligosaccharide and at least one monosaccharide by saccharification of starch, membrane filtering the aqueous composition to... Agent: Williams, Morgan & Amerson

20070172513 - Encapsulation of oxygen sensitive agents: The present invention relates to the use of a mixture of modified starch and protein for encapsulating oxygen sensitive agents, wherein the modified starch is a starch derivative containing a hydrophobic group or both a hydrophobic and a hydrophilic group which has been further enzymatically hydrolyzed by an exo-enzyme. The... Agent: National Starch And Chemical Company

20070172510 - Energy drink: Disclosed are nutritional energy drinks and supplements. Also disclosed are methods of making nutritional drinks. The drinks provide energy to the body by refueling the body's fuel tank. The drinks comprise a core formula, to which additional ingredients are added to make a energy, performance or diet enhancing formula. The... Agent: Squire Sanders & Dempsey LLP

20070172512 - Methods of preventing peritonitis by administering lactic acid bacterium: The present invention relates to the use of lactic acid bacteria capable of adhering to the mucosa of the intestine and especially colonizing it for the prevention of peritonitis. In particular, the present invention relates to the use of such lactic acid bacteria for the prevention of peritonitis caused by... Agent: Bell, Boyd & Lloyd LLP

20070172514 - Materials and methods for improving livestock productivity: The subject invention provides methods for improving livestock health. In specific embodiments, the invention provides methods for accelerating and/or augmenting livestock growth; improving immunity; and enhancing fertility in livestock. To do so, the present invention provides materials and methods for administering a cysteamine compound to livestock.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070172515 - Film bandage for mucosal administration of actives: The present invention relates to multi-component delivery systems that adhere to mucosal tissue. In particular, the delivery systems include a first delivery vehicle and a second delivery vehicle, which is in association with the first delivery vehicle. The first delivery vehicle may be one or more mucoadhesive films, which may... Agent: Hoffmann & Baron, LLP

20070172519 - Instant sterile adhering functional patch manufacturing machine: An instant sterile adhering functional patch manufacturing machine is disclosed. This machine can be installed at any location. After a consumer deposits the coins and presses the start button, the process is then initiated at the machine. Using the internal operating mechanisms contained inside the main body, the extract solution,... Agent: Wpat, PC Intellectual Property Attorneys

20070172517 - Compositions capable of facilitation penetration across a biological barrier: This invention relates to novel pharmaceutical compositions capable of facilitating penetration of at least one effector across biological barriers. The invention also relates to methods of treating or preventing diseases by administering these compositions to affected subjects.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070172516 - Increasing of the resorption of substances via skin and mucous membranes: The invention relates to the increasing of the resorption of substances via skin and mucous membranes. The invention also relates to substances having an increased capability of being resorbed by skin and mucous membranes, and to pharmaceutical compositions containing substances of this type.... Agent: Seed Intellectual Property Law Group PLLC

20070172518 - Method of making silicone pressure sensitive adhesives for delivering hydrophilic drugs: A hydrophobic matrix is prepared by forming a semi-solid composition containing a solid powdered hydrophilic drug and/or a solid powdered hydrophilic excipient, and a silicone polyether, and then adding the semi-solid composition to a silicone pressure sensitive adhesive or a solution containing a solvent and a silicone pressure sensitive adhesive,... Agent: Dow Corning Corporation Co1232

20070172520 - Immunotargeting of nonionic surfactant vesicles: An immunoniosmes for targeted delivery of therapeutic agents to specific tissues in a host and methods of synthesis of those niosomes. An antibody molecule having specificity for a target antigen, such as a cell surface marker or other marker differentially expressed on a target cell, is covalently coupled to a... Agent: Smith Hopen, Pa

20070172522 - Pharmaceutical composition comprising a bi-cyclic compound and method for stabilizing the bi-cyclic compound: comprising the step of: admixing the same with a polyol and/or a fatty acid ester other than glyceride and a composition obtained by the method. In addition a soft gelatin capsule formulation of the compound of formula (I) obtained by incorporating the compound in a soft gelatin capsule shell comprising... Agent: Sughrue Mion, PLLC

20070172521 - Levetiracetam formulations and methods for their manufacture: Substantially glidant free levetiracetam compositions, pharmaceutical compositions incorporating substantially glidant free levetiracetam compositions, and methods of preparing such compositions are provided.... Agent: Kenyon & Kenyon LLP

20070172523 - Soft-gelatin capsule formulation: The present invention discloses a soft gelatin capsule formulation of a 15-keto-prostaglandin compound, which comprises: a soft gelatin capsule shell comprising gelatin and sugar alcohol as a plasticizer, and a mixture comprising a 15-keto-prostaglandin compound and a pharmaceutically acceptable vehicle which is filled in the shell. By encapsulating the 15-keto-prostaglandin... Agent: Sughrue Mion, PLLC

20070172524 - Process for preparing a solid pharmaceutical composition: The invention relates to a process for preparing a solid pharmaceutical composition of perindopril or a salt thereof which avoids a wet granulation step and results in very stable pharmaceutical compositions, like tablets.... Agent: Swanson & Bratschun L.L.C.

20070172525 - Anti-diabetic combinations: This invention a pharmaceutical composition comprising a DPP inhibitor and a slow release biguanide. The invention further discloses a method of administering a combination comprising a DPP inhibitor and a slow release biguanide to a mammal in need of thereof.... Agent: Ramesh Sesha

20070172526 - Radiopaque fibers and filtration matrices: Medical devices with radiopaque three dimensional filtration matrices provide for improved visualization of the device within a vessel. In some embodiments, the three dimensional filtration matrix comprises fibers, such as surface capillary fibers. Visualization of the three dimensional filtration matrix provides for an evaluation of the proper deployment of the... Agent: Dardi & Associates, PLLC

20070172527 - Environmentally compatible processes compositions and materials treated thereby: Environmentally friendly processes for killing pathogens in water involves adding to the water an amount sufficient of a hydrogen peroxide solution having a pH of less than 4, to kill pathogens in the water, wherein the hydrogen peroxide solution contains metallic ions of silver and at least one of copper... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070172528 - Compositions containing vitamin e and saw palmetto: Mineral additives for preparing tablet compositions that comprise Vitamin E and optionally saw palmetto. The compositions are preferably formulated with a zinc compound and a selenium compound.... Agent: King & Spalding LLP

20070172529 - Herbal formulation for the treatment of piles: The present invention provides a novel herbal formulation for use in treatment of piles. Formulation(s) comprises of leaves of Moringa oliefera, tender leaves of Pongaemia pinnata, whole plant of Cassia occidentalis and leaves of Albizia lebbeck. The formulation can be used as an emulsion or as a soft gelatin capsule... Agent: Ladas & Parry

20070172530 - Beverage: e

20070172531 - Chinese traditional medicine composition for treatment of avian influenza, method for preparation, and application thereof: A Chinese traditional medicine composition for prevention and treatment of avian influenza is provided. Its activated ingredients are consisted of: herba houttuyniae 21.4 wt. %, Caulis lonicerae japonicae 17.9 wt. %, radix isatidis 14.3 wt. %, male fern rhizome 10.7 wt. %, radix et rhizoma sophorae tonkinensis 7.1 wt. %,... Agent: Ladas & Parry LLP

20070172532 - Complex mixtures exhibiting selective inhibition of cyclooxygenase-2: A novel formulation is provided that serves to specifically inhibit the COX-2 mediated inflammatory response in animals. The formulation comprises an effective amount of component I selected from the group consisting of alpha acids and beta acids and an effective amount of at least one component II selected from the... Agent: Mcdermott Will & Emery LLP

20070166272 - Hair cosmetic compositions and process for producing the same: There are provided a hair cosmetic composition capable of imparting a light moistened feel, a good smoothness and a good manageability to hair after drying which is free from frictional feel upon rinsing and exhibit an effect of mending damaged portions of the hair, and a process for producing the... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070166274 - 7-dimethylamino-6-demethyl-6-deoxytetracycline skin treatment kit: A method to ameliorate the skin-irritating effects of topical tretinoin treatment by providing the tretinoin-using patient with a skin-care kit which includes (1) topical tretinoin; and (2) a skin cleanser formulated to minimize tretinoin-induced skin irritation, and (3) a skin moisturizer formulated to reduce tretinoin-induced skin irritation; and (4) packaging... Agent: Pharmaceutical Patent Attorneys, LLC

20070166295 - Anti-diarrhea preparations for small domestic animals: A composition and method for treating diarrhea in small domestic animals wherein the composition includes an effective amount of kaolin, pectin, at least one probiotic, and a carrier, and the method includes the step of orally administering an effective dosage of the composition to the domestic animals.... Agent: Mcgarry Bair PC

20070166229 - Cardiovascular safety assay: The present invention provides assays and kits for the screening of test compounds for their capability to induce cardiotoxicity in a subject. Said assays and kits are based on the finding that the interaction of astemizole with the HERG potassium channel can be exploited to predict cardiotoxicity of compounds during... Agent: Philip S. Johnson Johnson & Johnson

20070166227 - Crowned dithiocarbamate metal complexes and methods for their use: Compositions containing crowned dithiocarbamate metal complexes and methods of using these compositions; neutral and cationic radioactive metal-nitrido complexes of crowned dithiocarbamates (DTCs) and methods of using these complexes as radiopharmaceuticals for diagnosis and treatment of cardiovascular disorders, infectious diseases, and cancer; tripodal chelatormetal complexes of crowned DTCs and methods of... Agent: Brinks Hofer Gilson & Lione

20070166228 - Neutral labeling reactants and conjugates derived thereof: This invention concerns novel neutral labeling reactants. The novel reactants are derivatives of diethylenetriaminepentaacetic acid (DTPA) diamides, wherein a suitable group is linked to the molecule allowing introduction of the chelating agent or the neutral chelate to bioactive molecules.... Agent: Buchanan, Ingersoll & Rooney PC

20070166230 - Ion channel: Provided are Kv9.2 polypeptides comprising the amino acid sequence shown in SEQ ID NO. 3 or SEQ ID NO: 5, and homologues, variants and derivatives thereof. Nucleic acids capable of encoding Kv9.2 polypeptide are also disclosed, in particular, those comprising the nucleic acid sequences shown in SEQ ID No. 1,... Agent: Frommer Lawrence & Haug

20070166232 - Magnetic nanoparticles: Magnetic nanoparticles are applicable in imaging, diagnosis, therapy, and biomaterial separation. The magnetic nanoparticles comprise a core represented as FexMavZy and a shell of an inner-transition element Mb or the compound thereof, wherein Ma is an inner-transition element, Z is an element of the group Vla, x is greater or... Agent: Thomas, Kayden, Horstemeyer & Risley, LLP

20070166231 - Methods and probes for identifying vulnerable plaque: The present application discloses methods for detecting and localizing injuries in the vascular system of a subject, and in particular provides methods for detecting vulnerable or unstable plaques using oligo-deoxynucleotides (ODNs).... Agent: Beyer Weaver LLP

20070166233 - Abuse resistant transdermal drug delivery: A transdermal drug delivery patch has an excipient matrix containing an agonist for administration across the skin of a user, with the matrix further containing a plurality of spaced apart hollow cilia filled with an antagonist, whereby if an abuser attempts to physically remove the agonist the cilia will break... Agent: Kenneth Watov, Esq. Watov & Kipnes, P..c.

20070166234 - Methods and compositions for deterring abuse of opioid containing dosage forms: This invention relates to an abuse deterrent dosage form of opioid analgesics, wherein an analgesically effective amount of opioid analgesic is combined with a polymer to form a matrix.... Agent: Morgan, Lewis & Bockius LLP

20070166235 - Bronchodilating beta-agonist compositions and methods: Bronchodilating compositions and methods are provided. The compositions are intended for administration as a nebulized aerosol. In certain embodiments, the compositions contain formoterol, or a derivative thereof. Methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders using the compositions provided herein are also provided.... Agent: Lucas & Mercanti, LLP

20070166236 - Bronchodilating beta-agonist compositions and methods: Bronchodilating compositions and methods are provided. The compositions are intended for administration as a nebulized aerosol. In certain embodiments, the compositions contain formoterol, or a derivative thereof. Methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders using the compositions provided herein are also provided.... Agent: Lucas & Mercanti, LLP

20070166237 - Method for the treatment of bone disorders: Disclosed are methods for treating bone disorders in mammals. The methods comprise a loading period with a bisphosphonate followed by a maintenance period. The loading dose is two to twenty times per day greater than the corresponding maintenance dose. Also disclosed are compositions and kits for implementing the methods disclosed... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070166240 - Bronchodilating beta-agonist compositions and methods: Bronchodilating compositions and methods are provided. The compositions are intended for administration as a nebulized aerosol. In certain embodiments, the compositions contain formoterol, or a derivative thereof. Methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders using the compositions provided herein are also provided.... Agent: Lucas & Mercanti, LLP

20070166238 - Composition and delivery system: A composition for nasal or buccal application comprising a distribution of multilayer microparticles in an inactive base, at least one ingredient having activity on the mucosa of the nose/throat, being adsorbed within the layers of the microparticles so as to be progressively released over time in use; a method for... Agent: Leydig Voit & Mayer, Ltd

20070166239 - Mucosal immunogenic substances comprising a polyinosinic acid - polycytidilic acid based adjuvant: The present invention provides a polynucleotide adjuvant composition and methods of use in eliciting an immune response, in particular a mucosal immune response. The present invention also provides an immunogenic composition comprising the polynucleotide adjuvant composition together with other immunogenic compositions such as an antigen (e.g., as in a vaccine).... Agent: Bozicevic, Field & Francis LLP

20070166241 - Salicylic acid acne spray formulations and methods for treating acne with same: A fine mist spray of a salicylic acid solution is provided for treating body acne. The pH of the solution may be adjusted to above about 4.5 to reduce the incidence of nasal irritation and coughing due to incidental inhalation of the spray.... Agent: Morrison & Foerster LLP

20070166242 - Oral care product and method for the reduction of dental caries through inclusion of mannan and galactomannan polysaccharides in dentifrice formulations: An oral care composition for reducing colonization of the oral cavity by plaque and disease-causing microorganisms, includes saccharides containing cis-hydroxy sugar units or a derivative thereof. The oral care composition is a dentifrice, mouthwash, chewing gum or a lozenge. The saccharides include monomeric sugars with the cis-hydroxy stereoisomeric structure, polysaccharides,... Agent: Edwin D. Schindler

20070166243 - Composition for toothbrushing: Provided is a dentifrice composition excellent in plaque and stain removing effect and feeling upon use. The dentifrice composition has the following components (A), (B) and (C): (A) from 0.2 to 3 weight % of powder cellulose; (B) a surfactant; and (C) from 10 to 30 weight % of an... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070166244 - Compositions comprising silicone pressure sensitive adhesives for delivering oral care substances: Disclosed are compositions for delivering one or more oral care substances to the oral cavity, comprising: (a) a silicone pressure sensitive adhesive selected from a silicone/resin copolymer with silicon-bonded hydroxyl radicals, a silicone/resin copolymer with endcapped silicon-bonded hydroxyl radicals and mixtures thereof; (b) a plasticizing material; (c) a water-soluble bioadhesive... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070166245 - Propellant free foamable toothpaste composition: Propellant free foamable aqueous dentifrice system which is capable of being delivered as a foam to a toothbrush and which is stable on the brush and when placed in the mouth and used for tooth cleaning, continues to generate more foam. The system is liquid and as such can not... Agent: Omri M. Behr

20070166246 - Composition for oral cavity: The present invention provides a composition for the oral cavity that comprises a pine bark extract that is extracted from the bark of a pine. The composition for the oral cavity of the present invention can provide a plurality of effects such as an effect of improving blood flow in... Agent: Amin, Turocy & Calvin, LLP

20070166248 - Aqueous photoprotective compositions comprising hydrophilic metal oxide nanopigments and polyalkylene glycols of low molecular mass: Stable, reduced whitening photoprotective compositions contain: a) at least one aqueous phase, b) at least hydrophilic inorganic nanopigments based on metal oxides, in an amount ranging from 1% to 25% by weight, with respect to the total weight of the composition, and c) at least one polyalkylene glycol having a... Agent: Buchanan, Ingersoll & Rooney PC

20070166247 - Method for improving moisturization and hydrating properties lip products: A structured color cosmetic composition comprising water, a phenyl-substituted silicone, nonionic surfactant, and particulates, and a method for improving moisturization and hydration of lips by applying such a composition.... Agent: Julie Blackburn Revlon Consumer Products Corporation

20070166250 - Cosmetic polymer composition and cosmetic: The present invention discloses a cosmetic polymer composition containing a straight-chain block copolymer, where the copolymer having a unit derived from a compound having an ethylenic unsaturated bond, having a number-average molecular weight of 1.0×103 to 1.0×106, and having at least two or more glass transition points or melting points;... Agent: Sughrue Mion, PLLC

20070166249 - Pharmaceutical and cosmetic formulations for treating fingernails: e

20070166251 - Composition and method for treating hyperpigmented skin: An improved cosmetic and dermatological composition and a method for treating hyperpigmented skin is disclosed. The composition demonstrates an enhanced ability to lighten mammalian skin color, and is nontoxic and nonirritating. The composition comprises a hydroxycinnamic acid or a methoxycinnamic acid dissolved in a compound having one or more hydroxy... Agent: Marshall, Gerstein & Borun LLP

20070166252 - Method of treating skin requiring tattoo removal: A treatment regimen for treating skin subject to tattoo removal procedures involves the application of supplemental composition(s) such as preparatory composition(s), protective composition(s), and combinations thereof, and a corrective composition.... Agent: Carter, Deluca, Farrell & Schmidt, LLP

20070166253 - Cosmetic and dermatological formulations with natural pigments: Pigment from plant products can be combined with a cosmetic carrier formulation to create a cosmetic and/or dermatological product for transferring color to the skin of the person. A plant product extract or reformulation, such as a concentrate, flake or powder of the plant, can be combined with a cosmetic... Agent: Blakely Sokoloff Taylor & Zafman

20070166254 - Antiperspirant stick compositions: Disclosed are antiperspirant stick compositions comprising specified amounts of antiperspirant active; carrier oil comprising volatile silicone oil and non-volatile masking oil; structurant comprising fatty alcohol and cosmetically acceptable wax having a melting point of 75 to 95° C., a portion of wax comprises polyethylene in specified amounts. Also disclosed are... Agent: Unilever Intellectual Property Group

20070166255 - Treatment of topical discomforts including acne, sunburn, diaper rash, wound, wrinkles and dandruff/hair loss by natural lignans via fatty acid desaturase inhibition: The present invention discloses compositions and methodology based on certain natural lignans that provide treatment of topical discomforts and ailments including sunburn, radiation burn, thermal burn and blisters, diaper rash, shaving burn, wound, venous cannulation, acne, darkened skin pigmentation, skin wrinkles, dandruff, and hair loss; said treatment having achieved via... Agent: Shyam K. Gupta Bioderm Research

20070166259 - Cosmetic composition comprising a tensioning agent and a particular block ethylenic polymer: The present invention relates to a cosmetic composition adapted for a topical application on the skin, especially an anti-wrinkle composition, comprising, in a medium compatible with the skin: at least one tensioning agent, the said tensioning agent being present in a content ranging from 0.01% to 20% relative to the... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070166260 - Hair conditioning compositions comprising polymeric thickeners and method of conditioning hair: The present invention provides the use of a thickening system to provide stable thickened hair treating composition, preferably hair care composition, that can provide enhanced touch, combability, alignment and volume reduction to the hair, with low or reduced greasy, oily hair feel, while being formulated having a thick viscosity with... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070166261 - Hair conditioning compositions comprising polymeric thickeners and methods of conditioning hair: The present invention provides the use of a thickening system to provide stable thickened hair treating composition, preferably hair care composition, that can provide enhanced touch, combability, alignment and volume reduction to the hair, with low or reduced greasy, oily hair feel, while being formulated having a thick viscosity with... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070166262 - Leave-on hair care composition: A leave on hair care composition comprising an oil in water emulsion wherein the oil phase comprises: (i) one or more non-volatile oils, where the dynamic viscosity of any single non-volatile oil or the dynamic viscosity of a blend of non-volatile oils is less than 1000 mPa.s at 25° C.... Agent: Unilever Intellectual Property Group

20070166264 - Method of manufacturing purified products of liquid medium-chain alkyl-modified polydimethysiloxane and cosmetics prepared therefrom: A method of manufacturing a purified product of a liquid medium-chain alkyl-modified polydimethylsiloxane that is free of a specific (unpleasant) odor and is practically odorless, the method comprising the steps of: [A] synthesizing a liquid medium-chain alkyl-modified polydimethylsiloxane by carrying out a hydrosilylation reaction between a hydrosilyl-containing polydimethylsiloxane and an... Agent: Dow Corning Corporation Co1232

20070166263 - Vesicles of high molecular weight silicone polyethers: Vesicle compositions from high molecular weight silicone polyether copolymers, methods for preparing the vesicle compositions, and personal, household, and healthcare formulations containing the vesicle compositions are disclosed.... Agent: Dow Corning Corporation Co1232

20070166271 - Mq and t-propyl siloxane resins compositions: Siloxane resin compositions obtained by mixing a MQ siloxane resin with a propyl silsesquioxane resin are disclosed. These siloxane resins are useful in a variety of personal, household, automotive and medical care applications, and in particular, as a resin additive in pigmented cosmetic formulations.... Agent: Dow Corning Corporation Co1232

20070166265 - Cosmetic microemulsion: The present invention relates to a cosmetic microemulsion comprising a non-ionic surfactant type emulsifying agent, a co-emulsifying agent and a solvent selected from the group consisting of hexadecane and isomers thereof and dodecane and isomers thereof, said cosmetic microemulsions having particle diameter smaller than 100 nm. Preferably, this cosmetic microemulsion... Agent: Alston & Bird LLP

20070166266 - Methods and compositions for improving the health and appearance of skin: Provided herein are skin care compositions and methods of improving the health and appearance of skin. Also provided are methods of using polysaccharides for applications such as topical personal care products, cosmetics, and wrinkle reduction compositions. The invention also provides novel polysaccharide molecules useful for improving the health and appearance... Agent: Solazyme, Inc.

20070166267 - Anti-wrinkle composition: A composition is disclosed for treating the skin comprising an acylated short chain bioactive peptide and Lycium barbarum extract product. Also disclosed is a method for topically administering the composition in an amount therapeutically effective to reduce wrinkles by building the dermal fibroblast matrix. The composition may contain dimethylisosorbide or... Agent: K.f. Ross P.C.

20070166268 - Thickener compositions comprising sclerotium gum and a copolymer: This invention relates to chemical compositions comprising two thickening components, which are sclerotium gum and a copolymer selected from the group consisting of methyl vinyl ether/maleic anhydride copolymer and acryloyldimethyltaurate vinylpyrrolidone copolymer, in particular the ammonium salt of the latter; which components provide good thickening properties in the presence of... Agent: Philip S. Johnson Johnson & Johnson

20070166269 - Cosmetic composition containing a statistical polymer with a linear chain of ethylenic nature: The present invention relates to a cosmetic composition comprising, in a physiologically acceptable medium, at least one statistical copolymer with a linear main chain of ethylenic nature, in which the said copolymer has a molecular mass of between 15,000 and 600,000 g/mol, contains at least 70% of monomer units derived... Agent: Oliff & Berridge, PLC

20070166256 - Hair cosmetic composition: The present invention relates to a hair cosmetic composition capable of treating hairs without causing damages to hairs and injuries of skins and having oxidation fixing effect of permanent wave and dyeing effect equal to or superior to those in a usual case. Specifically, it relates to a hair cosmetic... Agent: Morgan Lewis & Bockius LLP

20070166270 - Emulsifier concentrate for a cosmetic composition: The invention relates to emulsifier concentrates which are pourable at 20° C. and contain (a) up to 90 percent by weight of a polyethylene glycol fatty acid diester based on a C16-C22 fatty acid, C16-C22 hydroxy fatty acid, polyhydroxy stearic acid, or poly-(C16-C22 hydroxy fatty acid), (b) up to 80... Agent: Cognis Corporation Patent Department

20070166258 - Hair care composition: A hair styling cream comprising: i) an aqueous lamellar phase comprising a) cationic surfactant and b) fatty alcohol having a melting point greater than 35° C. and/or fatty acid having a melting point greater than 40° C.; and ii) 20 wt % or greater of one or more non-volatile liquid... Agent: Unilever Intellectual Property Group

20070166257 - Long wear cosmetic composition: The present invention relates to long-wearing, non-aqueous based cosmetic compositions, and related dermatological, pharmaceutical or hygiene compositions. The present invention provides a non-aqueous based composition comprising one or a mixture of two or more emulsifiers.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070166275 - Compositions comprising kakadu plum extract or acai berry extract: A topical skin care composition comprising kakadu plum extract or acai berry extract, or a combination of both, is disclosed. The composition can include a high oxygen radical absorbance capacity (ORAC) value. The composition can improve the skin's visual appearance, physiological functions, clinical properties, and/or biophysical properties.... Agent: Fulbright & Jaworski L.L.P.

20070166273 - Skin treatment educational kit: A method to ameliorate the skin-irritating effects of topical tretinoin treatment by providing the tretinoin-using patient with a skin-care kit which includes (1) topical tretinoin; and (2) a skin cleanser formulated to minimize tretinoin-induced skin irritation, and (3) a skin moisturizer formulated to reduce tretinoin-induced skin irritation; and (4) packaging... Agent: Pharmaceutical Patent Attorneys, LLC

20070166277 - Polymeric reagents comprising a ketone or a related functional group: Polymeric reagents comprising a polymer attached, either directly or through one or more atoms, to a ketone or a related functional group such as ketone hydrate, thione, monothiohydrate, dithiohydrate, hemiketal, monothiohemiketal, dithiohemiketal, ketal, or dithioketal are provided. The polymeric reagents are useful for, among other things, forming polymer-active agent conjugates.... Agent: Nektar Therapeutics

20070166276 - Releasable polymeric conjugates based on aliphatic biodegradable linkers: Activated polymeric bicine derivatives such as Formula (I), as well as conjugates made therewith are disclosed. Methods of making and using the bicine derivatives are also disclosed.... Agent: Lucas & Mercanti, LLP

20070166280 - Chemokines as adjuvants of immune response: Dendritic cells play a critical role in antigen-specific immune responses. Materials and methods are provided for treating disease states, including cancer, infectious diseases, autoimmune diseases, transplantation, and allergy by facilitating or inhibiting the migration or activation of a specific subset of antigen-presenting dendritic cells known as plasmacytoid dendritic cells (pDC).... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070166281 - Chloroquine coupled antibodies and other proteins with methods for their synthesis: This invention discloses compositions of chloroquine-coupled active agents such as therapeutic antibodies or insulin, including methods for their preparation. The prior art has shown that chloroquines given as free drug in high enough concentration, enhances the release of various agents from cellular endosomes into the cytoplasm. The purpose of these... Agent: Kenneth M. Kosak

20070166279 - Method for modulating hla class ii tumor cell surface expression with a cytokine mixture: A method for altering the composition of tumor infiltrating mononuclear cells, increasing CD4+/CD8+ ratio, increasing tumor stroma/epithelial ratio and modulating HLA (Human Leukocyte Antigen) class II expression on a tumor cell surface with a serum-free and mitogen-free mixture having specific cytokine ratios from the group of IL-1β, TNF-α, IFN-γ, GM-CSF,... Agent: Roger C. Hahn Hahn & Voight PLLC

20070166278 - Novel g-csf conjugates: The present application relates to novel PEG-G-CSF conjugates in which a PEG molecule is linked to the cyteine residue in position 17 of native G-CSF primary sequence or to the cysteine residue of the corresponding position of a G-CSF analogue. The present application also describes a process for the manufacture... Agent: Mark A Wilson Nektar Therapeutics

20070166282 - Homogeneous preparations of il-28 and il-29: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity... Agent: Zymogenetics, Inc. Intellectual Property Department

20070166283 - Compositions and methods for the treatment of hemophilia a: Improved materials and methods for the treatment of Hemophilia A are provided.... Agent: Dann, Dorfman, Herrell & Skillman

20070166286 - Self-rearranging dna vectors: Disclosed are replicatable viral DNA vectors encoding a site-specific DNA-altering enzyme and a DNA target recognized by the enzyme, the enzyme selectively converting, in a cell expressing the enzyme, the DNA vector to a rearranged form. The invention further relates to methods for assembling recombinant adenoviral DNAs. These methods include... Agent: Clark & Elbing LLP

20070166285 - Systems and methods related to degradation of uremic toxins: The present invention generally relates to the treatment of uremic toxins in vivo using uremic toxin-treating enzymes, and/or cells capable of producing uremic toxin-treating enzymes or otherwise reacting with uremic toxins. Non-limiting examples of cases where the treatment of uremic toxins is desired include renal disease or dysfunction, gout, subjects... Agent: Wolf Greenfield & Sacks, P.C.

20070166284 - Therapeutic regimen for treating cancer: The invention provides a method for treating cancer in a human comprising administering to the human a dose of a pharmaceutical composition comprising (i) a pharmaceutically acceptable carrier and (ii) an adenoviral vector comprising a nucleic acid sequence encoding TNF-α operably linked to a promoter, wherein the dose comprises about... Agent: Leydig Voit & Mayer, Ltd

20070166291 - Cell preparation: A method for transduction of cells with a genetic construct and selection of genetically modified cells, the method comprising performing the transduction and selection in a closed system.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070166293 - Method for growing stem cells: A method for growing stem cells comprising the steps of a providing stem cells with supporters said supporters being genetically modified in order to provide externally regulatable interactions between the supporters and the stem cells; supporters and stem cells are interchangeable upon genetic modification and interaction; applying an external signal... Agent: Jacobson Holman PLLC

20070166292 - System for exsanguinous metabolic support of an organ or tissue: An exsanguinous metabolic support system for maintaining an organ or tissue at a near normal metabolic rate is disclosed. The system employs a warm perfusion solution capable of supporting the metabolism of the organ or tissue thereby preserving its functional integrity. The system also monitors parameters of the circulating perfusion... Agent: Heslin Rothenberg Farley & Mesiti PC

20070166294 - Method for reducing aflatoxins in fodders, meats, milk and derivatives thereof and a composition suitable for said purpose: The invention relates to a method for reducing drastically and/or eliminating aflatoxins in feeds, thus enabling to produce meat and milk free from aflatoxins, by using specific lactic bacteria eliminating the presence of molds from feeds for cattle nutrition and the subsequent aflatoxin contamination of meats, milk and dairy products;... Agent: Pearne & Gordon LLP

20070166287 - Oncolytic virus: The present invention is directed to a method of reducing the viability of a tumor cell involving administering a virus that is not a common human pathogen to the tumor cell. Preferably, the virus exhibits differential susceptibility, in that normal cells are not affected by the virus. This differential susceptibility... Agent: Lewis J. Kreisler

20070166289 - Autologous human dna grafting - anti- & reverse aging process, method: Anti-aging process and method for delivering younger human DNA to tissues, through the periodic infusion (auto-transfusion) of previously harvested autologous younger stem cells, resulting in re-establishment of an earlier relative biological clock set-point, with respect to the number of cell generations-divisions.... Agent: Hogan & Hartson LLP

20070166288 - Formulation to improve survival of transplanted cells: The survival of cells during transplantation is enhanced. Cells to be transplanted are administered in a formulation that provides two ore more survival enhancing factors. Optionally, prior to administration, the cells are cultured in the presence of factors that enhance survival, and may be heat shocked prior to transplantation.... Agent: Bozicevic, Field & Francis LLP

20070166290 - Lineage restricted glial precursors from the central nervous system: A glial precursor cell population from mammalian central nervous system has been isolated. These A2B5+ E-NCAM− glial-restricted precursor (GRP) cells are capable of differentiating into oligodendrocytes, A2B5+ process-bearing astrocytes, and A2B5− fibroblast-like astrocytes, but not into neurons. GRP cells can be maintained by regeneration in culture. GRP cells differ from... Agent: Kathleen A. Tyrrell Licata & Tyrrell P.C.

20070166296 - Therapeutic systems: A compound comprising a target cell-specific portion and human NAD(P)H:quinone reductase 2 (NQO2) or a variant or fragment or fusion or derivative thereof which has substantially the same activity as NQO2 towards a given prodrug, or a polynucleotide encoding said NQO2 or said variant or fragment or fusion or derivative.... Agent: Patrea L. Pabst Pabst Patent Group LLP

20070166297 - Human analogs of murine deubiquitinating protease: The present invention is directed to human analogs of murine hematopoetic-specific, cytokine-inducible deubiquinating proteases (“DUBs”) clustered on chromosomes 4 and 8 and their respective regulatory regions. The nucleotides or proteins encoded thereby my be used in assays to identify inhibitors of human DUBs.... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070166298 - Formulations for the rectal administration of thrombolytically-active agents: Pharmaceutical formulations in suppository form, containing thrombolytic agents, which are able to penetrate rectal mucous, for the treatment of acute hemorrhoid diseases and/or diseases of thrombotic origin.... Agent: Hoffmann & Baron, LLP

20070166299 - Treatment for embolic stroke: Provided herein are methods and compositions for treating stroke that include contacting a subject suffering from a stroke with (1) an antioxidant; (2) an antioxidant and one or more of (i) a thrombolytic agent, (ii) an NMDA receptor antagonist and (iii) a spin trap agent; or (3) a thrombolytic agent... Agent: Buchanan, Ingersoll & Rooney LLP

20070166300 - Method of modulating the activity of functional immune molecules: The invention relates to a method for controlling the activity of an immunologically functional molecule, such as an antibody, a protein, a peptide or the like, an agent of promoting the activity of an immunologically functional molecule, and an immunologically functional molecule having the promoted activity.... Agent: Nixon & Vanderhye, PC

20070166301 - Method of modulating the activity of functional immune molecules: The invention relates to a method for controlling the activity of an immunologically functional molecule, such as an antibody, a protein, a peptide or the like, an agent of promoting the activity of an immunologically functional molecule, and an immunologically functional molecule having the promoted activity.... Agent: Nixon & Vanderhye, PC

20070166302 - Method of modulating the activity of functional immune molecules: The invention relates to a method for controlling the activity of an immunologically functional molecule, such as an antibody, a protein, a peptide or the liker an agent of promoting the activity of an immunologically functional molecule, and an immunologically functional molecule having the promoted activity.... Agent: Nixon & Vanderhye, PC

20070166303 - Method of modulating the activity of functional immune molecules: The invention relates to a method for controlling the activity of an immunologically functional molecule, such as an antibody, a protein, a peptide or the like, an agent of promoting the activity of an immunologically functional molecule, and an immunologically functional molecule having the promoted activity.... Agent: Nixon & Vanderhye, PC

20070166304 - Method of modulating the activity of functional immune molecules: The invention relates to a method for controlling the activity of an immunologically functional molecule, such as an antibody, a protein, a peptide or the like, an agent of promoting the activity of an immunologically functional molecule, and an immunologically functional molecule having the promoted activity.... Agent: Nixon & Vanderhye, PC

20070166305 - Method of modulating the activity of functional immune molecules: The invention relates to a method for controlling the activity of an immunologically functional molecule, such as an antibody, a protein, a peptide or the like, an agent of promoting the activity of an immunologically functional molecule, and an immunologically functional molecule having the promoted activity.... Agent: Nixon & Vanderhye, PC

20070166306 - Anti-cd19 antibody composition and method: A method of enhancing the antibody-dependent cellular cytotoxicity (ADCC) of a human or humanized CD19 antibody is disclosed. The antibody is produced in the presence of a beta.(1,4)-N-acetylglucosaminyltransferase III (GnTIII) enzyme, under conditions effective to produce in the antibody, an Fc fragment characterized by Asn297-linked oligosaccharides containing (i) at least... Agent: Perkins Coie LLP

20070166308 - Antibodies to madcam: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to MAdCAM, preferably human MAdCAM and that function to inhibit MAdCAM. The invention also relates to human anti-MAdCAM antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized,... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070166309 - Optimized anti-cd30 antibodies: An antibody that targets CD30, wherein the antibody comprises at least one modification relative to a parent antibody and the antibody binds with altered affinity to an FcγR or alters effector function as compared to the parent antibody. Also disclosed are methods of using the anti-CD30 antibody.... Agent: Morgan, Lewis & Bockius, LLP

20070166307 - Suppression of transplant rejection: The present invention relates to a transplant rejection in an animal suppressed by administration of an antibody directed at a cell surface antigen selected from the group consisting of CD4, CD8, CD154, LFA-1, CD80, CD86 and ICAM-1, preferably an anti-CD4 antibody, together with a non-cellular protein antigen to generate in... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070166310 - Prostatic growth factor: The present invention relates to human PGF polypeptides and DNA (RNA) encoding such polypeptides. Also provided is a procedure for producing such polypeptides by recombinant techniques, and antibodies and antagonist/inhibitors against such polypeptides. Also provided are methods of using such polypeptides therapeutically for treating prostate cancer, to promote tissue regeneration... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20070166311 - Monoclonal antibody: The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. The... Agent: King & Spalding LLP

20070166313 - Administration of gamma globulins to treat cancer: This invention relates to cancer therapy and in particular to the administration of gamma globulins to inhibit both primary tumor and metastasis and augment treatment of primary cancerous tumors. In accordance with this invention, the treatment of various cancerous diseases is accomplished by administering a preparation containing intact gamma globulins... Agent: Pearl Cohen Zedek Latzer, LLP

20070166312 - Antibody against tumor specific antigen as target: The present invention relates to a method of detecting cancer by use of an oncogene, a method of screening for an active compound useful to treat and/or prevent cancer, and a pharmaceutical composition for treatment and/or prevention of cancer. More specifically, the present invention provides a method of detecting cancer... Agent: Dorsey & Whitney LLP Intellectual Property Department

20070166314 - Epa2 monoclonal antibodies and methods of use thereof: The present invention relates to methods and compositions designed for the treatment, management, or prevention of cancer, particularly, metastatic cancer. In one embodiment, the methods of the invention comprise the administration of an effective amount of an antibody that binds to EphA2 and agonizes EphA2, thereby increasing EphA2 phosphorylation and... Agent: Jones Day

20070166315 - Vibrio cholerae o139 conjugate vaccines: The disclosure pertains to conjugates of the capsular polysaccharide of Vibrio cholerae O139, or a structurally and/or immunologically related oligo- or poly-saccharide, and a carrier. These conjugates are useful as pharmaceutical compositions and/or vaccines to induce serum antibodies which have bactericidal (vibriocidal) activity against V. cholerae, in particular V. cholerae... Agent: Klarquist Sparkman, LLP

20070166317 - Microparticles: The present invention relates to microparticles formed from polymer materials and comprising a peptide anchored thereto for binding to a cell surface receptor, for delivering agents to cells and to a method of making such microparticles.... Agent: Alston & Bird LLP

20070166316 - Tumor-derived biological antigen presenting particles: Disclosed is a biological anti-tumor approach that delivers specific antigen stimulation in the presence of co-stimulatory signals to the immune system. Tumor cells are engineered such that processed antigens and co-stimulatory molecules are incorporated into virus-like particles capable of modulating immune responses without cellular entry and nucleic acid genomic host... Agent: Joseph D Mosca

20070166318 - Compositions, splice variants and methods relating to ovarian specific nucleic acids and proteins: The present invention relates to newly identified nucleic acid molecules and polypeptides present in normal and neoplastic ovarian cells, including fragments, variants and derivatives of the nucleic acids and polypeptides. The present invention also relates to antibodies to the polypeptides of the invention, as well as agonists and antagonists of... Agent: Licata & Tyrrell P.C.

20070166319 - Human papilloma virus immunoreactive peptides: This invention provides immunogenic peptides from the HPV-18E6 protein that comprise class I restricted T cell epitopes and discloses methods of administering these peptides to individuals, and a method for monitoring or evaluating an immune response to HPV with these peptides.... Agent: National Institute Of Health C/o Needle & Rosenberg, P.C.

20070166320 - Agent for preventing/ameliorating diabetes and functional food for preventing/ameliorating diabetes: It is an object of the present invention to provide an agent for preventing/ameliorating diabetes mellitus in which the agent has an effect of suppressing an increase in blood glucose level, and to provide a functional food containing the agent for preventing/ameliorating diabetes mellitus and having an effect of preventing/ameliorating... Agent: Morgan & Finnegan, L.L.P.

20070166321 - Compositions and methods for reducing cholesterol and inflammation: Statin therapy has revolutionized the treatment of cardiovascular disease, but not all patients can take the appropriate level of statins because of their side effects. The present invention provides compositions that provide potent cholesterol lowering while minimizing the damaging side effects to liver, muscles, and neurons, and has the added... Agent: Bryant R. Villeponteau

20070166322 - Adjuvant viral particle: An immunopotentiating composition comprising a papaya mosaic virus (PapMV), or a virus-like particle (VLP) derived from PapMV coat protein, which is capable of functioning as an adjuvant and thus potentiating an immune response in an animal is provided. The immunopotentiating composition can further comprise an immunogen, which can be fused... Agent: Morrison & Foerster LLP

20070166328 - Genetic immunization against cervical carcinoma: An alphavirus vector system comprising nucleic acid of a human papilloma virus origin is disclosed. A method of treating or preventing cervical cancer is also disclosed. The method includes administering the alphavirus vector system and/or a cell comprising nucleic acid derived from human papilloma virus (HPV) to a subject. The... Agent: Trask Britt

20070166327 - Mammalian antigen-presenting t cells and bi-specific t cells: The present invention is directed to mammalian bi-specific T cells and methods for using these bi-specific T cells. More specifically, the invention relates to viral specific T cells that express chimeric anti-tumor receptors. These bi-specific T cell clones are a source of effector cells that persist in vivo in response... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070166324 - West nile vaccine: The present invention provides a safe and effective vaccine composition against West Nile virus disease. An immunogenically active component of West Nile virus or plasmid DNA, an adjuvant such as a metabolizable oil, and a pharmacologically acceptable carrier are formulated into an immunizing vaccine. The invention also provides a method... Agent: Wyeth Patent Law Group

20070166325 - West nile vaccine: The present invention provides a safe and effective vaccine composition against West Nile virus disease. An immunogenically active component of West Nile virus or plasmid DNA, an adjuvant such as a metabolizable oil, and a pharmacologically acceptable carrier are formulated into an immunizing vaccine. The invention also provides a method... Agent: Wyeth Patent Law Group

20070166326 - West nile vaccine: The present invention provides a safe and effective vaccine composition against West Nile virus disease. An immunogenically active component of West Nile virus or plasmid DNA, an adjuvant such as a metabolizable oil, and a pharmacologically acceptable carrier are formulated into an immunizing vaccine. The invention also provides a method... Agent: Wyeth Patent Law Group

20070166323 - Yeast-dendritic cell vaccines and uses thereof: Disclosed is a vaccine that includes a dendritic cell loaded with a yeast vehicle and antigen. Also disclosed are methods of making the vaccine and using the vaccine to elicit cellular and humoral immune responses in a mammal. Additionally, a method to elicit an immune response by administration of a... Agent: Sheridan Ross PC

20070166329 - Methods for preventing flavivirus infection: The present invention encompasses isolated nucleic acids containing transcriptional units which encode a signal sequence of one flavivirus and an immunogenic flavivirus antigen of a second flavivirus. The invention further encompasses a nucleic acid and protein vaccine and the use of the vaccine to immunize a subject against flavivirus infection.... Agent: Klarquist Sparkman, LLP

20070166330 - Gm-negative ehv-mutants without heterologous elements: The present invention relates to the field of animal health and in particular of Equine Herpes Viruses (EHV) wherein the gene encoding the protein gM is absent, and which is free of heterologous elements. Further aspects of the invention relate to pharmaceutical compositions comprising said viruses, uses thereof, and methods... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070166331 - Modified seb and prophylactics/remedies for immunopathy containing the same: A novel prophylactic/remedy for immunopathy is provided which is not neutralized by a neutralizing antibody to Staphylococcal enterotoxin B (SEB), known as one of superantigens, and may effectively act as a superantigen. A modified SEB having a reduced reactivity with a neutralizing antibody to SEB (anti-SEB antibody) and a prophylactic/remedy... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070166332 - Clostridial toxin activatable clostridial toxins: The specification discloses modified Clostridial toxins comprising a Clostridial toxin substrate cleavage site located within the di-chain loop region; polynucleotide molecules encoding such modified Clostridial toxins comprising a Clostridial toxin substrate cleavage site located in the di-chain loop region; and method of producing modified Clostridial toxins comprising Clostridial toxin substrate... Agent: Allergan, Inc.

20070166333 - Method of antigen incorporation into neisseria bacterial outer membrane vesicles and resulting vaccine formulations: Method for the insertion of protein antigens, of recombinant or synthetic origin, in outer membrane vesicles of Gram-negative bacteria without disruption of the vesicle structure, therefore maintaining the immunogenicity and immunostimulatory properties of said vesicles, and with the reported advantage that the immune response generated against the incorporated antigen is... Agent: Hoffmann & Baron, LLP

20070166334 - Coccidiosis vaccines: The present invention relates to hydrophilic Eimeria polypeptides, DNA-fragments encoding those peptides, recombinant DNA molecules comprising such DNA-fragments, live recombinant carriers comprising such DNA-fragments or recombinant DNA molecules and host cells comprising such DNA-fragments, recombinant DNA molecules or live recombinant carriers. Furthermore, the invention relates to antibodies against the polypeptides... Agent: Intervet Inc. Patent Department

20070166335 - Allergy inhibitor compositions and kits and methods of using the same: Compositions and kits for inhibiting an allergic response against an allergenic protein are disclosed. The compositions comprise a eukaryotic cell expression vector containing nucleotide sequences encoding an allergenic protein or a polypeptide that comprises an antigenic epitope of said allergenic protein; and an allergenic protein or a polypeptide that comprises... Agent: Cozen O'connor, P.C.

20070166336 - Stable and palatable oral liquid sumatriptan compositions: The present invention is directed to improved oral liquid compositions that include sumatriptan, or a pharmaceutically acceptable salt or metabolite thereof, and a pharmaceutically acceptable carrier that includes a liquid portion of the composition. The compositions are substantially free of oxidation impurities. Typically, the compositions include a sweetening agent and... Agent: Winston & Strawn LLP Patent Department

20070166338 - Dermabrasion composition and process: A composition of matter for abrading the epidermis of a human body to expose the underlying dermis, consisting of: (a) an abrasive; (b) a dessicant; and (c) a thickening agent (d) in the absence of an emollient in an aqueous medium. A method of removing the epidermis of a human... Agent: Briggs And Morgan P.A.

20070166339 - Skin whitening methods and compositions based on zeolite - active oxygen donor complexes: The present invention discloses certain complexes of anionic zeolites with active oxygen donor agents, such as organic or inorganic peroxides, and methods and compositions based on said complexes for skin whitening.... Agent: Shyam K. Gupta Bioderm Research

20070166337 - Skincare compositions and methods: There is disclosed a skincare composition suitable for topical application to the skin. The composition comprises from 0.5 to 10% by weight of salicylic acid and from 0.5 to 10% of hydrogen peroxide, but is substantially free of other therapeutic agents selected from the group consisting of anti-microbial agents, anti-bacterial... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070166340 - Fungicidal composition for through periderm bark application to woody plants: A fungicidal composition for topical application to woody plant periderm, the composition comprising (a) a systemic fungicide, (b) an organosiloxane surfactant, and (c) water.... Agent: Arthur M Reginelli Renner Kenner Greive Bobak Taylor & Weber

20070166342 - Insect repellent composition: The present application provides insect repellent compositions that include lemongrass oil and p-menthane-3,8-diol. Vanillin or a vanillin-type component may also be included in the insect repellent composition.... Agent: Darby & Darby P.C.

20070166341 - Solid volatile composition and method and system for making the same: This invention provides a solid air freshener and method for manufacturing the same wherein a composition is constructed from a first material being a solid volatile material at an ambient temperature and a second material being a vicious oily fluid volatile material at ambient temperature. The present invention combines the... Agent: Lackenbach Siegel, LLP

20070166349 - Orthopaedic implants fabricated from amorphous or partially amorphous calcium-based metal alloys: Orthopaedic implants are formed using processes whereby a metal alloy is cooled at a rate rapid enough that an amorphous or partially amorphous structure is retained. In the preferred embodiment, the metal alloy is a calcium-based metal alloy. The fabrication process may include die-casting or additive manufacturing process of the... Agent: Gifford, Krass, Sprinkle,anderson & Citkowski, P.c

20070166347 - Channeled endomural therapy: Diseases, aging, trauma, environmental exposure, infection and other events or agents can alter tissue function. In one embodiment, treatment is provided by therapeutically altering tissue function. This may be by continuing normal tissue function, suppressing tissue function, or enhancing tissue function. In a preferred embodiment, this treatment is effectuated by... Agent: Patrea L. Pabst Pabst Patent Group LLP

20070166350 - Compositions and methods for promoting attachment of cells of endothelial cell lineage to medical devices: The present invention provides compositions and methods for an improved coating for medical devices. Provided is a biofunctional coating composition comprising at least one binding domain that has binding specificity for a metallic surface material of a medical device, and at least one binding domain that has binding specificity for... Agent: M. Bud Nelson, Ph.d., J.d. Affinergy, Inc.

20070166348 - Keratin bioceramic compositions: A malleable bone graft composition is described. The composition comprises: (a) keratose; (b) particulate filler; (c) antibiotic; and (f) water. The invention may be provided in sterile form in an container, and optionally lyophilized. Methods of treating a fracture with such compositions are also described.... Agent: Myers Bigel Sibley & Sajovec

20070166343 - Matrix, cell implantation and method for their production and use: The invention relates to porous matrices based on a biologically compatible polymer or polymer mixture, to a cell implantation that is established on said matrices and to additional cell implantation based on cell mixtures of hepatocytes and islets of Langerhans. The invention also relates to a method for producing porous... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070166346 - Method for coating an object with hydrophobin at low temperatures: The invention relates to methods for coating objects with hydrophobins. Provided is a method for providing the surface of an object with a hydrophobin coating, comprising contacting at least a part of an object with a hydrophobin-containing solution to form a hydrophobin layer on the surface of the object and... Agent: Trask Britt

20070166344 - Non-leaching surface-active film compositions for microbial adhesion prevention: Surface-active, non-leaching antimicrobial film forming compositions and methods for their application to preferably medical device surfaces are provided. The compositions form durable coatings with long-lasting antimicrobial efficacy without formation of a zone of inhibition. Optionally the films can be hydrophilic. Specific long-chain molecules of certain chemical reactivity are covalently bonded... Agent: Hoffmann & Baron, LLP

20070166351 - Polycationic peptides for cardiovascular therapy: Implantable medical devices including polycationic peptide coatings are disclosed.... Agent: Squire, Sanders & Dempsey LLP

20070166345 - Vascular occlusion methods, systems and devices: Described are devices, methods and systems useful for achieving occlusion of vascular vessels. Percutaneous procedures are used to occlude and obliterate the greater saphenous vein, for example in the treatment of varicose vein condition caused by venous reflux. Certain embodiments encompass the deployment of one or more vascular occlusion devices... Agent: Woodard, Emhardt, Moriarty, Mcnett & Henry LLP

20070166353 - Osteogenic proteins: Disclosed are (1) osteogenic devices comprising a matrix containing substantially pure natural-sourced mammalian osteogenic protein; (2) DNA and amino acid sequences for novel polypeptide chains useful as subunits of dimeric osteogenic proteins; (3) vectors carrying sequences encoding these novel polypeptide chains and host cells transfected with these vectors; (4) methods... Agent: Kirkpatrick & Lockhart Preston Gates Ellis LLP Formerly Kirkpatrick & Lockhart Nicholson Graham()

20070166352 - Polymer-based sustained release device: This invention relates to compositions for the sustained release of biologically active polypeptides, and methods of forming and using said compositions, for the sustained release of biologically active polypeptides. The sustained release compositions of this invention comprise a biocompatible polymer having dispersed therein, a biologically active polypeptide and a sugar.... Agent: Andrea G. Reister, Esq. Covington & Burling

20070166354 - Method of reducing the risk of retinopathy of prematurity in preterm infants: Disclosed is a method of reducing the risk or severity of retinopathy of prematurity in preterm infants. The method comprises (a) measuring skin carotenoid levels in preterm infants, preferably by Raman Spectroscopy, and then (b) administering supplemental carotenoids to those infants in need thereof, wherein the supplemental carotenoids comprise lutein,... Agent: Ross Products Division Of Abbott Laboratories Department 108140-ds/1

20070166355 - Food and feed supplement and its use: The present invention relates to a food and feed supplement, and its use, where the supplement comprise as the basic component at least one carboxylic acid and/or its salt, an iron component and vitamins B6, B9 and B12 in amounts corresponding to at least that which theoretically can be consumed... Agent: Brooks Kushman P.C.

20070166356 - Food supplement for animals, comprising an olfactory additive: The present invention generally relates to the feeding of animals, and in particular to the complementation of this feeding with an active compound, i.e., an amino acid, or an amino acid derivative, for example methionine. The present invention in particular relates to a feed complement for animals comprising at least... Agent: Oliff & Berridge, PLC

20070166357 - Bandage for facilitating transdermal respiration and healing: A bandage includes a reservoir filled with a perfluorochemical fluid, saturated with oxygen. Oxygen passes through a permeable membrane to the skin or wound to promote healing, and carbon dioxide travels from the skin or wound to the reservoir.... Agent: Paul And Paul

20070166358 - Nasal mucus absorber pad: A nasal mucus absorber pad for a person includes a fluid absorber, a backing part, and a fixing part. The fluid absorber, for absorbing bodily fluids, includes an inner side, an outer side, a top edge, a bottom edge, and side edges. The backing part, for backing the outer side... Agent: Park Law Firm

20070166359 - Hoxd3, hoxa3 and hoxb3 compositions and methods for improved wound healing: The present invention provides methods and compositions useful in localized transfer of genetic material or proteins. Moreover, the present invention provides methods and compositions for improving and/or controlling wound healing by applying a wound care device comprising HoxD3 and/or HoxA3 and/or HoxB3. In addition, the present invention provides methods and... Agent: Medlen & Carroll, LLP

20070166360 - External preparation: e

20070166361 - Formulations for transdermal or transmucosal application: The present invention relates generally to formulations for transdermal or transmucosal administration of an active agent such as estradiol. The invention is a substantially malodorous-free and irritation free transdermal formulation which is substantially free of long chain fatty alcohols, long-chain fatty acids, and long-chain fatty esters.... Agent: Winston & Strawn LLP Patent Department

20070166365 - Fentanyl suspension-based silicone adhesive formulations and devices for transdermal delivery of fentanyl: Silicone adhesive formulations are provided, in which fentanyl particles are suspended one or more a solvated silicone adhesives. The formulations can be used for manufacturing improved, matrix-type transdermal devices for administering fentanyl.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070166362 - Transdermal and transmucosal preparations: Transdermal and transmucosal preparations are often insufficiently absorbed. Thus, there is a need for additives that can enhance the transdermal and/or transmucosal absorption of various drugs. The present invention provides compositions for enhancing transdermal and/or transmucosal absorption, comprising a hydroxyapatite and essential ingredients. The hydroxyapatite has a maximum particle size... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070166364 - Transdermal therapeutic system: This present invention concerns a cover layer that is impermeable to the active substances and/or a removable protective layer of a transdermal therapeutic system, comprising a thermoplastic film which either directly contains the absorbing agents and channel-forming agents or is coated with a polymer support (thermoplast) containing these substances. The... Agent: Jane Massey Licata, Esquire Licata & Tyrrell P.C.

20070166363 - Use of cholinesterase inhibitors for treating vascular depression: The invention discloses the use of cholinesterase inhibitors in treating vascular depression.... Agent: Novartis Corporate Intellectual Property

20070166369 - Photodynamic cosmetic procedure and healing method: Innovative non-surgical methods and compositions are provided for administering PDT to promote tissue regeneration or augmentation while minimizing scarring and risk of infection. Among several areas of application, is the treatment of acute and chronic wounds which have afflicted epidermal and connective tissue layers of the body. Another application area... Agent: Bolesh J. Skutnik Ceramoptec Industries, Inc.

20070166367 - Adept or gdept producing acetaldehyde: The present invention includes compounds, comprising a portion capable of converting a substrate, for example ethanol, to acetaldehyde and a means of directing the compounds to selected cells, and their use in therapeutic compositions and methods. The compounds may be administered with the substrate, for example ethanol, and an inhibitor... Agent: Marshall, Gerstein & Borun LLP

20070166366 - Autologous upregulation mechanism allowing optimized cell type-specific and regulated gene expression cells: The present invention provides methods for high level, regulated transgene transcription that is restricted to cell populations of specific types. The process is designed to work with any inducible expression regulation systems, adapting them to a tissue-specific expression pattern while simultaneously delivering maximal achievable expression levels. In particular, the invention... Agent: Fulbright & Jaworski L.L.P.

20070166368 - Protein-stabilized liposomal formulations of pharmaceutical agents: The present invention relates to protein stabilized liposomes. Specifically, the present invention discloses compositions and methods for protein stabilized liposomes, the creation of protein stabilized liposomes, and the administration of protein stabilized liposomes.... Agent: David L. Parker Fulbright & Jaworski L.L.P.

20070166372 - Preparation of solid coprecipitates of amorphous valsartan: A novel coprecipitate of amorphous valsartan with a pharmaceutically acceptable carrier, e.g. polyvinylpyrolidone (PVP), crosslinked-polyvinylpyrolidone, polyvinylpyrolidone vinyl acetate copolymer (PVP-VA64), a process for the preparation of said novel co-precipitate and the use of said novel coprecipitate in the treatment and/or prophylaxis of hypertension, cardiovascular diseases and conditions associated with thereof... Agent: Mai De Ltd.

20070166371 - Methods of producing films and capsules made from modified carboxymethylcellulose materials: Films and/or capsules for the delivery of and/or coating of active ingredients are provided. Such edible films and/or capsules comprise particular modified carboxymethylcellulose (CMC) materials either alone or in combination with other types of hydrocolloids or biogums. The utilization of such modified CMC products aids in the production of such... Agent: J M Huber Corporation

20070166370 - Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient: An oral pharmaceutical composition comprises multiple populations of at least one of beads, pellets, tablets and granules provided in a capsule, the composition comprising: a first population of a pharmaceutical active comprising a pharmaceutical active substance releasable at a first rate; a population of a basic substance; and a second... Agent: Thomas, Kayden, Horstemeyer & Risley, LLP

20070166373 - Pre-fabricated semi-permeable capsule shells containing a semipermeable layer on a water-dispersible/soluble gelatinous shell for osmotic drug delivery system: The present invention is centered on the design, manufacturing and use of a novel capsule system made up of a bi- or multi-layered two piece capsule shell made of a water soluble/dispersible layer coated with water-insoluble semi-permeable membrane capsule shell. The therapeutic agent is formulated in the drug layer and... Agent: Hasmukh B. Patel

20070166374 - Composition and method for tissue repair and regeneration: The present invention provides novel compositions and methods for protecting and promoting cell growth and restoring physiological structure and function to tissue or organ of the body, especially mucosa in the gastrointestinal tract. The composition can be used as a pharmaceutical or nutraceutical to treat a gastrointestinal disorder or to... Agent: Wilson Sonsini Goodrich & Rosati

20070166375 - Modified release oral dosage form using co-polymer of polyvinyl acetate: Once a day modified release oral dosage form comprising of granules or pellets which are either compressed into tablet or filled inside the capsule, wherein the pellet has a core of active ingredient coated on non pareil seeds with a rate controlling functional coating of co-polymer of polyvinyl acetate optionally... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20070166376 - Solid pharmaceutical preparation: The present invention provides a solid preparation containing an insulin sensitizer and an active ingredient (except insulin sensitizers), which shows in vivo dissolution behavior of an insulin sensitizer, which is similar to the dissolution behavior of an insulin sensitizer from “a solid preparation containing an insulin sensitizer alone as an... Agent: Edwards Angell Palmer & Dodge LLP

20070166377 - Sustained-release drug formulations: The present invention relates to a formulation for implantation having a novel constitution, which accomplishes controlled releases of active ingredients. The formulation comprises one of combinations (a), (b) and (c), as well as a carrier comprising a hydrophobic polymer, wherein the particle combination is dispersed into the carrier: (a) particles... Agent: Birch Stewart Kolasch & Birch

20070166378 - Oral ribavirin pharmaceutical compositions: The invention relates to oral pharmaceutical compositions for the prevention and/or the treatment of viral diseases. This invention also addresses methods of prevention and/or treatment of these viral diseases, using these oral compositions. One of the main problems considered in the present invention is to enhance the efficiency of anti-viral... Agent: Patton Boggs LLP

20070166379 - Coated tablet containing venlafaxin or its salts with controlled release: A venlafaxin containing coated tablet with controlled release, which contains venlafaxin, or its salt with an inorganic or carboxylic acid, in amounts from 20 to 60 weight %, and a hydrophilic polymer in amounts from 30 to 70 weight %, based on the weight of the core, in its core,... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070166380 - Zolpidem tablets: A zolpidem tablet having modified release is designed as a tablet-in-tablet dosage form.... Agent: SynthonIPInc

20070166381 - Osmotic dosage form with controlled release and fast release aspects: Disclosed are osmotic dosage forms and methods that provide for fast release of drugs together with controlled release of drugs. In an aspect, disclosed are osmotic dosage forms including: a semi-permeable membrane; a lubricating subcoat located within the semi-permeable membrane; an orifice in the semi-permeable membrane located at an end... Agent: Philip S. Johnson Johnson & Johnson

20070166383 - Anionic hydrogel matrices with ph dependent modified release as drug carriers: Compositions with pH-dependent modified release are described, consisting of hydrogel matrices containing one or more active ingredients, in which said matrices are suitable for releasing said active ingredients in a prolonged manner in given sites of the body.... Agent: Lucas & Mercanti, LLP

20070166382 - Bioresponsive polymer system for delivery of microbicides: The polymer systems of the present invention degrade in the presence of an ejaculate. They may further provide degradable sequences that degrade upon contact with an ejaculate and/or microbicides. The polymer systems of the present invention are of use in the oral, rectal or vaginal cavities of an individual for... Agent: The Mccallum Law Firm, P. C.

20070166384 - Methods , composition and preparations for delivery of immune response modifiers: A soluble IRM-polymer complex, preparations thereof, and methods of use, wherein the soluble IRM-polymer complex includes one or more IRM compounds attached (e.g., covalently attached) to a polymer (e.g., an alkylene oxide-containing polymer).... Agent: 3m Innovative Properties Company

20070166388 - Combinations and modes of administration of therapeutic agents and combination therapy: The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents (such as... Agent: Morrison & Foerster LLP

20070166387 - Hemostatic compositions, assemblies, systems, and methods employing particulate hemostatic agents formed from chitosan and including a polymer mesh material of poly-4-hydroxy butyrate: A granule or particle made of a chitosan material either carries within it a polymer mesh material of poly-4-hydroxy butyrate, or has interspersed with it a polymer mesh material of poly-4-hydroxy butyrate. The granule or particle can be carried within a polymer mesh socklet made of a material consisting essentially... Agent: Ryan Kromholz & Manion, S.c.

20070166385 - Method of inhibiting restenosis using bisphosphonates: A method of inhibiting the activity or production of cytokines or growth factors associated with vascular restenosis, by administering to an individual an effective amount of an active ingredient comprising a bisphosphonate particle or a bisphosphonate particulate. The bisphosphonate may be encapsulated, embedded or adsorbed within the particle, dispersed uniformly... Agent: Morgan & Finnegan, L.L.P.

20070166386 - Nanoparticle formation of pharmaceutical ingredients: A pharmaceutical ingredient is dissolved within a solvent. The solvent is evaporated until nanoparticles of the pharmaceutical ingredient are at least partially formed without employing a substrate for them. A portion of the solvent remains, within which the nanoparticles are located.... Agent: Hewlett Packard Company

20070166389 - Stabilized lyophilized blood platelets: A lyophilized platelet preparation, which is preferably a platelet enhanced plasma preparation, was obtained by stabilizing separated platelets with glyceraldehyde. In contrast to fixed preparations of cells, the platelet preparation is made and provided without toxins. Not fixing the platelets according to the invention provides increases utility and allows for... Agent: James Remenick Novak Druce & Quigg LLP

20070166390 - Method for cancer therapy using herbal extracts: A new method is described for the treatment of cancer. In one alternative, the method utilizes two main compositions. The first composition is Soma, a healing herb described in the Rig Veda, the sacred scriptures of the Hindus. The second composition is a composite of plant-derived substances and a mineral.... Agent: Catalyst Law Group, Apc

20070166391 - Material for treating mammalian joint maladies by biological fluid transplantation: Disclosed is a product and method for transplanting biological fluids into a host animal (including humans) that have been collected from donor animals. These biological fluids have been purified and processed so that they are acellular, sterile, pathogen free, and a form that can be stored for considerable periods of... Agent: Cochran Freund & Young LLC

20070166392 - Method of production of material for treating mammalian joint maladies by biological fluid transplantation: Disclosed is a product and method for transplanting biological fluids into a host animal (including humans) that have been collected from donor animals. These biological fluids have been purified and processed so that they are acellular, sterile, pathogen free, and a form that can be stored for considerable periods of... Agent: Cochran Freund & Young LLC

20070166393 - Pure pearl powder preparation method: A pure pearl powder preparation method of preparing a pure pearl powder by: (a) preparing pearl and washing the prepared pearl to remove sands and other, and then infusing the washed pearl in milk/soybean milk till that the milk/soybean milk becomes rancid, (b) washing the pearl with water to remove... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070166394 - Method for manufacturing biomedical bone material with concrete characteristic: A method for manufacturing biomedical bone material with concrete characteristic includes mixing different sizes of biomedical bones to form bone filler with concrete feature and characteristic. The biomedical bone material thus produced is featured by a solid having particles of different sizes, and a predetermined strength.... Agent: Rosenberg, Klein & Lee

20070166396 - Extracellular matrix based gastroesophageal junction reinforcement device: Provided are medical devices for implantation in patients having suffered the loss of or damage to at least part of their esophagus. The medical device connects the esophagus or remaining part thereof with the stomach to form a gastro-esophageal junction that promotes healing and encourages new host tissue growth while... Agent: Jesse A. Hirshman, Esq.

20070166395 - Medical graft products with differing regions and methods and systems for producing the same: Described are methods and systems for drying remodelable materials, such that selective regions of the remodelable materials have differing properties. Also described are medical graft products having selective regions of differing material properties. Advantageous remodelable materials include collagenous extracellular matrix material, such as small intestine submucosa.... Agent: Woodard, Emhardt, Moriarty, Mcnett & Henry LLP

20070166397 - Biocompatible tissue graft material for implant and method of making: This invention provides an antigen-free and immunologically inert tissue graft material and methods of preparing and using these tissue graft materials.... Agent: Faegre & Benson LLP Patent Docketing

20070166398 - Enhanced activity biocidal hydrogen peroxide composition: wherein X is H or OH, Y is H or CH3, n is 2-6 and R is an alkyl radical containing 4-18 carbon atoms, in a concentration of 0.01-60% (w/w). A especially preferred compound according to Formula 1 is a compound wherein X is OH, Y is H, n is... Agent: Oliff & Berridge, PLC

20070166399 - Silver-containing antimicrobial articles and methods of manufacture: A silver composition comprising silver sulfate, methods of making antimicrobial articles, particularly packaged antimicrobial articles, methods of whitening antimicrobial articles, and packaged antimicrobial articles.... Agent: 3m Innovative Properties Company

20070166400 - Pharmaceutical composition comprising i.a. vitamin c, magnesium green tea extract for retarding cardiovascular disease: The present invention provides pharmaceutical compositions comprising lysine, proline, arginine, vitamin C, magnesium, green tea extract, N-acetylcysteine, selenium, copper, manganese and one pharmaceutical acceptable component selected from the group consisting of a carrier, a diluent, and an excipient, wherein the pharmaceutical composition without the acceptable component contains 7-9 wt %... Agent: Kenyon & Kenyon LLP

20070166401 - Anticancer or antiviral composition: Disclosed is an anticancer or an antiviral composition comprising therapeutically effective amounts of citric acid and/or zinc and L-arginine along with a pharmaceutically acceptable carrier. The anticancer composition of the present invention has a strong anticancer effect while not having harmful side effects. The antiviral composition of the present invention... Agent: Sheridan Ross PC

20070166402 - Compositions, methods and kits for removing debris from an ocular area: The present invention is directed to compositions and kits for removing debris from an ocular area. The present invention is also directed to a method of removing debris from an ocular area.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070166403 - Method and compound for treating mold: A compound that both kills mold and prevents mold re-growth contains a mold killing disinfectant and a film-forming substance that forms a film layer on the treated surface for retaining the mold killing disinfectant in place. The film-forming substance preferably includes a prolamine. The preferred disinfectant includes iodine and a... Agent: Edell, Shapiro & Finnan, LLC

20070166404 - Composition and method for supporting cancer treatments: The present invention relates to a novel composition comprising geranium oil and extracts from the roots of the plants of the genus Sophora, preferably Sophora tonkinesis. Said composition can be administered to mammalian animals undergoing cancer treatments, such as chemotherapy and radiation therapy, that would induce the side effect of... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070166405 - Extracts of houttuynia cordata and rubus coreanus and their composition for preventing and treating allergic diseases: The present invention relates to an extract of Houttuynia cordata and Rubus coreanus, and a composition for the prevention and treatment of allergic diseases, comprising the same. The inventive extract and the composition comprising the same have the effect of preventing and treating allergic diseases by inhibiting the degranulation and... Agent: Buchanan, Ingersoll & Rooney PC

20070166406 - Hotplate emanation: A method of deactivating Der P and Der f allergens involves dispersing into an airspace an allergen deactivant, The deactivant being provided in a vessel and the vessel being in contact with a hotplate.... Agent: Norris, Mclaughlin & Marcus

20070166407 - Plant extracts and uses thereof: The present invention generally relates to plant extracts obtainable by extracting various plant materials with an alkaline agent, to methods for preparing such extracts, to compositions comprising such extracts, and to methods for using the extracts or compositions thereof.... Agent: Howrey LLP

20070166408 - Composition and method to augment and sustain neurotransmitter production: This invention describes a method and composition to enhance the synthesis and release of the neurotransmitters by the oral administration of neurotransmitter precursors, along with natural plant substances that stimulate uptake of the neurotransmitters precursors, while adding natural plant substances that activate adenylate cyclase in order to avoid attenuation and... Agent: Patton Boggs, L.L.P.

20070166409 - Therapeutic compositions containing trimethoprim and cranberry extract and methods for treating and preventing urinary tract infections: Therapeutic compositions for treating or preventing urinary tract infections in warm-blooded animals, including humans, contains a combination of trimethoprim or pharmaceutically salts thereof and cranberry extract in an effective amount to prevent, reduce or eliminate symptoms associated with the infection, and a pharmaceutically acceptable carrier. The resulting therapeutic composition can... Agent: Kenneth Watov, Esq. Watov & Kipnes, P.C.

20070166410 - Follicle-stimulating hormone releasing agent: The composition of the present invention comprising Cucurbita moschata, Carthamus tinctorius, Plantago asiatica and Lonicera japonica has a follicle-stimulating hormone reduction action. Based on this action, the composition is usable as a preventive, remedy, health food or functional food for diseases, for example, climacteric disturbance, primary hypogonadism (including ovarian hypofunction... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070166411 - Nutritional supplement containing long-chain polyunsaturated fatty acids: The present invention relates to a nutritional supplement for administration to children. The supplement comprises a protein component, a carbohydrate component, and a fat or lipid component which further comprises a source of DHA. The supplement has an ω-6:ω3 fatty acid ratio of about 6:1 or less. The present invention... Agent: Bristol-myers Squibb Company - Mead Johnson

20070166412 - Aspirin formulation for cardiovascular health: The invention relates generally to an aspirin formulation which may comprise additional vitamins, minerals, herbs and supplements and methods for using the same for maintaining cardiovascular health. The aspirin formulation may comprise supplements such as vitamin B6, vitamin B12, folic acid, arginine and garlic. The invention also encompasses methods for... Agent: Frommer Lawrence & Haug

20070166413 - Cholestrol-reducing agent containing an n-3 fatty acid: This invention relates to a cholesterol-reducing active substance combination containing at least one cholesterol-reducing carob product, particularly water-insoluble carob fibers, at least one n-3 fatty acid and at least one cholesterol-reducing active substance. The invention also relates to a method for producing active substance combinations of this type and to... Agent: Propat, L.L.C.

20070166414 - Method for enhancing tamoxifen efficacy as a cancer therapeutic: Disclosed is a method for enhancing the effectiveness of tamoxifen in the prevention and treatment of hormone-associated cancer such as breast cancer. Also disclosed is a method for decreasing the risk of endometrial hyperplasia and endometrial cancer associated with tamoxifen therapy. In the method, tamoxifen therapy is combined with administration... Agent: Donna J. Russell

20070166415 - Safe medicine for treating and preventing cancer and method of use: The present invention provides a new method for extracting Homoharringtonine (HHT) by culture cells or culture plant tissues. Also, disclosed are methods of obtaining HHT from semi-synthesis and biosynthesis. The present invention disclosed that HHT combined with some botanical drugs could induce cancer cells to resemble normal cells. To add... Agent: Yaguang Liu

20070166416 - Formulations and methods for preventing and treating substance abuse and addiction: The invention relates to formulations and methods for preventing and/or treating substance abuse, addiction, withdrawal symptoms, and anticipation associated with substance abuse. In particular the invention relates to formulations comprising at least one processed Morinda citrifolia L. product, and methods comprising the administration of at least one processed Morinda citrifolia... Agent: Kirton And Mcconkie

20070166417 - Formulation and methods for use of morinda citrifolia seed oil: The present invention relates to nutraceutical formulations and methods for use of fetid oil derived from Morinda citrifolia seeds. Research supporting this invention indicates that processed Morinda citrifolia seed products may be used for weight management and health promotion. The present invention is supported by research findings related to the... Agent: Kirton And Mcconkie

20070166418 - Treatment modalities for autoimmune diseases: Compositions of reduced isoalpha acids, vitamins and minerals are disclosed as well as methods of using the same for the treatment of autoimmune diseases. Additional combinations including other compounds are also contemplated. Synergistic properties and methods exploiting such synergy are also disclosed.... Agent: Mcdermott Will & Emery LLP

20070160562 - Delivery devices for hair-promoting cosmetic agent: The field of the present invention relates to improved cosmeceuticals capable of stimulating the growth of hair, e.g., natural eyelashes, in a human subject. More specifically, the present invention relates to delivery devices that provide for effective, targeted application of a therapeutically effective amount of the improved cosmeceuticals. Importantly, the... Agent: Craig A. Crandall, Apc

20070160526 - Detection, monitoring and treatment of cancer: and compounds comprising these aptamers and sequences. There are also disclosed compounds having the structure formula (I) and (II). There are also disclosed methods of treatment, diagnosis, detection and imaging using these compounds, their use in such methods, and their use in the preparation of medicaments and products for such... Agent: Woodcock Washburn LLP

20070160527 - Use of n-acetyl-d-aminoglycosamine in treatment of local lesions or systematic symptoms related to autoimmune reactions: The present invention discloses a method for treating local lesions or systematic symptoms caused by autoimmune reactions, a use of N-acetyl-D-glucosamine for treating local lesions or systematic symptoms caused by autoimmune reactions, and a use of N-acetyl-D-glucosamine in the manufacture of a medicament for treating local lesions or systematic symptoms... Agent: Seyfarth Shaw LLP

20070160530 - Antibodies and molecules derived therefrom that bind to steap-1 proteins: Antibodies and molecules derived therefrom that bind to novel STEAP-1 protein, and variants thereof, are described wherein STEAP-1 exhibits issue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, STEAP-1 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The... Agent: Heller Ehrman LLP

20070160528 - Method to evaluate the likelehood of development of bone metastasis based on the determination of calcium binding proteins: This invention provides methods to determine which patients with cancer will develop bone metastasis by determining the presence or levels of calcium binding proteins in the blood or other tissues of these patients. These calcium binding proteins include MRP14. In addition, this invention provides methods for treating patients with cancer... Agent: Novartis Corporate Intellectual Property

20070160529 - Radioimmunoconjugates for targeted alpha therapy: A radioimmunoconjugate for targeted alpha therapy comprises an alpha-emitter (e.g. Bi-213) linked to the monoclonal antibody C595. This radioimmunoconjugate is widely applicable in cancer therapy and is particularly efficient for treatment of pancreatic and prostate cancer, as well as for breast and ovarian cancer.... Agent: Cantor Colburn, LLP

20070160531 - Targeting endothelium for tissue-specific delivery of agents: Mechanisms and routes by which molecules can be delivered into cells, particularly endothelial cells, through the action of caveolae, G domains and other plasma membrane domains and components, are described, as are delivery systems comprising antibodies to caveolar proteins or receptors and also agents conjugated to the antibody or ligand,... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070160532 - Composition for medical use having improved water-solubility of peptide and metal-labeling efficiency and preparation for medical use comprising metal-labeled peptide: By preliminarily dissolving a basic organic compound in an aqueous solvent in which a peptide usable in metal-labeling is to be dissolved, the solubility of the peptide is improved and thus metal-labeling can be carried out without heating. A composition for medical use containing a peptide usable in metal-labeling and... Agent: Sughrue Mion, PLLC

20070160534 - Methods and compositions for prolonging elimination half-times of bioactive compounds: Peptide ligands having affinity for IgG or for serum albumin are disclosed. Also disclosed are hybrid molecules comprising a peptide ligand domain and an active domain. The active domain may comprise any molecule having utility as a therapeutic or diagnostic agent The hybrid molecules of the invention may be prepared... Agent: Heller Ehrman LLP

20070160533 - Pharmacokinetic modulation and compositions for modified fn3 polypeptides: The present disclosure relates to novel vascular endothelial growth factor receptor (VEGFR)-binding polypeptides and methods for using these polypeptides to inhibit biological activities mediated by vascular endothelial growth factors (VEGFs). The present disclosure also provides various improvements relating to single domain binding polypeptides.... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070160535 - Vexotoxin pharmaceutical compositions and medical treatments therewith: Pharmaceutical compositions comprising known verotoxins, particularly, verotoxin 1, have been found to be useful in the treatment of mammalian neoplasia, particularly, ovarian cancer and skin cancer. Surprisingly, although verotoxin 1 has previously been shown to have anti-neoplastic activity in vitro, non-lethal doses of verotoxin 1 have been shown to be... Agent: Lahive & Cockfield, LLP

20070160536 - Tumor activated prodrugs: The instant invention provides compositions comprising a prodrug, the prodrug comprising a therapeutically active drug; and a peptide selected from the group consisting of the sequences: Ser-Ser-Lys-Tyr-Gln (SEQ ID NO:1);Gly-Lys-Ser-Gln-Tyr-Gln (SEQ ID NO:2); and Gly-Ser-Ala-Lys-Tyr-Gln (SEQ ID NO:3) wherein the peptide is linked to the therapeutically active drug to inhibit... Agent: Edwards Angell Palmer & Dodge LLP

20070160538 - Antianxiety drugs and a method of screening the same: An anxiolytic drug of the invention comprises an orexin receptor antagonist, a pharmacologically acceptable salt thereof, or a solvate thereof as an active ingredient. A method for screening a compound having an anxiolytic action of the invention comprises a step of using orexin-A.... Agent: Darby & Darby P.C.

20070160539 - Hprp4s modifiers of the p53 pathway and methods of use: Human hPRP4 genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of hPRP4 are provided.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070160537 - In vivo screening method of therapeutic agent for memory/learning dysfunctions by schizophrenia: A method of evaluating memory/learning functions with the use of a model with glutamic acid N-methyl-D-aspartate (NMDA) type receptor hypofunction as an animal model for schizophrenia and with the use of reference memory task, wherein there has been found concrete means for detecting any differences in activity between typical anti-psychosis... Agent: Birch Stewart Kolasch & Birch

20070160540 - Ultrasonic diagnostic apparatus: There are provided transducers, transmission pulse generators for transmitting pulses to the transducers, a transmission power source for supplying power to the transmission pulse generators, and an output side capacitor 7 for stabilizing a voltage of the transmission power source. The transmission power source includes a plurality of mode-specific power... Agent: Hamre, Schumann, Mueller & Larson P.C.

20070160541 - Bronchodilating beta-agonist compositions and methods: Bronchodilating compositions and methods are provided. The compositions are intended for administration as a nebulized aerosol. In certain embodiments, the compositions contain formoterol, or a derivative thereof. Methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders using the compositions provided herein are also provided.... Agent: Lucas & Mercanti, LLP

20070160542 - Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile: The present invention relates to methods and systems for the delivery of a corticosteroid comprising (1) an inhalable aqueous mixture comprising a corticosteroid and a solubility enhancer and (2) an inhalable nebulizer, wherein the delivery of the aqueous mixture comprising the corticosteroid by the nebulizer results in an enhanced pharmacokinetic... Agent: Wilson Sonsini Goodrich & Rosati

20070160543 - Haemostatic sprays and compositions: The present invention is directed to a powder delivery system containing a composition comprising gelatine or collagen powder having a mean particle size of at least 10 μm. The gelatine or collagen powder is typically in dry form, i.e. no liquid components and/or propellants are added to the composition. The... Agent: King & Spalding LLP

20070160544 - Methods of modulating cell surface receptors to prevent or reduce inflammation: The invention includes a method of distinguishing among oral bacteria species to determine whether a species is orally deleterious. Such method includes contacting at least one bacterium or portion of a bacterium of a species of oral bacteria a gingival cell; and detecting the presence of an indicator compound. The... Agent: Colgate-palmolive Company

20070160545 - Method for reducing ultraviolet light induced apoptosis: The present invention provides a method for enhancing resistance to the onset of skin damage caused by irradiation of the skin with ultraviolet light by inhibiting ultraviolet irradiation-induced apoptosis of epidermal cells as a result of increasing expression of SCCA-1 and/or SCCA-2 in epidermal cells. Moreover, the present invention provides... Agent: Snider & Associates

20070160547 - Method of applying a composition: in which RD and RF each independently is a monovalent, divalent or trivalent hydrocarbon radical possessing from 2 to 8 carbon atoms or a monovalent, divalent or trivalent hydrocarbon radical possessing from one to sixty carbon atoms other than from 2 to 8 carbon atoms, provided that at least one... Agent: Dilworth & Barrese, LLP

20070160548 - Moisturizing sunless tanning composition: There is provided a sunless tanning composition having a tanning active system and a moisturizing system. The moisturizing system is oil-free, which mitigates and/or eliminates skin irritation and/or tanning active occlusion.... Agent: Charles N.j. Ruggiero Ohlandt, Greeley, Ruggiero & Perle, L.L.P.

20070160546 - Use of stinging cells/capsules for the delivery of active agents to keratinous substances: A composition of matter comprising an agent beneficial to a non-skin keratinous substance and at least one stinging capsule and methods of use are disclosed.... Agent: Martin D. Moynihan Prtsi, Inc.

20070160549 - Uv-radiation protectant compositions: A substantially aqueous composition comprising one or more particle encapsulated sunscreen active agents, at least one volatile additive, and at least one UV-radiation scattering agent, whereby the composition provides an SPF greater than 30.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070160551 - Penetrating carrier, anti-fungal composition using the same and method for treatment of dermatophytes: A liquid carrier for topical administration is provided that contains a mineral oil, turpentine and, optionally, camphor, and optionally other terpenoid components containing pinene, and its use to provide an antifungal composition a mixture of antifungal essential oils and the carrier system, wherein the mixture of antifungal essential oils includes... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070160550 - Skin lightening compositions: A skin lightening composition is provided which comprises components (a) a flavanoid, (b) vitamin C and (c) vitamin E wherein at least component (b) is provided in a form suitable for systemic administration with the other components being provided in a form suitable for topical administration.... Agent: Unilever Intellectual Property Group

20070160554 - Acyl ribonucleosides and acyl deoxyribonucleosides, compositions of, and methods of making same: The present invention is concerned with acyl ribonucleosides and with acyl deoxyribonucleosides. It is furthermore concerned with an enzymatic process for the manufacture of acyl ribonucleosides and of acyl deoxyribonucleosides. It is furthermore concerned with the use of acyl ribonucleosides and of acyl deoxyribonucleosides for cosmetic and for pharmaceutical purposes... Agent: Cognis Corporation Patent Department

20070160555 - Personal care compositions containing cationically modified starch and an anionic surfactant system: Personal care compositions comprise (a) from about 0.01 wt. % to about 10 wt. % of a water-soluble cationically modified starch polymer, wherein said water-soluble cationically modified starch polymer has a molecular weight from about 250,000 to about 15,000,000 and a charge density from about 0.2 meq/g to about 5... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070160557 - Preparation of polysaccharide betainate type compounds, compounds obtained, their use and compositions comprising them: A process for preparing compounds from the polysaccharide betainate family, novel compounds so obtained, and their use in. cosmetics or in dermatology, as well as the compositions, such as cosmetic or dermatological compositions, comprising said novel compounds.... Agent: Thomas L. Irving Finnegan, Henderson, Farabow, Garrett

20070160556 - Surfactant, and an emulsion-type cosmetic composition and a liposome containing said surfactant: wherein R represents a saturated or unsaturated acyl group having 8-22 carbon atoms, and may have a hydroxyl group or other substituents, and an emulsion-type cosmetic composition comprising said surfactant and a water-soluble polymer. The surfactant of the invention has excellent surface activity and safety. Also, the emulsion-type cosmetic composition... Agent: Day Pitney LLP

20070160558 - Peptide composition: Provided is use of a peptide, or a derivative of a peptide, in the manufacture of a medicament effective in stimulating fibroblasts to produce fibrillin,wherein the peptide comprises an amino acid sequence present in an α-S2 casein precursor, said sequence comprising 3 or more amino acids, and not comprising at... Agent: Dechert LLP

20070160560 - Cosmetic composition comprising at least one fixative polymer and at least one surfactant chosen from ionic and nonionic surfactants: o

20070160559 - Skin disinfectant composition and methods for using: A skin disinfectant composition is provided according to the invention. The skin disinfectant composition comprises an effective amount of a disinfectant active component to provide disinfectant properties to skin tissue, an effective amount of a skin bonding polymer component to hold the disinfectant active component to skin tissue so that... Agent: Merchant & Gould PC

20070160561 - Amphiphilic star block copolymers: The present invention relates to a basically spherical hyperbranched block copolymer having an internal hydrophobic block and an external hydrophilic block. Within the spherical copolymer, the hydrophobic block constitutes a hydrophobic layer, suitable to associate or encapsulate hydrophobic bioactive agents, while the hydrophilic block provides an outer layer, which is... Agent: Winston & Strawn LLP Patent Department

20070160552 - Hair cosmetizer and process for producing the same: A hair cosmetizer of the present invention is such that the hair cosmetizer including an oily material, which is solid at ordinary temperature, is dissolved into water or is dispersed therein by compounding a water-soluble organic medium with a cosmetic material being the major component of the hair cosmetizer. And,... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070160553 - Use of agents for the cosmetic treatment of keratin-containing material: h

20070160564 - Compositions containing legume products: The present invention features legume products having trypsin inhibitory activity and reduced microbial content, methods of decontaminating such legume products, compositions containing such legume products, and the topical application of such legume products or compositions to skin, nails, and hair.... Agent: Philip S. Johnson Johnson & Johnson

20070160563 - Extract of r. miehei: Topical compositions comprising extracts of Rhizomucor miehei that are substantially devoid of acid-protease activity and their use in treating dermatologic conditions, including reducing the appearance of signs of skin aging.... Agent: Louis C. Paul, Esq.

20070160565 - Polymeric aromatic n-halo sulfonamides: p

20070160567 - Allergen suppressor, allergen-suppression processed fiber and method of producing the same: It is an object of the present invention to provide an allergen suppressor exerting an effect of suppressing an allergen under humidities normally used, and an allergen-suppression processed fiber, which can suppress an allergen adhering to fibers automatically without applying an allergen-suppression process and a method of producing the same.... Agent: Sughrue Mion, PLLC

20070160569 - Medical adhesive and methods of tissue adhesion: An adhesive including a mixture of isocyanate capped molecules formed by reacting multi-isocyanate functional molecules with multi-functional precursor molecules including terminal functional groups selected from the group consisting of a hydroxyl group, a primary amino group and a secondary amino group. Preferably, the functional groups are hydroxyl groups. The multi-functional... Agent: Bartony & Hare, LLP

20070160568 - Polyamino acids functionalized by at least one hydrophobic group and the therapeutic application thereof: The invention relates to novel materials based on biodegradable polyamino acids that are useful for vectorizing active principle/s (AP). The aim of the invention is to supply a new polymeric raw material that is used for vectorizing AP and optimally fulfills all requirements concerning biocompatibility, biodegradability, the ability to be... Agent: Patton Boggs LLP

20070160566 - Anti-microbial and oxidative co-polymer: A process for preparing aseptic water and an apparatus useful for carrying out that process, both of which utilize a contemplated polymeric oxidizing medium are disclosed, as are processes for oxidizing trivalent arsenic or antimony to pentavalent arsenic or antimony and for removing arsenic from water. Alumina particles containing meta-periodate,... Agent: Welsh & Katz, Ltd

20070160575 - Anth1 chimeric antagonist: A recombinant chimeric antagonist formed by a 60 amino acid fragment of the N-terminal region of human interleukin 2 (IL-2) fused to the N-terminal of the extracellular region of the alpha subunit of the gamma IFN (IFN γ) receptor. In vitro this protein has a T cell growth stimulating activity,... Agent: Hoffmann & Baron, LLP

20070160570 - Chimeric polypeptides containing chemokine domains: This invention provides a chimeric DNA molecule comprising a sequence encoding a chemokine polypeptide covalently attached to a heterologous polypeptide, the encoded chimeric polypeptide, and uses thereof.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070160572 - Colloidal metal compositions and methods: The present invention comprises compositions and methods for delivery systems of agents, including therapeutic compounds, pharmaceutical agents, drugs, detection agents, nucleic acid sequences and biological factors. In general, these vector compositions comprise a colloidal metal, derivatized PEG (polyethylene glycol) and an agent. The invention also comprises methods and compositions for... Agent: John S. Pratt, Esq Kilpatrick Stockton, LLP

20070160571 - Composition and method for inducing protective vaccine response: A method for inducing a protective immune response is disclosed, the method utilizing a composition comprising a CXCR3-binding chemokine such as CXCL10 (IP-10) administered in conjunction with a protein, peptide, polynucleotide, or other target antigen.... Agent: Donna J. Russell

20070160574 - Design of cxc chemokine analogs for the treatment of human diseases: The present invention generally relates to the design, preparation, derivation, and use of mimetics of CXC chemokines (CXCL1-CXCL17) in the prevention, treatment, and ameliorization of a wide variety of diseases and disorders. Generally speaking, this invention is directed to the design, synthesis, and use of chemokine analogs which bind to... Agent: Perkins Coie LLP

20070160573 - Peptide conjugated anti-cancer prodrugs: The present invention relates to pharmaceutical compositions that include a targeting peptide, a protease specific cleavable peptide, and a chemotherapeutic drug that when conjugated are substantially inactive, but upon degradation of the cleavable sequence by a proteolytic enzyme abundant in or within the target cancer cell, the chemotherapeutic drug is... Agent: Winston & Strawn LLP Patent Department

20070160578 - Expansion of natural killer and cd8 t-cells with il-15r/ligand activator complexes: The disclosure provides methods, and compositions for use in methods, for expanding lymphocyte populations in vitro, ex vivo, and in vivo using IL-15Rα/IL-15 activator complexes.... Agent: Klarquist Sparkman, LLP

20070160576 - Il-17a/f heterologous polypeptides and therapeutic uses thereof: The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17F designated herein as interleukin 17A/F (IL-17A/F). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present... Agent: Genentech, Inc.

20070160577 - Interleukin-11 compositions and methods of use: The present invention provides methods for the treatment and/or prevention of thrombocytopenia including thrombocytopenia associated with drug-induced liver damage and thrombocytopenia associated with drug-induced bone marrow destruction. The methods of treatment of the invention include administration of interleukin-11 to a subject suffering from or susceptible to thrombocytopenia and/or receiving or... Agent: Choate, Hall & Stewart LLP

20070160579 - Methods of modulating a mammalian cytokine: Provided are methods of modulating cytokine activity, e.g., for the purpose of treating immune and inflammatory disorders, including tumors and cancer. Also provided are methods of administering agonists or antagonists of IL-33 and IL-33 receptor.... Agent: Dnax Research Inc. Legal Department

20070160580 - Interferon gamma therapies for idiopathic pulmonary fibrosis: The present invention provides methods of treating idiopathic pulmonary fibrosis (IPF); methods of increasing survival time in an individual with IPF; and methods of reducing risk of death in an individual with IPF. The methods generally involve administering a therapeutically effective amount of IFN-&ggr, to an individual with IPF.... Agent: Marshall, Gerstein & Borun LLP

20070160581 - Production of ssdna in vivo: Methods and compositions comprising a DNA expression cassette for producing ss-cDNA inside a host cell (in vivo). The expression system optionally contains a reverse transcriptase/RNAse H coding gene, and a restriction endonuclease gene. The cassette carries cloning sites in two distinct locations for cloning and expressing a sequence of interest.... Agent: Cytogenix, Inc.

20070160587 - Allogeneic tumor therapeutic agent, a vaccine using allogeneic tumor cells for the therapeutic treatment of tumor diseases, and a method for the making of such a vaccine, and transfected human tumor cells for use as a vaccine: Vaccine on the basis of allogeneic tumor cells for the therapeutic treatment of tumor diseases, and a method for the making of such vaccine, furthermore transfected human tumor cells for their use as a vaccine. The abstract of the disclosure is submitted herewith as required by 37 C.F.R. §1.72(b). As... Agent: Nils H. Ljungman, Esquire Nils H. Ljungman & Associates

20070160586 - Methods for extending the replicative lifespan of cells: The present invention is directed to methods for enhancing the replicative capacity of cells, by culturing the cells in the presence of an active agent or compound which inhibits SIRT1. One method provides expanding stem cells by culturing the cells in the presence of a SIRT1 inhibitor. The resulting cultured... Agent: David S. Resnick

20070160585 - Remedy for prion disease and method of producing the same: It is intended to provide a drug which is efficacious in treating a prion disease and has a high safety. A remedy for a prion disease which contains a mesenchymal stem cell as the active ingredient and a method of producing the same. A remedy for a prion disease which... Agent: Licata & Tyrrell P.C.

20070160588 - Treatment of peripheral vascular disease using postpartum-derived cells: Compositions and methods of using cells derived from postpartum tissue such as the umbilical cord and placenta, to stimulate and support angiogenesis, to improve blood flow, to regenerate, repair, and improve skeletal muscle damaged by a peripheral ischemic event, and to protect skeletal muscle from ischemic damage in peripheral vascular... Agent: Woodcock Washburn LLP

20070160589 - Probiotic food, process for its preparation and dietary regimen: A probiotic food item containing a beneficial amount of dry active probiotic cultures is provided. The food item also contains a substantial continuous fat-based coating with an effectively low water activity level. The food item is packaged in a substantially moisture impermeable package marked with a use by or sell... Agent: Morrison & Foerster LLP

20070160582 - Apparatus and methods for amplification of blood stem cell numbers: The present invention provides an apparatus and methods for expansion of hematopoietic stem cell numbers. The stem cells are cultured and differentiated cells and endogenous growth factors are removed (depleted), permitting long term culture and expansion of the stem cells. The hematopoietic stem cells are used in numerous therapeutic procedures.... Agent: Foley & Lardner LLP

20070160583 - Method for purifying mesenchymal stem cells: The invention relates to a method for purifying mesenchymal stem cells, producing cells corresponding to prior art, the cells obtained being characterised by an increased proliferation capacity while maintaining the multipotency and typical antigen characteristics. To this end, mesenchymal stem cells that can be multiplied in a significantly improved manner... Agent: Arnold & Porter LLP Attn:IPDocketing Dept.

20070160584 - Method of bone regeneration: It is an object of the present invention to provide a method for effectively regenerating bone, and more specifically to provide a method for regenerating bone that is capable of treating patients suffering from bone defect or bone injury. The present invention provides a method for regenerating bone, which comprises... Agent: Antonelli, Terry, Stout & Kraus, LLP

20070160590 - Metabolic uncoupling therapy: A combination of chemical agents reduces reductive stress by limiting the accumulation of high-energy electrons potentially available to the electron transport chain. A method of metabolic uncoupling therapy comprises: analyzing a specific physiologic process involving reductive stress; identifying a plurality of MUT agents that modulate metabolic pathways by influencing electron... Agent: Patton Boggs LLP

20070160591 - Peri-operative and peri-procedure nutritional supplementation: The invention provides a nutritional supplement system and program for patients undergoing or who have undergone a surgical or other invasive or stressful procedure, or who have suffered an injury. This nutritional supplement for the peri-operative period is designed to prevent deficiencies of nutrients needed for optimal health and healing... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070160592 - Method for treatment of macular degeneration: The present invention provides a method for treating macular degeneration utilizing a therapeutic agent delivery system that is disposed in proximity of the sclera after which one or more therapeutic agents are injected or diffused into the sclera to provide for the dissolution of waste products in Bruch's membrane.... Agent: Offices Of Craig Gregersen

20070160593 - Sugar chain-cleaving agent: A sugar chain-cleaving agent, which comprises a protein having activity of degrading chondroitin and/or chondroitin sulfate; a medicament which comprises the sugar chain-cleaving agent as an active ingredient; a method for specifically cleaving a sugar chain, which comprises reacting the protein with chondroitin and/or chondroitin sulfate; and a method for... Agent: Sughrue Mion, PLLC

20070160594 - Method of diagnosing and treating cartilaginous disorders: The present invention is directed to novel polypeptides having sequence similarity to human inter-alpha-trypsin inhibitor and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide... Agent: Genentech, Inc.

20070160595 - Human tumor necrosis factor tr20 and methods based thereon: The present invention relates to TR20 polypeptides. In particular, isolated nucleic acid molecules are provided encoding human TR20 protein. TR20 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR20... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20070160598 - Binding polypeptides with diversified and consensus vh/vl hypervariable sequences: The invention provides variant hypervariable regions comprising selected amino acid sequence diversity. Libraries comprising a plurality of these polypeptides are also provided. In addition, methods of and compositions for generating and using these polypeptides and libraries are provided.... Agent: Genentech, Inc.

20070160597 - Optimized fc variants and methods for their generation: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.... Agent: Morgan, Lewis & Bockius, LLP

20070160596 - Proline rich acidic protein and uses thereof: The present invention relates to isolated polynucleotide comprising a sequence selected from the group consisting of: (a) a polynucleotide comprising a sequence encoding the polypeptide SEQ ID NO:3 or a biologically active or immunogenic fragment thereof; (b) a polynucleotide comprising a sequence encoding the polypeptide SEQ ID NO:4 or a... Agent: Conley Rose, P.C.

20070160599 - Thimerosal removal device: A device for the removal of heavy metals and heavy metal complexes, such as thimerosal, from medications is provided wherein the device comprises a dosing device or a solid support having at least one substantially purified metallothionein protein associated therewith. Additionally, methods to remove thimerosal from medications are provided.... Agent: Kirkpatrick & Lockhart Preston Gates Ellis LLP

20070160603 - Antibodies against tumor necrosis factor delta (april): The present invention relates to antibodies and related molecules that immunospecifically bind to Tumor Necrosis Factor Delta (TNF-delta; APRIL). The present invention also relates to methods and compositions for detecting, diagnosing, prognosing, treating, preventing, or ameliorating a disease or disorder associated with aberrant APRIL or APRIL receptor expression or aberrant... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20070160600 - Compositions and methods of monoclonal and polyclonal antibodies specific for t cell subpopulations: The invention provides compounds and methods for the ex vivo or in vivo expansion of NK T cells, CD1d-reactive T cells, and JαQ+ T cells, and the modulation of their activities. These compounds and methods have diagnostic and therapeutic applications.... Agent: Clark & Elbing LLP

20070160602 - Compositions and methods of using galectin-8 as an inhibitor of tumor cell growth: The present invention provides compositions that enhance or inhibit the interactions of galectin-8 and galectin-8-like proteins with other extracellular matrix proteins or cell surface receptors, and methods for the use thereof as physiological modulators of cell adhesion and in treatment of tumors, both in vivo or ex vivo. It further... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070160601 - Neutralizing antibodies against primate psgl-1 and uses therefor: This application relates to neutralizing antibodies that specifically bind primate PSGL-1, as well as their production and use. The antibodies reduce one or more activities of PSGL-1, such as human PSGL-1. Methods to detect or quantitate PSGL-1 in a biological sample by adding an antibody that specifically binds to PSGL-1... Agent: Wyeth/finnegan Henderson, LLP

20070160604 - Methods of identifying compounds capable of modulating t cell immune responses involving sema4a protein: The invention relates to a novel costimulatory pathway mediated by a member of the semaphorin protein family, Sema4A, which is selectively expressed on the surface of dendritic cells. In addition, the invention relates to the use of Sema4A protein and protein derivatives in a method for the identification of immunomodulatory... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070160607 - Humanized monoclonal antibodies that protect against shiga toxin induced disease: The present invention describes the preparation and use of biologically and immunologically active humanized monoclonal antibodies to Shiga toxin, a toxin associated with HC and the potentially life-threatening sequela HUS transmitted by strains of pathogenic bacteria. The present invention describes how these humanized antibodies may be used in the treatment... Agent: Clark & Elbing LLP

20070160609 - Interferon antagonists useful for the treatment of interferon related diseases: The present invention relates to a process for ameliorating or preventing diseases that are caused, in part, by an increased level of, and/or an abnormal responsivity to, interferon. Specifically, the invention provides compositions and methods for preventing and treating subjects suffering from, or at risk for, such diseases. Such methods... Agent: Burns & Levinson, LLP

20070160612 - Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders: The present invention is directed to interleukin-22 polypeptides and nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of... Agent: Genentech, Inc.

20070160605 - Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody: The invention features methods and compositions for preventing or treating post-surgical pain by administering an anti-NGF antagonist antibody.... Agent: Morrison & Foerster LLP

20070160610 - Methods of treating pain and inflammation in neuronal tissue using il-31 antagonists: Use of antagonists to IL-31 are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.... Agent: Zymogenetics, Inc. Intellectual Property Department

20070160611 - Methods of treating pain and inflammation in neuronal tissue using il-31ra and osmrb antagonists: Use of antagonists to IL-31Ra and OSMRb are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include soluble receptors, antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.... Agent: Zymogenetics, Inc. Intellectual Property Department

20070160613 - Monoclonal antibodies to hepatocyte growth factor: The present invention is directed toward a neutralizing monoclonal antibody to hepatocyte growth factor, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.... Agent: Townsend And Townsend And Crew, LLP

20070160606 - Treating renal cell carcinoma with an anti-tnf human antibody or fragment: The present invention relates to at least one novel anti-TNF antibody, including isolated nucleic acids that encode at least one anti-TNF antibody, TNF, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices, including the treatment of renal cell carcinoma.... Agent: Philip S. Johnson Johnson & Johnson

20070160608 - Treatment with anti-vegf antibodies: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.... Agent: Genentech, Inc.

20070160614 - Human timp-1 antibodies: Human antibodies that bind to TIMP-1 can be used as reagents to diagnose and treat disorders in which TIMP-1 is elevated, such as liver fibrosis, alcoholic liver disease, cardiac fibrosis, acute coronary syndrome, lupus nephritis, glomerulosclerotic renal disease, benign prostate hypertrophy, colon cancer, lung cancer, and idiopathic pulmonary fibrosis.... Agent: Lisa A. Haile, J.d., Ph.d. Dla Piper Rudnick Gray Cary US LLP

20070160615 - Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease: The subject invention provides methods of treating amyloidogenic diseases, comprising the administration of therapeutically effective amounts of a composition comprising a carrier and an agent that interferes with the interaction of CD40L and CD40R to an individual afflicted with an amyloidogenic disease. Also provided are methods and/or assay systems for... Agent: King & Spalding LLP

20070160616 - Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof: Monoclonal antibodies directed against amyloid beta peptide and methods of using same for treatment and prevention of Alzheimer's disease and Down's syndrome are described.... Agent: Morrison & Foerster LLP

20070160618 - Cardiotrophin-1 compositions and methods for the treatment of tumor: The invention concerns compositions and methods for the diagnosis and treatment of neoplastic cell growth and proliferation in mammals, including humans. The invention is based on the identification of cardiotrophin-1 gene amplified in the genome of tumor cells. Such gene amplification is expected to be associated with the overexpression of... Agent: Genentech, Inc.

20070160619 - Ctla-4 antibody dosage escalation regimens: A disease or condition, such as cancer or an infectious disease, can be treated in a patient by administering a CTLA-4 antibody in an escalating dosage regimen until a partial or complete response is elicited in the patient or a predetermined maximum dosage is reached.... Agent: Baker Botts L.L.P.

20070160617 - Psma antibody-drug conjugates: This invention relates generally to antibody-drug conjugates (ADCs). In particular, the invention relates to ADCs which comprise an antibody or antigen-binding fragment thereof which binds to prostate-specific membrane antigen (PSMA) and is conjugated to monomethylauristatin norephedrine or monomethylauristatin phenylalanine. The antibody-drug conjugate has a PC-3™ cell to C4-2 or LNCaP™... Agent: Wolf Greenfield & Sacks, P.C.

20070160620 - Immune responses using compositions containing stress proteins: The present invention relates to a vaccine for inducing an immune response to an antigen in a vertebrate (e.g., mammal) comprising an antigen and all or a portion of a stress protein or all or a portion of a protein having an amino acid sequence sufficiently homologous to the amino... Agent: Fish & Richardson PC

20070160621 - Heat shock proteins from mycobacterium leprae and uses thereof: The present invention is directed to heat shock proteins from Mycobacterium leprae as well as their encoding polynucleotides and vectors and host cells containing these polynucleotides. These heat shock proteins and their encoding polynucleotides are useful in detection of Mycobacterium leprae. In addition, the heat shock protein can be used... Agent: Nixon Peabody LLP - Patent Group

20070160623 - Innate immune system-directed vaccines: The present invention provides novel vaccines, methods for the production of such vaccines and methods of using such vaccines. The novel vaccines of the present invention combine both of the signals necessary to activate native T-cells—a specific antigen and the co-stimulatory signal—leading to a robust and specific T-cell immune response.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070160622 - Method for assembling a polymer-biologic delivery composition: A one-step method for assembly of delivery compositions for one or more antigens or therapeutic biologics is based on non-covalent affinity capture of molecules from solution using a biodegradable polymer having functional groups to which the affinity ligand binds. The polymer-bound affinity complex, which includes the molecule(s) of interest is... Agent: Dla Piper US LLP

20070160624 - Anthrax and small pox replikins and methods of use: Isolated peptides of the Bacillus anthracis Anthrax Toxin Lethal factor Protein pX01-107, antibodies specific for the peptides and methods of stimulating the immune response of a subject to produce antibodies to the Bacillus anthracis Anthrax Toxin Lethal factor Protein pX01-107 are disclosed. Also disclosed are isolated peptides of the Small... Agent: Kenyon & Kenyon LLP

20070160625 - Marasmius androsaceus l.es fr extract, piperidone derivative, and their use for the preparation of antihypertensives: The present invention relates to Marasmius androsaceus L.es Fr extract, a compound of formula I, or pharmaceutically acceptable salts thereof, and to methods for their preparation, pharmaceutical composition comprising the same as well as use of the extract or the compound in the preparation of a medicament for the prevention... Agent: Alston & Bird LLP

20070160626 - Medicinal composition for liver diseases: The invention provides a composition containing extracts from salvia miltiorrhiza bunge, gynostemma pentaphyllummak, Chinese magnoliavine, cordyceps extract piece, pollen pini, and semen persicae and methods of and using the same.... Agent: Squire, Sanders & Dempsey L.L.P.

20070160627 - Modified vaccinia virus ankara (mva) mutant and use thereof: The present invention is directed to a MVA mutant and its use in the immunotherapy and vaccination against numerous diseases, in particular in the prevention and therapy of cancer and infectious diseases.... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20070160630 - Hepatitis-c virus 4, 5 and 6: The present invention relates to a polynucleic acid composition comprising or consisting of at least one polynucleic acid containing 8 or more contiguous nucleotides corresponding to a nucleotide sequence from the region spanning positions 417 to 957 of the Core/E1 region of HCV type 3; and/or the region spanning positions... Agent: Alston & Bird LLP

20070160629 - Purified active hcv ns2/3 protease: A method for producing a refolded, inactive form of recombinantly produced NS2/3 protease which comprises the steps of: a) purifying the protease from inclusion bodies in the presence of a chaotropic agent; and b) refolding the purified protease by contacting it with a reducing agent and lauryldiethylamine oxide (LDAO) in... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070160628 - Stabilized virus-like particles and epitope display systems: A chimeric polypeptide is disclosed that comprises: i) a first portion that self-assembles into an organized, repetitive, supramolecular structure that contains at least about 9 subunits, covalently linked to ii) a second polypeptide portion that comprises a peptide having a length of about 15 to about 80 amino acid residues.... Agent: Edward P. Gamson

20070160631 - Novel immunogenic lipopeptides comprising t-helper and cytotoxic t lymphocyte (ctl) epitopes: The present invention provides synthetic immunogenic lipopeptide molecules comprising co-linear T-helper and CTL epitopes, and methods for their production and use in the generation of primary and secondary immune responses, and for the vaccination of animal subjects against particular CTL epitopes. More particularly, the present invention provides highly soluble lipopeptides... Agent: Fenwick & West LLP

20070160632 - Polyinosinic acid-polycytidylic acid-based adjuvant: The present invention provides a polynucleotide adjuvant composition and methods of use in eliciting an immune response. The present invention also provides an immunogenic composition comprising the polynucleotide adjuvant composition together with an antigen (e.g., as in a vaccine). The adjuvant compositions of the invention have particular physical properties (e.g.,... Agent: Bozicevic, Field & Francis LLP

20070160633 - Methods for enhancing therapeutic effects of a neurotoxin: The present invention relates to methods for enhancing the therapeutic effects of a neurotoxin, e.g., a botulinum toxin, where the methods comprise a “wash-down” (e.g., a decreased intake) of a current pain medication and an administration of a neurotoxin. In some embodiments, the present inventions relates to methods for enhancing... Agent: Stephen Donovan Allergan, Inc.

20070160634 - Methods for reducing somatic cell count in milk: In an embodiment, the present invention is directed to a method of reducing the somatic cell count in milk including administering an effective amount of a toxin to a mammal. In some embodiments, the toxin administered has a modified disulfide loop region. For example, at least 40% of the amino... Agent: Klarquist Sparkman, LLP

20070160635 - Cosmetic composition textured with a specific asymmetric bis-urea derivative: The present invention relates to a cosmetic composition with a liquid fatty phase, comprising, in a physiologically acceptable medium, at least one liquid fatty phase, in which the said phase is textured with an effective amount of at least one asymmetric bis-urea compound of defined formula.... Agent: Oliff & Berridge, PLC

20070160636 - Low-density expanded cosmetic composition: The present invention relates to an expanded cosmetic composition for caring for and/or making up keratin materials, comprising, in a physiologically acceptable medium, at least one aqueous phase and a filler, the said composition having a density of less than or equal to 0.12 g/cm3.... Agent: Oliff & Berridge, PLC

20070160637 - Pest control agent, method for manufacture of pest control agent, and method for pest control: Disclosed are a pest control agent, a method for preparing a pest control agent, and a method for controlling a pest. Generally, the pest control agent is formed by providing a porous starch and an active control agent absorbed within the porous starch, and compressing the porous starch in the... Agent: Banner & Witcoff, Ltd.

20070160638 - Hemostatic agent delivery system: A hemostatic agent delivery system includes a hemostatic agent which is inert and non-reactive yet is capable of forming a stable clot when applied to an actively bleeding wound. The system also includes a delivery assembly to structure to facilitate delivery of the hemostatic agent proximate the hemorrhage site. More... Agent: Malloy & Malloy, P.A.

20070160643 - Siloxane prepolymer containing pendant cationic and polymerizable groups: The present invention relates to polymeric compositions useful in the manufacture of biocompatible medical devices. More particularly, the present invention relates to certain cationic random copolymers capable of polymerization to form polymeric compositions having desirable physical characteristics useful in the manufacture of ophthalmic devices. Such properties include the ability to... Agent: Glenn D. Smith Bausch & Lomb Incorporated

20070160641 - Coated medical devices and methods of making the same: The present invention relates generally to coated medical devices, preferably a stent, that has a drug-eluting surface completely or partially coated with a coating that comprises two or more forms of a biologically active material. In particular, the invention is directed to a coated medical device having a coating that... Agent: Jones Day

20070160639 - Drug delivery systems using mesoporous oxide films: Sustained-release drug-delivery devices employing a mesoporous oxide coating that functions as a drug reservoir, and the use of mesoporous oxide coatings for improved adhesion of organic polymers to inorganic substrates.... Agent: Kirkpatrick & Lockhart Preston Gates Ellis LLP Attn: C. Rachal Winger

20070160640 - Halofuginone delivering vascular medical devices: A medical device comprising halofuginone is provided. The medical device is adapted for implantation or insertion into a blood vessel and it provides a cumulative, in vivo, 14 day release that lies between 0.02 μg and 0.2 μg of halofuginone per mm2 of stent surface area.... Agent: Mayer & Williams PC

20070160642 - Implantable medical devices coated with a polymer-bound superoxide dismutase mimic: This invention relates to implantable medical devices having a coating comprising small molecule superoxide dismutase mimics bonded to biocompatible durable polymers and to uses thereof in the treatment or prevention of vascular diseases.... Agent: Squire, Sanders & Dempsey LLP

20070160647 - Materials for medical implants and occlusive devices: An embodiment is a swellable medical device that swells after introduction into a patient to occlude a lumen or void in a patient. The device may be anisotropically swellable so that it swells unequally in some dimensions to create an improved fit of the device into the patient. Anisotropically swellable... Agent: Dardi & Associates, PLLC US Bank Plaza

20070160644 - Methods and compositions for promoting attachment of cells of endothelial cell lineage to medical devices: The present invention provides compositions and methods for an improved coating for medical devices. Provided is a biofunctional coating composition comprising at least one binding domain that has binding specificity for a surface material of a medical device, and at least one binding domain that has binding specificity for cells... Agent: M. Bud Nelson, Ph.d., J.d. Affinergy, Inc.

20070160645 - Postconditioning system and method for the reduction of ischemic-reperfusion injury in the heart and other organs: A postconditioning method and system for preventing injury to an organ or tissue in a subject during or after reperfusion following an ischemic event to the organ or tissue. The system can exemplarily include a catheter configured for insertion therein a vessel of the subject; a means for modulating the... Agent: Needle & Rosenberg, P.C.

20070160646 - Stent coated by a compound: p

20070160648 - Methods for treating otic disorders: Loss of hearing can be treated by implanting a sustained-release drug delivery device in the inner ear. The slow delivery of medication from the implanted device to the tissues of the ear, including the inner ear, can treat numerous conditions of the ear while avoiding the side effects associated with... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070160649 - Siloxane prepolymer containing pendant and end-capping cationic and polymerizable groups: The present invention relates to polymeric compositions useful in the manufacture of biocompatible medical devices. More particularly, the present invention relates to certain cationic random copolymers capable of polymerization to form polymeric compositions having desirable physical characteristics useful in the manufacture of ophthalmic devices. Such properties include the ability to... Agent: Glenn D. Smith Bausch & Lomb Incorporated

20070160650 - Composition and method to augment and sustain neurotransmitter production: This invention describes a method and composition to enhance the synthesis and release of the neurotransmitters by the oral administration of neurotransmitter precursors, along with natural plant substances that stimulate uptake of the neurotransmitters precursors, while adding natural plant substances that activate adenylate cyclase in order to avoid attenuation and... Agent: Patton Boggs, L.L.P.

20070160653 - Hemostatic textile: The present invention is directed to a hemostatic textile, comprising: a material comprising a combination of glass fibers and one or more secondary fibers selected from the group consisting of silk fibers; ceramic fibers; raw or regenerated bamboo fibers; cotton fibers; rayon fibers; linen fibers; ramie fibers; jute fibers; sisal... Agent: Wiggin And Dana LLP Attention: Patent Docketing

20070160652 - Microemulsions: A microemulsion with a mean particle diameter of 5-20 nm includes 5-50% by weight of at least one alkyl and/or alkenyl oligoglycoside carboxylic acid salt corresponding to formula (I): R1O[G]pO[(CH2)mCOO−X+]n (I) wherein R1 is an alkyl and/or alkenyl group containing 4-22 carbon atoms, G is a sugar unit containing 5... Agent: Cognis Corporation Patent Department

20070160651 - Nanoemulsions: A nanoemulsion with a mean particle diameter of 20 to 250 nm including 5 to 50% by weight of at least one alkyl and/or alkenyl oligoglycoside carboxylic acid salt corresponding to formula (I): R1O[G]pO[(CH2)mCOO−X+]n wherein R1 is an alkyl and/or alkenyl group containing 4-22 carbon atoms, G is a sugar... Agent: Cognis Corporation Patent Department

20070160654 - Gel-forming fabric composite: A method for the manufacture of a reinforced gel-forming fabric composite comprising a reinforcing layer and gel-forming fibre material is characterized in that the gel-forming fibre material in non-woven fabric form is needled into the reinforcing layer from one side so as to penetrate through the reinforcing layer and form... Agent: Bristol-myers Squibb Company

20070160655 - Hydroxyamate-containing materials for the inhibition of matrix metalloproteinases: Therapeutic polymers containing a hydroxamate group that preferentially binds to active forms of a matrix metalloproteinases, thus inhibiting their enzymatic activity. The implantation of such material modifies tissue turnover and remodelling in its vicinity.... Agent: Riches, Mckenzie & Herbert LLP

20070160658 - Delivery system for diagnostic and therapeutic agents: Nanovesicles are specifically targeted to abnormal cells. The targeting moiety is conjugated to the nanovesicle which comprises a therapeutic composition. These nanovesicles are useful in treatment of a wide spectrum of disorders.... Agent: Akerman Senterfitt

20070160656 - Lipid platinum complexes and methods of use thereof: This invention provides novel lipid platinum complexes, liposomally encapsulated lipid platinum complexes, pharmaceutical compositions comprising a lipid platinum complex, and methods for treating cancer using a lipid platinum complex. Kits comprising a unit dosage form of a compound or composition of the invention are also provided.... Agent: Jones Day

20070160657 - Targeting and intestinal-absorption controlled liposome having sugar chain and therapeutic drug for cancer and diagnostic drug containing the liposome: An object of the present invention is to provide a liposome having a sugar chain bonded thereto, the sugar chain having an activity of specifically binding to various lectins (sugar chain recognizing proteins) present on the cell surfaces of various tissues and thus being capable of actually distinguishing a cell... Agent: Sughrue Mion, PLLC

20070160660 - Compositions for oral use based on s-adenosylmethionine and a process for their preparation:

20070160661 - Aspirin formulation for cardiovascular health: The invention relates generally to an aspirin formulation which may comprise additional vitamins, minerals, herbs and supplements and methods for using the same for maintaining cardiovascular health. The aspirin formulation may comprise supplements such as vitamin B6, vitamin B12, folic acid, arginine and garlic. The invention also encompasses methods for... Agent: Frommer Lawrence & Haug

20070160662 - Method and apparatus for blowmoding capsules of polyvinylalcohol and blowmolded polyvinylalcohol capsules: A capsule is formed from a PVA composition by blow moulding. Such capsules can at last provide a viable alternative to gelatin for biodegradable capsules containing a pharmaceutical or consumable or other substance, for example, a detergent. The capsules may contain solid or liquid substances. Blow moulding apparatus suitable for... Agent: Stites & Harbison PLLC

20070160659 - Stabilized formulations of phosphatidylserine: Disclosed are stable PS preparations, in powder, liquid and dispersion forms, as well as methods of producing thereof. Most importantly, the stable PS preparations are particularly devoid of residual phospholipase D activity, and the methods of eliminating such activity are also described herein. Lastly, uses of these PS preparations in... Agent: Fleit Kain Gibbons Gutman Bongini & Bianco

20070160664 - Pharmaceutical compositions comprising of proton pump inhibitor and prokinetic agent: Oral pharmaceutical compositions and process for preparation thereof are provided comprising at least one gastric acid suppressing agent, preferably a proton pump inhibitor or its pharmaceutically acceptable salts, esters, hydrates, derivatives or prodrugs, and one or more prokinetic agent or its pharmaceutically acceptable salts, esters, hydrates, derivatives or prodrugs, optionally... Agent: Ladas & Parry

20070160663 - Single unit pharmaceutical composition comprising a mixture of fenofibrate and a modified release form of a homocysteine reducing agent: An oral lipid lowering pharmaceutical unit form comprising a first solid or semi solid composition comprising fenofibrate and a second solid or semi solid composition comprising at least a modified release form of an homocysteine lowering agent.... Agent: Merchant & Gould PC

20070160665 - Chlorthalidone combinations: The invention relates to favourable combinations of the thiazide diuretic chlorthalidone with Angiotensin II Receptor Blockers (ARBs) for the treatment of hypertension.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070160666 - Pharmaceutical formulation: The instant invention provides a pharmaceutical composition comprised of a cholesterol absorption inhibitor and an HMG-CoA reductase inhibitor, one or more anti-oxidants, microcrystalline cellulose, hydroxypropyl methylcellulose, magnesium stearate and lactose. The composition need not contain ascorbic acid in order to obtain desirable stability.... Agent: Foley And Lardner LLP Suite 500

20070160667 - Controlled release formulation of divalproex sodium: The present invention provides a controlled release dosage formulation comprising a) about 40% to about 80% of a valproic acid compound such as Divalproex Sodium and b) at least two, preferably hydrophilic, polymers each in an amount of less than about 20% of the dosage weight.... Agent: Kenyon & Kenyon LLP

20070160668 - Prolonged release bioadhesive therapeutic systems: The present invention concerns a prolonged release bioadhesive mucosal therapeutic system containing at least one active principle, with an active principle dissolution test of more than 70% over 8 hours and to a method for its preparation. Said bioadhesive therapeutic system comprises quantities of natural proteins representing at least 50%... Agent: Birch Stewart Kolasch & Birch

20070160669 - Delayed release carnitine: A sustained release, orally administered pharmaceutical composition comprising carnitine and an acceptable pharmaceutical excipient is described for the treatment of carnitine deficiency and other carnitine responsive conditions. The sustained release formulation avoids the characteristic problems of gastrointestinal invitation, dumping in the urine and bacterial degradation attendant previously known oral formulations... Agent: Lucas & Mercanti, LLP

20070160670 - Compression-coated tablets and manufacture thereof: Tablets for the treatment of migraine comprise a core, containing the active agent sumatriptan or a pharmaceutically-acceptable salt or ester thereof, and a mantle, free of sumatriptan. Tablets are prepared by compressing mantle components, free of the active agent, around a partially-compressed, active-containing core.... Agent: Christensen, O'connor, Johnson, Kindness, PLLC

20070160671 - Biguanide formulations: In certain embodiments, the invention is directed to a pharmaceutical dosage form consisting essentially of a single phase matrix comprising metformin or a pharmaceutically acceptable salt thereof and at least one controlled release excipient; said dosage form providing a mean Tmax of metformin from about 3 to about 12 hours... Agent: Davidson, Davidson & Kappel, LLC

20070160672 - Methods of making bioabsorbable drug delivery devices comprised of solvent cast films: A bioabsorbable drug delivery device and various methods of making the same. The devices are preferably formed from bioabsorbable materials using low temperature fabrication processes, whereby drugs or other bio-active agents are incorporated into or onto the device and degradation of the drugs or other agents during processing is minimized.... Agent: Philip S. Johnson Johnson & Johnson

20070160673 - Amoxicilline instant granulate: A novel process for preparing stable granulate which comprises amoxicillin trihydrate and a sugar, and to novel stable granulate comprising amoxicillin trihydrate and the sugar as well, for reconstitution with water into fine stable homogeneous aqueous suspension is described. The novel process omits preliminary process step for preparing fine particle... Agent: Novartis Corporate Intellectual Property

20070160674 - Method for producing calcium component powder containing oil-soluble substance: The present invention provides a method for producing a powder containing an oil-soluble substance, fromn which substantially no oil-soluble substances are eluted upon application of pressure, heat, or water. The present invention relates to a method for producing a powder containing an oil-soluble substance, which comprises, dispersing an oil-soluble substance... Agent: Greenblum & Bernstein, P.L.C

20070160675 - Nanoparticulate and controlled release compositions comprising a cephalosporin: The present invention provides a composition comprising cephalosporin useful in the treatment and prevention of a bacterial infection. In one embodiment, the composition comprises nanoparticulate particles comprising cephalosporin and at least one surface stabilizer. The nanoparticulate particles have an effective average particle size of less than about 2000 nm. In... Agent: Synnestvedt & Lechner LLP

20070160676 - Stable dispersion of dbnpa in viscosified brine: A dispersion of 2,2-dibromo-3-nitrilopropionamide (“DBNPA”) particles in a restrictedly viscosified concentrated brine solution effectively negates gelling of the brine solution because the naturally occurring gum used does not exhibits Ellis-Plastic behavior in the concentrated brine at a pH of from about 1 to 4. Because the DBNPA particles are much... Agent: Alfred D. Lobo & Co., L.p.a.

20070160677 - Encapsulation of lipid-based formulations in enteric polymers: A microcapsule comprising a lipid-based core that is encapsulated in an enteric polymer shell providing enhanced bioavailability of a sparingly water-soluble drug as well as modulated release of the drug, wherein the microcapsule is, on one embodiment, prepared by a centrifugal coextrusion process. The lipid-based core comprises lipids carriers, either... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070160678 - Microcapsules with modified release of active principles with low solubility for oral delivery: The present invention is directed to microcapsules for reliably modified release and adapted to industrial reproduction of an active principle hardly water-soluble, other than anti-hyperglycemia agents. Each of said microcapsules comprises a core of hardly soluble active principle and a coating film applied on the core. Their mean diameter is... Agent: Patton Boggs LLP

20070160679 - Repair of ruptured membrane by injection of naturally occurring protein in amniotic fluid: The present invention provides compositions and methods for use in treatment of premature rupture of membranes. The compositions of the invention include a therapeutic amount of an avian thick egg white composition. Preferably, the compositions include the purified thick egg white protein, ovomucin. The methods of the invention involve injecting... Agent: Fulbright & Jaworski L.L.P.

20070160680 - Fluid composition used to stimulate human synovial fluid: An artificial synovial fluid comprising a serum, a chelator, and a buffer is provided. In particular embodiments, the artificial synovial fluid may further comprise an antibiotic. The artificial synovial fluid is generally used in tribological testing of medical device implants such as artificial joints. Methods of using and making the... Agent: Foley & Lardner LLP

20070160681 - Bone graft and scaffolding materials immobilized with osteogenesis enhancing peptides on the surface: The present invention relates to a bone graft material and a scaffold for tissue engineering applications, which have an osteogenesis-promoting peptide immobilized on the surface. More particularly, the invention relates to a bone graft material and a scaffold for tissue engineering applications, which have a cell adhesion-inducing peptide and/or tissue... Agent: Intellectual Property / Technology Law

20070160682 - Inorganic boranophosphate salts: The invention provides novel inorganic boranophosphate salts that can be used as fertilizers, in detergent formulations, as additive in melts for the glass industry, in boron neutron-capture therapy of cancer, and as synthetic building blocks in the synthesis of boranonucleotides of various lengths.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070160683 - Electrolyte supplement and method of use: A method of managing dehydration in an animal includes administering a first electrolyte solution having an SID range at or below 25 mEq/l. After administering the first electrolyte solution, the animal's health condition is observed to determine the effect of the first solution. If the animal's health condition has not... Agent: Westman Champlin & Kelly, P.A.

20070160684 - Methods for increasing cancer cell chemosensitivity: The expression of HMGA2 is often associated with neoplastic transformation. The present disclosure establishes a correlation between increased HMGA2 expression and enhanced chemosensitivity towards DNA-damaging therapeutic agents such as doxorubicin, cisplatin, and X-ray irradiation.... Agent: Perkins Coie LLP

20070160685 - Methods for treating a neoplastic disease in a subject using inorganic selenium-containing compounds: The invention features methods and selenium-containing compositions for treating a neoplastic disease in a subject. In particular, the invention features methods for enhancing sensitivity of a tumor to cancer therapy by treating the tumor with an inorganic selenium-containing (iSe) compound and with a cancer therapy, particularly a cancer therapy that... Agent: Bozicevic, Field & Francis LLP

20070160687 - Composition for prevention and treatment of diabetic complication: The present invention relates to a composition for the prevention and treatment of diabetic complications, which contains an extract obtained by: crushing and drying any one selected from Euphorbiae radix, gingered Magnolia bark, parched Puerariae radix and Glycyrrhizae radix; extracting the dried herbal material with alcohol or aqueous alcohol solution:... Agent: Ladas & Parry

20070160686 - Oil of coriander, oil of coriander-containing compositions having anitmicrobial and antiphlogistic effects and their use: The invention relates to the use of oil of coriander for the prophylaxis and/or therapy of inflammatory diseases and/or of microbe caused or secondary infection diseases of the skin, of the mucous membranes and of the oral cavity.... Agent: Greenblum & Bernstein, P.L.C

20070160688 - Use of flavonoids to increase blood serum levels of dehydroepiandrosterone: A method is disclosed for increasing blood serum levels of dehydroepiandrosterone by administering the combination of one of a flavonoid, isoflavonoid, coumarin and a flavonolignan; dehydroepiandrosterone; and a plant extract.... Agent: Miller, Canfield, Paddock And Stone P.L.C C/o Robert Kelley Roth

20070160689 - Compositions and methods for treatment of coughing, sneezing, rhinorrhea, and/or nasal obstruction: The present invention relates to compositions that comprise an expectorant, an extended release antitussive, and an extended release decongestant. Specifically, the compositions comprise guaifenesin, phenylephrine tannate, and dextromethorphan tannate. The present invention also includes methods for using these compositions for treatment of patients suffering from, for example and without limitation,... Agent: Kirkpatrick & Lockhart Preston Gates Ellis LLP

20070160690 - Composition and method to augment and sustain neurotransmitter production: This invention describes a method and composition to enhance the synthesis and release of the neurotransmitters by the oral administration of neurotransmitter precursors, along with natural plant substances that stimulate uptake of the neurotransmitters precursors, while adding natural plant substances that activate adenylate cyclase in order to avoid attenuation and... Agent: Patton Boggs, L.L.P.

20070160691 - Pharmaceutical composition for treating and preventing cancer comprising cinnamoni cortex extract and zizyphi fructus extract: Disclosed is a pharmaceutical composition for treating and preventing cancer, comprising a Cinnamoni Cortex extract and a Zizyphi Fructus extract. The pharmaceutical composition has effects of inducing apoptosis of cancer cells and inhibiting metastasis of cancer cells, as well as having a synergistic effect in inhibiting the growth of cancer... Agent: Lucas & Mercanti, LLP

20070160692 - Compositions that treat or inhibit pathological conditions associated with inflammatory response: A natural formulation of compounds that would to modulate inflammation is disclosed. The formulation would also inhibit expression of COX-2, inhibit synthesis of prostaglandins selectively in target cells, and inhibit inflammatory response selectively in target cells. The compositions containing at least one fraction isolated or derived from hops. Other embodiments... Agent: Mcdermott Will & Emery LLP

20070160693 - Plant-based medicament for the treatment of hepatitis c: The present invention relates to a botanical drug or dietary supplement for use in the treatment of patients suffering from Hepatitis C virus infection. More particularly, it relates to a botanical drug consisting essentially of four botanical drug substances, optionally formulated with excipients, for use either in alleviating the symptoms... Agent: Dickinson Wright PLLC

20070160694 - Preventives or remedies for tumor or human papillomaviral disease: A composition for foods or medicaments, containing a fermentation product or an enzyme-treated product that is either obtained by fermenting or treating with an enzyme at least one type of component selected from the husks, pellicles and astringent skin of Coix seeds.... Agent: Birch Stewart Kolasch & Birch

20070160695 - Pharmaceutical preparations for treating hypertension and dyslipidemia with allium ursinum and allium sativum: Wild Garlic (Bear's or Forest Garlic, Allium ursinum) can be combined with cultivated high-allicin garlic (Allium sativum) and extracts of the same to take advantage of the previously unknown synergism of preparations made from these two garlic species. There is a substantial cost savings over the use of pure, Wild... Agent: Dallas L Clouatre

20070160696 - Compositions and methods useful for prevention or treatment of respiratory illness: Disclosed herein are compositions and methods useful for the treatment of respiratory illness in a mammal, such as wherein these compositions and methods are effective in preventing the onset of one or more of the symptoms of such respiratory illness or significantly mitigating the symptom if the mammal is already... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070160697 - Cancer metastasis inhibitory composition: It is intended to provide a cancer metastasis inhibitor which shows a potent effect of inhibiting cancer metastasis comparable to bikunin, has no side effect and can be obtained in a large amount at a low cost. As the results of studies on the cancer metastasis inhibitory effect by administration... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070160698 - Muscular strength enhancing agent: The present invention relates to a muscular strength enhancing agent produced from fruits, and provides a strength enhancing agent or a body-fat regulating agent, derived from natural products, that may enhance muscle strength, decrease body fat or suppress body-fat accumulation without decreasing the amount of skeletal muscle or the weight... Agent: Jackie Jay Schwartz

20070160699 - Composition comprising hovenia dulcis thunb. extract, lindera obtusiloba blume extract, or herbal mixture extract thereof: Hovenia dulcis Thunb extract, Lindera obtusiloba extract or herbal mixture extract thereof of the present invention promotes cell viability in liver and kidney cell lines, indicating that the extract has excellent liver and kidney cell protective effects. Therefore, the composition of the present invention can be effectively used not only... Agent: Greenlee Winner And Sullivan P C

20070160701 - Hemostatic mistura of ipomoea balatas leaves, methods of preparation and use thereof: Jinshuye styptic compositions, preparation methods and applications thereof are disclosed. A Jinshuye styptic composition is a plant preparation made by extracting leaf and stem of sweet potato (Ipomoea batatas, Jinshu), by purification and water extraction to obtain polysaccharides as active ingredients from the raw materials. Such a composition has the... Agent: Osha Liang L.L.P.

20070160700 - Methods and compositions for reactivating acetylcholinesterase: The present invention relates to methods and compositions for reactivating Acetylcholinesterase in living organisms using contents from the Morinda citrifolia L. plant. More particularly, the present invention relates to methods and compositions involving the reactivation of Acetylcholinesterase using fruit juice obtained from the Morinda citrifolia L. plant.... Agent: Michael F. Krieger

20070160703 - Method of using guava extract and composition including guava extract: A method of using guava extract is disclosed that includes administering alcohol to a mammal, and administering guava extract within no greater than about 12 hours of administering of the alcohol. A composition is also disclosed that includes a pharmaceutically acceptable carrier and guava extract.... Agent: Mr Keith S Campbell

20070160702 - Method of using guava extract and composition including guava extract: A method of using guava extract is disclosed that includes administering alcohol to a mammal, and administering guava extract within no greater than about 12 hours of administering of the alcohol. A composition is also disclosed that includes a pharmaceutically acceptable carrier and guava extract.... Agent: Allison Johnson, P.A.

20070160704 - Colonies of nostoc commune, methods for cultivating edible nostoc commune and edible nostoc commune formulations and their use for promoting health: Nostoc formulations, dietary supplements comprising the Nostoc formulations, and food products comprising Nostoc commune, (also known as Nostoc sphaericum, or Nostoc commune var. sphaericum) are disclosed. Nostoc formulations that may additionally comprise a medicinal composition are described. The present invention further relates to processes for producing these Nostoc formulations. In... Agent: Kilpatrick Stockton LLP

20070154390 - Nuclear molecular imaging contrast agent: and 1 is not less than 1; D is a C3-30 dendritic moiety having a plurality of oxygen residue; Z is a C3-20 moiety having a plurality of functional groups, wherein the functional groups comprise carbonyl, carboxyl, amine, ester, amide, or chelate group; L is a radioisotope or analyte-specific moiety... Agent: Birch Stewart Kolasch & Birch

20070154396 - Block copolymers and nano micelles comprising the same: A block copolymer. The block copolymer has formula A-B-C, wherein A represents polyester, B represents polyamide, and C represents specific molecular groups or metal complexes. The invention also provides a nano micelle and drug carrier including the block copolymer.... Agent: Birch Stewart Kolasch & Birch

20070154397 - Thermosensitive nanostructure for hyperthermia treatment: A thermosensitive nanostructure for hyperthermia treatment. Magnetic nanoparticles are encapsulated in a thermosensitive polymer nanostructure having a lower critical solution temperature (LCST) of about 40-45° C. The thermosensitive polymer nanostructure may carry a drug. When the magnetic nanoparticles are heated to 40-45° C. by application of an alternating magnetic field... Agent: Birch Stewart Kolasch & Birch

20070154412 - Dentifrices comprising biogenic silica materials: Unique dentifrices comprising unique abrasive biogenic silica materials are provided. Such compositions exhibit excellent abrasive characteristics, either alone, or in combination with other types of abrasives. In such combinations (with precipitated silica materials, as one example), simultaneously high pellicle film cleaning properties and moderate dentin abrasion levels are possible in... Agent: J M Huber Corporation

20070154413 - Dentifrices comprising biogenic silica materials: Unique dentifrices comprising unique abrasive biogenic silica materials are provided. Such compositions exhibit excellent abrasive characteristics, either alone, or in combination with other types of abrasives. In such combinations (with precipitated silica materials, as one example), simultaneously high pellicle film cleaning properties and moderate dentin abrasion levels are possible in... Agent: J M Huber Corporation

20070154391 - Antibodies to vascular endothelial cell growth factor: The present invention provides monoclonal antibodies, and portions thereof, which are capable of specifically binding to human vascular endothelial cell growth factor (hVEGF) or hVEGF-related protein. The invention also provides hybridoma cell lines that produce such monoclonal antibodies. The monoclonal antibodies of the invention are useful as therapeutic agents, either... Agent: Genentech, Inc.

20070154392 - Treatment process using somatostatin analogues: wherein Z is optionally present or absent and when present is selected from the group consisting of DOTA-based chelators, DTPA-based chelators, NOTA-based chelators, carbonyl compounds, hydrazino nicotinamide, N4-chelators, desferrioxamine, NXSY-chelators, tyrosine for halogenation, a fluorescent dye, and biotin; L is optionally present or absent and when present is a linker... Agent: Patterson & Sheridan, L.L.P.

20070154393 - Bioassay for volatile low molecular weight insecticides and methods of use: The subject invention pertains to materials and methods for screening of volatile insecticides for activity against pests, such as those that pose a threat to public health (e.g., dipterans such as flies and mosquitoes). One aspect of the invention pertains to an apparatus and bioassay for screening volatile compounds for... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070154394 - Diagnostic agents for pancreatic exocrine function: e

20070154398 - Block copolymers and nano micelles comprising the same: A block copolymer. The block copolymer has formula A-B-C, wherein A represents polyester, B represents polyamide, and C represents specific molecular groups or metal complexes. The invention also provides a nano micelle and drug carrier including the block copolymer, wherein the drug carrier is delivered by oral, transdermal administration, injection,... Agent: Birch Stewart Kolasch & Birch

20070154395 - Methods and kits for assays of rapid screening of diabetes: The invention provides an in vivo screening assay and an in vitro screening assay for rapid screening of diabetes. A method of the invention includes determining a first glucose concentration in an ocular fluid of a patient; administering orally a load of carbohydrate to the patient; determining a second glucose... Agent: Ciba Vision Corporation Patent Department

20070154399 - Immunotherapy for immune suppressed patients: A diagnostic skin test for predicting treatment outcome, consisting essentially of an effective amount of an NCM or a T lymphocyte mitogen of muromonab-CD3. A kit for performing a skin test consisting essentially of an effective amount of an NCM or a T lymphocyte mitogen of muromonab-CD3. A method of... Agent: Kenneth L. Kohn Kohn & Associates, PLLC

20070154400 - Compositions and methods for enhanced mucosal delivery of parathyroid hormone: Pharmaceutical compositions and methods are described comprising at least a parathyroid hormone peptide (PTH) preferably PTH1-34 and one or more mucosal delivery-enhancing agents for enhanced nasal mucosal delivery of PTH, for treating or preventing osteoporosis or osteopenia in a mammalian subject, preferably a human.... Agent: Nastech Pharmaceutical Company Inc

20070154401 - Compositions and methods for enhanced mucosal delivery of parathyroid hormone: Pharmaceutical compositions and methods are described comprising at least a parathyroid hormone peptide (PTH) preferably PTH1-34 and one or more mucosal delivery-enhancing agents for enhanced nasal mucosal delivery of PTH, for treating or preventing osteoporosis or osteopenia in a mammalian subject, preferably a human.... Agent: Nastech Pharmaceutical Company Inc

20070154403 - Oral, pulmonary and transmucosal delivery composition: Provided, among other things, is a delivery composition comprising: an aqueous carrier; a lipid component suspended in the carrier comprising significant amounts of type A lipid, fatty acid, and bilayer-stabilizing steroid(s), wherein type A lipid is one or more of any of phospholipid, ceramide(s) sphingomyelin(s) and glucocerebroside(s); and a bioactive... Agent: Law Offices Of Arthur E. Jackson

20070154402 - Topical pharmaceutical foam composition: A stable topical alcohol-free aerosol foam containing one or more keratolytic agents is provided. The foam-forming formulation is an emulsion which contains an HFA propellant and one or more keratolytic agents. The emulsion has an oil phase and an aqueous, i.e. water-containing, phase. The active agent(s) may be present in... Agent: Patrea L. Pabst Pabst Patent Group LLP

20070154405 - aerosol apparatus containing a composition for applying simultaneously several topical stimuli: The invention comprises an aerosol apparatus containing a non-flammable, water-based composition, the viscosity of which composition is from 0.2 to 30 mPa·s at 20° C., which apparatus is adapted in use to release cool water-based particles for the simultaneous topical application of thermal and mechanical kinetic energy stimuli for skin... Agent: Nelly K. Rizk 8 Knighton Close

20070154408 - Inhalable biodegradable microparticles for target-specific drug delivery in tuberculosis and a process thereof: The present invention relates to a biodegradable microparticle composition useful for the target specific drug delivery to manage pulmonary tuberculosis, said composition comprising two anti-tuberculosis drugs, and a biodegradable polymer for drug delivery in a ratio of about 1:2 to 2:1, wherein the anti-tubercular drugs are in the ratio of... Agent: Sughrue Mion, PLLC

20070154407 - Inhaler and store for a dry medicament formulation and related methods and use thereof: An inhaler, a store and a method for atomizing a dry medicament formulation are disclosed. The medicament formulation is first dissolved by a liquid solvent and then atomized together with the solvent. This allows easy metering and satisfactory storage of the medicament formulation in the dry state. Particularly preferably, the... Agent: Roberts, Mlotkowski & Hobbes

20070154404 - Insulin highly respirable microparticles: The invention describes novel dried powders of peptide therapeutic agent useful for producing highly respirable aerosols and the methods for their manufacture. Insulin is the peptide therapeutic agent in the preferred embodiment. The powders of insulin prepared for pulmonary administration are characterized by the peculiar structure and shape of the... Agent: William Collard Collard & Roe, P.C.

20070154406 - Spray-dried collectin compositions and process for preparing the same: The present invention relates to a spray-dried composition comprising as an active ingredient at least one member protein of the collectin family or its functional equivalent for treating and preventing microbial infectious diseases. The present invention also relates to a method for producing the same composition. The composition produced by... Agent: Gordon & Rees LLP

20070154409 - Chewable tooth paste tablet: The present invention is a method of brushing teeth consisting of the steps of placing a tooth cleansing tablet into the user's month, chewing the tablet into a paste and then manually brushing the teeth with the paste using a tooth brush. The tooth cleansing tablet consists of a quantity... Agent: Elias C. Borges

20070154410 - Mouthwash composition for the prevention of dental diseases: A mouthwash composition for inhibiting the buildup of plaque on dental surfaces and preventing dental diseases consisting essentially of an aqueous solution of alkali metal chlorides as active agents wherein the active agents include 0.5 % to 8.0 % by weight of at least one of the alkali metal chlorides... Agent: Julia Joungmy Kim

20070154411 - Oral and dental care product: The invention relates to oral and dental hygiene products comprising a) a composite material consisting of calcium salts which are slightly soluble in water, in the form of nanoparticulate primary particles having a length of from 5 to 150 nm and a cross section of from 2 to 50 nm... Agent: Paul & Paul

20070154414 - Antibacterial oral rinse formulation for preventing coronary artery disease: The present invention provides an antibacterial oral rinse formulation having enhanced antibacterial activity against oral bacteria associated with infectious and inflammatory processes for preventing and/or treating inflammatory diseases or inflammatory processes associated with diseases in an individual by inhibiting the transient bacteremia associated with oral hygiene activities by the individual.... Agent: Eckert Seamans Cherin & Mellott

20070154415 - Inorganic light-absorbing micropigments and use thereof: Inorganic light-absorbing micropigments to which aluminium phosphates are applied are used in sunscreens or cosmetics emulsions.... Agent: Birch Stewart Kolasch & Birch

20070154422 - Method of treating skin needing ablative treatment: A treatment regimen for treating skin subject to an ablative treatment involves the application of supplemental composition(s) such as preparatory composition(s), protective composition(s), and combinations thereof, and a corrective composition.... Agent: Carter, Deluca, Farrell & Schmidt, LLP

20070154421 - Method of treating skin needing collagen treatment: A treatment regimen for treating skin subject to a collagen procedure involves the application of supplemental composition(s) such as preparatory composition(s), protective composition(s), and combinations thereof, and a corrective composition.... Agent: Carter, Deluca, Farrell & Schmidt, LLP

20070154416 - Method of treating skin needing hyaluronic acid treatment: A treatment regimen for treating skin subject to a cosmetic hyaluronic acid procedure involves the application of supplemental composition(s) such as preparatory composition(s), protective composition(s), and combinations thereof, and a corrective composition.... Agent: Carter, Deluca, Farrell & Schmidt, LLP

20070154419 - Method of treating skin requiring chemical peel procedure: A treatment regimen for treating skin subject to chemical peel procedures involves the application of supplemental composition(s) such as preparatory composition(s), protective composition(s), and combinations thereof, and a corrective composition.... Agent: Carter, Deluca, Farrell & Schmidt, LLP

20070154417 - Method of treating skin requiring non-ablative procedure: A treatment regimen for treating skin subject to non-ablative procedures involves the application of supplemental composition(s) such as preparatory composition(s), protective composition(s), and combinations thereof, and a corrective composition.... Agent: Carter, Deluca, Farrell & Schmidt, LLP

20070154418 - Method of treating skin requiring radiofrequency procedure: A treatment regimen for treating skin subject to radiofrequency procedures involves the application of supplemental composition(s) such as preparatory composition(s), protective composition(s), and combinations thereof, and a corrective composition.... Agent: Carter, Deluca, Farrell & Schmidt, LLP

20070154420 - Method of treating skin subject to or affected by aesthetic surgical procedures: A treatment regimen for treating skin subject to aesthetic surgical procedures involves the application of supplemental composition(s) such as preparatory composition(s), protective composition(s), and combinations thereof, and a corrective composition.... Agent: Carter, Deluca, Farrell & Schmidt, LLP

20070154423 - Nail varnish comprising a cellulose ester and short ester solvents in a defined ratio: The subject of the present invention is a nail varnish comprising a cellulose ester and an organic solvent medium comprising ethyl acetate and butyl acetate in an ethyl acetate/butyl acetate ratio ranging from 87/25 to 100/1. The subject of the present invention is also the use of such a varnish... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070154424 - Cosmetic: A cosmetic containing L-ascorbic acid 2-phosphate sodium salt that excels in long-term stability. In particular, there is provided a cosmetic characterized in that L-ascorbic acid 2-phosphate sodium salt (A) and at least one compound (B) selected from the group consisting of arginine, urea and triethanolamine are contained in a mixing... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070154425 - Use of tyrosine-arginine dipeptide and niacinamide as substance p antagonist: Use of the combination of the tyrosine-arginine dipeptide or derivatives thereof and of niacinamide as a substance P antagonist for treating red blotches on the skin, skin oedema and sensitive skin. Use of this combination for the preparation of a composition for use in treating disorders associated with an excess... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070154426 - Powdered water cosmetic compositions and related methods: A powdered water color cosmetic composition comprising a water phase comprised of water droplets, and a particulate phase comprised of non-wetting particulates operable to surround and sequester the individual water droplets from each other in the composition, and a stabilizing effective amount of at least one water insoluble super absorbent... Agent: Julie Blackburn Revlon Consumer Products Corporation

20070154427 - Preparations with deodorizing action comprising the zinc salt of ricinoleic acid and at least one amino functional amine acid: Preparations with deodorizing action are provided. The preparations include the zinc salt of ricinoleic acid; amino-functional amino acids; solubility promoters; organic and/or inorganic acids; and, optionally, water.... Agent: Scully Scott Murphy & Presser, PC

20070154428 - Thiazole derivative: e

20070154429 - Perfluorocyclobutane crosslinked hydrogels: This invention provides water-swellable articles and hydrogels that contain a hydrophilic polymer and perfluorocyclobutane crosslinking segments. The perfluorocyclobutane crosslinking segments are covalently attached to the polymeric chains of the hydrophilic polymer so that the crosslinking segments chemically link the polymeric chains to each other. The present invention also provides a... Agent: Wood, Herron & Evans, LLP (zimmer)

20070154430 - Polymeric antioxidants: wherein: R is —H or a substituted or unsubstituted alkyl, acyl or aryl group; Ring A is substituted with at least one tert-butyl group or substituted or unsubstituted n-alkoxycarbonyl group; Ring B is substituted with at least one —H and at least one tert-butyl group or substituted or unsubstituted n-alkoxycarbonyl... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070154432 - Compositions and methods for hair growth: A composition that promotes hair growth includes a lipophilic compound, such as a fatty acid, an allantoin, and a therapeutically effective amount of a biologically active substance. The fatty acid can be a palmitic, palmitoleic, stearic, oleic, linoleic, linolenic, arachidic, eicosenoic, behenic, erucic, myristic acid, and lignoderic fatty acid. The... Agent: Rutan & Tucker, LLP. Hani Z. Sayed

20070154434 - Cosmetic compositions containing a particular aminosilicone and a thickener, and uses thereof: A novel cosmetic composition comprising, in a cosmetically acceptable medium, at least one aminosilicone of as defined herein having, for example, a contact angle ranging from 90° to 180° and at least one thickener, being able to afford at least one improved cosmetic property (such as lightness, disentangling, volume and... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070154431 - Novel polymers and uses thereof: wherein A is an olefin polymer having a weight average molecular weight of 400 to 500,000; R is H, an alkyl group, or an aralkyl group; W and Z are each O, HN, or S; and x and y are each 0 or 1, with the proviso that at least... Agent: Buchanan, Ingersoll & Rooney PC

20070154433 - Tissue treatment method: A method of treatment of a scar comprising applying a topical silicone gel to the scar, and wiping off the excess to leave a thin layer of the gel on the scar. Applications of the topical silicone gel can be alternated with applications of silicone gel sheeting to the scar.... Agent: Barnes & Thornburg LLP

20070154441 - Cosmetic compositions containing a particular aminosilicone and a conditioner, and uses thereof: A novel cosmetic composition comprising, in a cosmetically acceptable medium, at least one aminosilicone as defined herein having, for example, a contact angle with water ranging from 90° to 180° and at least one conditioner, being able to afford, for example, at least one improved cosmetic property (such as lightness,... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070154440 - Long wearing cosmetic compositions: Cosmetic compositions comprising high molecular weight polyurethane polymers are disclosed. The polyurethane polymers typically will have a molecular weight greater than about 50,000. The cosmetic compositions provide cosmetic films on the lips which are comfortable, long-wearing, transfer-resistant, and have a shiny finish.... Agent: Avon Products, Inc.

20070154435 - Compositions and methods for skin conditioning: Methods and cosmetic compositions for conditioning the skin, utilizing as active ingredients selected compounds structurally related to astragenols, cycloastragenols, and/or protopanaxatriols, are provided. Such compounds include those of formulas (I), (II) and (III) described herein.... Agent: Perkins Coie LLP

20070154436 - Non-absorbent articles including aromatic compositions as inhibitors of exoprotein production: and NH2 and salts thereof; R5 is a monovalent saturated or unsaturated aliphatic hydrocarbyl moiety; R6 is a divalent saturated or unsaturated aliphatic hydrocarbyl moiety; R7 is a trivalent saturated or unsaturated aliphatic hydrocarbyl moiety; R8 is a monovalent substituted or unsubstituted saturated or unsaturated aliphatic hydrocarbyl moiety which may... Agent: Senniger Powers (kcc)

20070154437 - Peptide-tagged proteins and methods of making and using thereof: A method for the treatment of a skin or hair condition or for the alteration of a physical feature of the hair and skin is disclosed. The method utilizes a fusion protein comprising a peptide having SOD activity and a membrane transport sequence for the treatment of skin and hair... Agent: Dla Piper US LLP

20070154438 - Method for producing a water-in-water polyvinyl lactam dispersion with a k value of = 120: Method for producing water-in-water polyvinyl lactam dispersions with a K value of =120 by radical polymerisation.... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070154439 - Cosmetic composition for use around the eyes: A cosmetic composition is provided that is particularly intended for application to areas surrounding the eyes. The composition contains skin conditioning emollients, skin conditioning occlusives, moisturizers, a rich source of vitamin E, dipalmitoyl hydroxyproline, botanical extracts, antioxidants, and preservatives specifically designed to soften, nourish, and moisturize the skin around the... Agent: Ward & Olivo

20070154442 - Method of treating skin requiring hair removal procedure: A treatment regimen for treating skin subject to hair removal procedures involves the application of supplemental composition(s) such as preparatory composition(s), protective composition(s), and combinations thereof, and a corrective composition.... Agent: Carter, Deluca, Farrell & Schmidt, LLP

20070154443 - Cosmetic composition comprising camel milk or components thereof: The present invention provides cosmetic compositions and products that contain camel milk or components thereof, wherein the milk or components may be pre-treated by a physical or biochemical process. The invention further relates to a process for preparing cosmetic compositions containing camel milk or components thereof.... Agent: Fleit Kain Gibbons Gutman Bongini & Bianco

20070154444 - Extracts from black yeast for whitening skin: The present invention relates to topical skin whitening compositions comprising a whitening effective amount of a black yeast-derived melanin-degrading enzyme extract and a method of preparing the compositions. The compositions provide a whitening effect by degrading melanin on the surface of the skin, the hair and the nails. The enzyme... Agent: The Estee Lauder Cos, Inc

20070154445 - Compositions, methods and kits for preventing the decomposition of urine: The present disclose relates to a method for preventing the decomposition of urine. The method includes adding a chemical to a liquid urine solution in a collection device to alter the pH of the resulting solution to a level that substantially prevents or significantly reduces the metabolism and reproduction of... Agent: Martin & Henson, P.C.

20070154446 - Homogeneous preparations of il-28 and il-29: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity... Agent: Zymogenetics, Inc. Intellectual Property Department

20070154447 - Linear polyethylenimine-sterol conjugates for gene delivery: Linear polyethylenimine was modified with sterols, such as cholesterol, in three different geometries: linear shaped (L), T-shaped (T), and a combined linear- and T-shaped (LT), to result in linear polyethylenimine-sterol conjugates. These conjugates were mixed with nucleic acids to form complexes for delivery of the nucleic acids into cells. Mammalian... Agent: Alan J. Howarth

20070154450 - Blocking leukocyte emigration and inflammation by interfering with cd99/hec2: The present invention provides methods and compositions for modulating transendothelial migration (TEM) of leukocytes. In particular, inhibition of TEM can provide a potent therapeutic approach to treating inflammatory conditions. The invention specifically relates to the discovery that CD99 mediates TEM, because blocking CD99 on either endothelial cells or monocytes bloks... Agent: Darby & Darby P.C.

20070154448 - Methods and compositions using substance p to promote wound healing: Healing of wounds in mammalian tissue may be enhanced by the application of certain neuropeptides, optionally in combination with known growth promoting hormones. Exemplary neuropeptides include tachykinins, such as Substance P, Substance K, and the like, as well as calcitonin gene-related peptides. The compositions may further include a polymeric delivery... Agent: Dunlap, Codding & Rogers P.C.

20070154449 - Tight junction modulating peptides for enhanced mucosal delivery of therapeutic compounds: Compositions and methods are provided that include a biologically active agent and a permeabilizing agent effective to enhance mucosal delivery of the biologically active agent in a mammalian subject, in which the permeabilizing peptide is a tight junction modulating peptide (TJMP), a TJMP analogue, a conjugate of a TJMP, a... Agent: Nastech Pharmaceutical Company Inc

20070154451 - Enhancer of anticancer activity in viral therapy and method of preventing or treating cancer: The present invention provides a pharmaceutical that safely and effectively enhances the anticancer activity of viral therapy and particularly the antitumor immunity of viral therapy. The present invention also provides a method of preventing or treating cancer that uses this drug. The anticancer activity enhancer according to the present invention... Agent: Morgan Lewis & Bockius LLP

20070154453 - Interleukin-12p40 variants with improved stability: Modified interleukin-12 (IL-12) p40 polypeptides are disclosed. The modified polypeptides have alterations in the IL-12p40 subunit to eliminate the protease site between positions Lys260 and Arg261. The modified IL-12p40 polypeptides according to the invention have improved stability compared to wild-type mature human IL-12p40 polypeptides.... Agent: Kirkpatrick & Lockhart Preston Gates Ellis LLP Formerly Kirkpatrick & Lockhart Nicholson Graham()

20070154452 - Therapeutic agent for pancreas cancer: The present invention is aiming to provide further advantageous effects on treating pancreas cancer, thus providing the means therefor is the subject. The present invention was obtained by finding that there were differences in prognosis in accordance with intrinsic IL-12-producing ability when Novel Immunotherapy for Cancer (NITC) was conducted in... Agent: Jhk Law

20070154454 - Compositions and methods for treating poxvirus infection: The present invention provides methods of treating a poxvirus infection, e.g., a vaccinia virus or a variola virus infection; and methods of reducing viral load, or reducing the time to viral clearance, or reducing morbidity or mortality in the clinical outcomes, in patients suffering from a poxviral infection. The present... Agent: Thelen Reid Brown Raysman & Steiner LLP

20070154458 - Combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector: A composition of matter comprising a vaccinia virus expression vector with a negative thymidine kinase phenotype and a negative vaccinia virus growth factor phenotype.... Agent: Klarquist Sparkman, LLP

20070154456 - Insulated herpesvirus-derived gene expression cassettes for sustained and regulatable gene expression: Disclosed are genetic expression cassettes, and vector comprising them useful for the delivery of nucleic acid segments encoding selected therapeutic constructs (including for example, peptides, polypeptides, ribozymes, and catalytic RN molecules), to selected cells and tissues of vertebrate animals. The disclosed genetic constructs are useful in the development of gene... Agent: Haynes And Boone, LLP

20070154455 - Monoparamunity inducers based on attenuated rabbit myxoma viruses: The invention relates to monoparamunity inducers that are based on paramunizing viruses or viral components of a myxoma virus strain of diseased rabbits that show general symptoms of the disease. The invention also relates to a method for producing the inducers and to their use as drugs for the regulatory... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070154457 - Use of eif-5a to kill multiple myeloma cells: The present invention relates to eucaryotic initiation factor 5A and the use of polynucleotides encoding the same to inhibit cancer cell growth and inhibit metastases. In a preferred embodiment, eIF-5A1 is used to kill multiple myeloma cells.... Agent: Kenyon & Kenyon LLP

20070154464 - Methods for screening for agents capable of modulating t lymphocyte function in response to a herpes simplex virus-infected cell: Disclosed are methods for screening an agent for activity in modulating a T lymphocyte. The methods generally comprises contacting a HSV US3-expressing cell with a T lymphocyte in the presence or absence of the agent and monitoring a physiological change associated with CTL function to determine whether the agent modulates... Agent: Townsend And Townsend And Crew, LLP

20070154465 - Stem cell therapy for retinal disease: Method of treating retinal disease by intravitreally injecting defined cytokine-transfected stem cell population; adipose-derived stem cell comprising transient wound-healing trangenes; defined homogeneous and heterogeneous populations of cytokine-transfected adipose-derived stem cells; method of treating retinal disease involves step of laser-inducing retinal injury followed by intravitreally injecting a population of stem cells... Agent: Stemedica Cell Technologies, Inc

20070154459 - Method for bacteriophage delivery and amplification: Disclosed are methods of selecting wide host range bacteriophage capable of growing in a plurality of bacteria including pathogenic and non-pathogenic bacteria and bacteriophage selected by the methods. Also disclosed are methods of treating a subject infected with a pathogenic bacterium using bacteriophage and methods of decontaminating objects using bacteriophage.... Agent: Michael Best & Friedrich LLP

20070154462 - Augmentation and repair of tissue defects with in vitro cultured fibroblasts: Certain embodiments here in are directed to a method of treating a tissue associated with a defect in a human including wrinkles, rhytids, depressed scar, cutaneous depressions, stretch marks, hyperplasia of the lip, nasolabial fold, melolabial fold, scarring from acne vulgaris, and post-rhinoplasty irregularity. The tissue defect may be treated... Agent: Dardi & Associates, PLLC

20070154460 - Device and method for rapid aspiration and collection of body tissue from within an enclosed body space: Device and method for rapid extraction of body tissue from an enclosed body cavity. Hollow entry cannula with optional core element provides entry into body tissue space such as bone marrow. Aspiration cannula is inserted through cannula into body tissue and is manipulated to advance directionally through body cavity. Optional... Agent: Levine Bagade Han LLP

20070154463 - Stem cell originated from salivary gland duct epithelium and use of the same: A stem cell which can be differentiated to a hepatic cell, a pancreas cell or to a salivary gland cell is disclosed. The stem cell according to the present invention is originated from salivary gland duct epithelium, which can be differentiated to an alpha-fetoprotein-positive cell, an albumin-positive cell, an amylase-positive... Agent: Birch Stewart Kolasch & Birch

20070154461 - Tissue treatments with adipocyte cells: Certain embodiments here in are directed to a method of treating a tissue associated with a defect in a human including wrinkles, rhytids, depressed scar, cutaneous depressions, stretch marks, hyperplasia of the lip, nasolabial fold, melolabial fold, scarring from acne vulgaris, and post-rhinoplasty irregularity. The tissue defect may be treated... Agent: Dardi & Associates, PLLC

20070154466 - Internal medical devices containing peroxide-converting catalysts: The present invention is directed to implantable and insertable medical devices (also referred to herein as internal medical devices), which contain one or more peroxide-converting catalysts. According to an aspect of the invention, internal medical devices are provided, which contain (a) a substrate and (b) a peptide-containing, peroxide-converting catalyst disposed... Agent: Mayer & Williams PC

20070154467 - Detection of mutations in a gene associated with resistance to viral infection, oas1: A method for detecting a mutation related to the gene encoding OAS1. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the mutated gene, or a polynucleotide encoding the... Agent: Davis Wright Tremaine, LLP

20070154468 - Use of cd28-specific monoclonal antibodies for producing a pharmaceutical composition for treating virus infections: The invention teaches the application of monoclonal antibodies being specific for CD28 and activating T lymphocytes of several to all sub-groups without occupying an antigen receptor of the T lymphocytes and thus in an antigen-unspecific manner, or an analogue thereto, for producing a pharmaceutical composition in an embodiment as a... Agent: Millen, White, Zelano & Branigan, P.C.

20070154473 - Anti-cd19 antibodies with reduced immunogenicity: Anti-CD19 B4 antibodies with modified variable regions are disclosed. The modified anti-CD19 variable region polypeptides have alterations to one or more framework regions or complementarity determining regions of the heavy chain variable region or light chain variable region, thereby to reduce a T-cell response.... Agent: Kirkpatrick & Lockhart Preston Gates Ellis LLP Formerly Kirkpatrick & Lockhart Nicholson Graham()

20070154470 - Holt's o(log n) method to search a massively poly-clonal collection of hybridomas to detect, select and isolate target-antigen-specific high-affinity monoclonal-antibody-generating hybridomas for the rapid development and manufacture of highly specific an: This invention is an O(Log N) technique that searches a massively poly-clonal collection of hybridomas (or other monoclonal antibody generators) to detect, select and isolate target-antigen-specific high-affinity monoclonal-antibody-generating hybridomas (or other monoclonal antibody generators) for the rapid development and manufacture of highly specific and effectively targeted monoclonal antibodies. It expedites... Agent: Gerhard B. Holt

20070154469 - Igm production by transformed cells and methods of quantifying said igm production: IgM can be obtained in the form of a pentamer by placing the genes encoding the H, L, and J chains on the same vector to transform appropriate host cells. The gene encoding the J chain may be introduced by co-transfection. When no J chain is expressed, the IgM is... Agent: Fish & Richardson PC

20070154471 - Method for generating f(ab')2 antibody fragments: Methods for generating F(ab′)2 fragments from antibodies using thermolysin as well as F(ab′)2 fragments and compositions comprising F(ab′)2 fragments generated by the method are described.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070154472 - Sulfotyrosine specific antibodies and uses therefor: This application relates to sulfotyrosine specific antibodies that are capable of binding selectively to sulfated tyrosine (sulfotyrosine), as well as their production and use. In certain embodiments, the antibodies distinguish sulfated tyrosine containing proteins from phosphorylated tyrosine containing proteins. Methods to detect or quantitate the presence of sulfotyrosine and/or sulfotyrosine... Agent: Wyeth/finnegan Henderson, LLP

20070154474 - Human prostate specific g-protein receptor hpraj70: The present invention relates to PSGR, a novel prostate specific gene with homology to a G-protein coupled receptor overexpressed in prostate cancer. More specifically, the invention relates to PSGR polynucleotides and the polypeptides encoded by these polynucleotides, and the use of PSGR polynucleotides and polypeptides for detecting disorders of the... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20070154475 - Novel polypeptides having sequence similarity to gdnfr and nucleic acids encoding the same: The present invention is directed to novel polypeptides having sequence similarity to GDNFR and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies... Agent: Heller Ehrman LLP

20070154477 - Humanized anti-cd3 specific antibodies: Novel aglycosylated antibodies having a binding affinity for the CD3 antigen complex are of value for use in therapy, particularly in immunosuppression.... Agent: Nixon & Vanderhye, PC

20070154476 - Receptor coupling agents and therapeutic uses thereof: Receptor coupling agents, including multivalent constructs comprising anti-TNF receptor binding moieties, for treating cancer and inhibiting tumor volume in a subject are disclosed.... Agent: Lahive & Cockfield, LLP

20070154479 - Effect of bst2 on inflammation: The application disclose a method of preventing immune cells from binding to other cells, which includes contacting the immune cells and the other cells with a composition comprising Bst2 antagonist.... Agent: Jhk Law

20070154481 - Antibody molecules having specificity for human il-6: The invention relates to antibody molecules having specificity for antigenic determinants of IL-6, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.... Agent: Woodcock Washburn LLP

20070154480 - Humanized antibodies that recognize beta amyloid peptide: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Preferred agents include humanized antibodies.... Agent: Lahive & Cockfield, LLP

20070154478 - Therapeutic composition: Use of an inhibitor of an hsp 90 protein for the manufacture of a medicament for the treatment or prophylaxis of a condition involving raised levels of TNFα and/or IL-6.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070154482 - Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state: Disclosed herein are methods for treating a vascular leak disorder, hypotension, or a procoagulant state using angiopoietin-2 (Ang-2) antagonist compounds. Also disclosed are methods for treating a vascular leak disorder associated with high dose IL-2 therapy using angiopoietin-2 antagonist compounds. Methods for diagnosing and monitoring vascular leak disorders, hypotension, or... Agent: Clark & Elbing LLP

20070154483 - Treatment with anti-vegf antibodies: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.... Agent: Genentech, Inc.

20070154484 - Oral use of specific antibodies for intestinal health: Methods and compositions are provided to treat enteric disease. The methods and compositions use passive immunity to treat diseases of the gut, including diseases caused by Salmonella sp., E. Coli, Clostridium difficile, Clostridium perfringens A, Clostridium perfringens C, Clostridium perfringens D, canine distemper, feline distemper, Rotavirus, and Parvovirus. Specific antibodies... Agent: Davis, Brown, Koehn, Shors & Roberts, P.C. The Financial Center

20070154485 - Anticancer agents using verotoxin variants: An attenuated verotoxin comprising a verotoxin A subunit amino acid sequence in which at least one of the amino acids at positions 167 to 172 and positions 202 to 207 from the N terminus is mutated; an attenuated verotoxin A subunit thereof; a complex of the A subunit with a... Agent: Knobbe Martens Olson & Bear LLP

20070154487 - Compositions and methods for modulation of rorgammat functions: The present invention relates to expression of RORγt in cells and tissues and the effect of expression of this gene on proliferation of specific immune cells and in promotion of immune cell aggregates and in induction of IL17 producing cells. Furthermore, the invention relates to methods and agents that may... Agent: Klauber & Jackson

20070154488 - Compositions and methods for the therapy and diagnosis of lung cancer: Compositions and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compositions comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides.... Agent: Seed Intellectual Property Law Group PLLC

20070154486 - Nucleic acid molecule comprising a nucleic acid sequence coding for a haemocyanin: A nucleic acid molecule or construct alone or with a promoter suitable for expression control is contemplated that codes for a HLH2 haemocyanin polypeptide and comprises at least one intron sequence, as well as haemocyanin fusion proteins. The construct further can comprise a nucleic acid sequence that codes for an... Agent: Welsh & Katz, Ltd

20070154489 - Infectious bronchitis virus with an altered spike gene: The present invention provides a vaccine for use in the protection of poultry against infectious bronchitis comprising an attenuated infectious bronchitis virus (IBV) and a pharmaceutical acceptable carrier or diluent, characterized in that the attenuated IBV comprises a heterologous spike gene. Such a vaccine is based on IBV strain Beaudette... Agent: Intervet Inc. Patent Department

20070154491 - Edible vaccine: The object of the present invention is to provide an edible vaccine which is effective for human papilloma virus (HPV) type 16 and available in large amounts inexpensively. An edible human papilloma virus vaccine obtained by culturing a transformant of an avirulent fission yeast host, wherein the transformant carries a... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070154490 - Sequence of reverse transcriptase gene and method of use: The present invention provides an isolated polynucleotide acid comprising a polynucleotide sequence having a substantial amount of sequence identity to the entire length of the polynucleotide sequence as set forth in SEQ ID NO: 1 or its complementary strand (SEQ ID NO: 2), the sequence is derived from RT domain... Agent: Yuan Qing Jiang

20070154492 - Method for purifying polysaccharides: This invention relates to improved methods for purifying polysaccharides from cellular components, such as a cell wall. The method relates to hydrolyzing and separating the polysaccharides, thereby resulting in purified polysaccharides useful for producing antigens, antibodies, and vaccines comprising the polysaccharides alone or conjugated to carrier molecules. This method is... Agent: King & Spalding

20070154493 - Method of treating skin needing botulinum toxin type a treatment: A treatment regimen for treating skin subject to a botulinum toxin type A cosmetic procedure involves the application of supplemental composition(s) such as preparatory composition(s), protective composition(s), and combinations thereof, and a corrective composition.... Agent: Carter, Deluca, Farrell & Schmidt, LLP

20070154494 - Anthrax vaccines and delivery methods: Immunogenic anthrax compositions, such as anthrax vaccines, and methods for delivering immunogenic anthrax compositions and/or vaccines to a mammal. Methods include delivery to mucosal membranes and to skin.... Agent: Becton, Dickinson And Company Alston & Bird LLP

20070154495 - Modified whole cell, cell extract and omv-based vaccines: Live vaccines, live-attenuated vaccines, dead vaccines, protein preparations for use in vaccines and OMVs for use in vaccines are free of CEACAM1-binding Opa, though max contain Opa variants that are antigenic but don't bind to CEACAM1.... Agent: Hodgson Russ LLP The Guaranty Building

20070154496 - Dna sequence, and recombinant preparation of the grass pollen allergen lol p4: The present invention relates to the provision of a DNA sequence of the major grass pollen allergen Lol p 4. The invention also encompasses fragments, new combinations of partial sequences and point mutants having a hypoallergenic action. The recombinant DNA molecules and the derived polypeptides, fragments, new combinations of partial... Agent: Millen, White, Zelano & Branigan, P.C.

20070154498 - Intravenous essential fatty acid emulsion: A method for preventing stenosis and thrombosis of an AV graft is disclosed. An essential fatty acid emulsion is administered to the patient through the AV graft, preferably during dialysis, whereby the anti-inflammatory properties of the essential fatty acid emulsion prevent complications typical of AV grafts.... Agent: Kenyon & Kenyon LLP

20070154497 - Stable, palatable syrup containing ibuprofen and method of its preparation: The invention concerns stable, palatable syrups for oral administration, containing S(+)-ibuprofen, hydroxypropyl beta-cyclodextrin, at least one sweetener and water, optionally essential oils. It also includes methods of preparation of the syrups of the invention, wherein crystalline S(+)-ibuprofen is dissolved in a hydroxypropyl beta-cyclodextrin aqueous solution and the final concentration of... Agent: Notaro And Michalos

20070154499 - Masculine homeopathic personal lubricant and method of use: The personal lubricants of the present invention are lubricants, preferably made from substantially wholly organic ingredients, which include homeopathic ingredients which are known to be useful to support the male reproductive system and to support the strength of the male erection and increase sexual stamina. The lubricants are preferably water-based.... Agent: Jason Fleming

20070154500 - Composition containing concave particles and a dispersant, processes and uses: The present invention relates to a composition containing concave particles, at least one dispersant for these concave particles, and optionally porous particles. This composition is nonpulverulent. The present invention also relates to a treatment process employing this composition and to the uses of this composition, in particular for conferring a... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070154501 - Method of treating skin having incision from surgical procedures: A treatment regimen for treating skin in which an incision is made during a surgical procedure involves the application of supplemental composition(s) such as preparatory composition(s), protective composition(s), and combinations thereof, and a corrective composition.... Agent: Carter, Deluca, Farrell & Schmidt, LLP

20070154502 - Method of treating skin requiring microdermabrasion: A treatment regimen for treating skin subject to microdermabrasion involves the application of supplemental composition(s) such as preparatory composition(s), protective composition(s), and combinations thereof, and a corrective composition.... Agent: Carter, Deluca, Farrell & Schmidt, LLP

20070154503 - Method of treating skin requiring skin cancer treatment: A treatment regimen for treating skin subject to skin cancer treatments involves the application of supplemental composition(s) such as preparatory composition(s), protective composition(s), and combinations thereof, and a corrective composition.... Agent: Carter, Deluca, Farrell & Schmidt, LLP

20070154507 - Antimicrobial agent to inhibit the growth of microorganism on clothing: The present disclosure relates to an article having a fiber including an antimicrobial agent to inhibit growth of microorganisms on clothing. The article inhibits the growths of microorganisms in biological and physiological fluids. The article includes a fibrous structure and silver halide particles applied to the fibers to inhibit the... Agent: Pamela R. Crocker Patent Legal Staff

20070154505 - Antimicrobial agent to inhibit the growth of microorganisms on building materials: The present disclosure relates to building materials having a fiber including an antimicrobial agent to inhibit growth of microorganisms. The building materials inhibit the growths of microorganisms in biological and physiological fluids. The building materials include a fibrous structure and silver halide particles applied to the fibers to inhibit the... Agent: Pamela R. Crocker Patent Legal Staff

20070154506 - Antimicrobial agent to inhibit the growth of microorganisms on disposable products: The present disclosure relates to an article having a fiber including an antimicrobial agent to inhibit growth of microorganisms. The article inhibits the growths of microorganisms in biological, physiological fluids, and non-biological solutions. The article includes a fibrous structure and silver halide particles applied to the fibers to inhibit the... Agent: Pamela R. Crocker Patent Legal Staff

20070154508 - Antimicrobial agent to inhibit the growth of microorganisms on outerwear used in the medical profession: The present disclosure relates to an article having a fiber including an antimicrobial agent to inhibit growth of microorganisms. The article inhibits the growths of microorganisms in biological, physiological fluids, and non-biological solutions. The article includes a fibrous structure and silver halide particles applied to the fibers to inhibit the... Agent: Pamela R. Crocker Patent Legal Staff

20070154504 - Biorational repellents obtained from terpenoids for use against arthropods: The compositions comprise an effective repellent amount of one or more monoterpenoids, one or more sesquiterpenoids or a blend of one or more monoterpenoids and one or more sesquiterpenoids in combination with a carrier, wherein the compositions are formulated to repel a target pest from a target area. In one... Agent: Schwegman, Lundberg, Woessner & Kluth, P.A.

20070154509 - Adsorbent-containing hemostatic devices: The present invention utilizes a combination of a porous carrier and an adsorbent such as a molecular sieve to make a more effective hemostatic device to treat wounds in mammalian animals. These hemostatic devices provide a lower heat rise to the skin as compared to direct application of zeolites to... Agent: Honeywell Intellectual Property Inc Patent Services

20070154510 - Adsorbent-containing hemostatic devices: The present invention utilizes a combination of a porous carrier and inorganic material is selected from the group consisting of diatomaceous earth, glass powder or fibers, precipitated or fumed silica, kaolin and montmorillonite clays, and Ca exchanged permutites to make a more effective hemostatic device to treat wounds in mammalian... Agent: Honeywell Intellectual Property Inc Patent Services

20070154515 - Implantable graft material: Described are graft materials suitable for implantation within a patient including isolated tissue material remodeled in a body cavity. Also described are methods of treating a patient that include implanting these materials and prosthetic devices comprising these materials within the patient's body.... Agent: Woodard, Emhardt, Moriarty, Mcnett & Henry LLP

20070154514 - Therapeutic structures: The invention includes skeletal support structures. The structures can be spinal plates (such as cervical plates), rods, hooks, vertebral spacers, vertebral structural replacement, joint replacement prosthetics, or screws; and can be formed of a carbon/metal matrix encapsulated with pyrocarbon. The screws and/or hooks can contain pores configured to receive growing... Agent: Wells St. John P.s.

20070154516 - Drug delivery system: A pharmaceutical composition comprises a first active (e.g., antibacterial) agent and a second (e.g., antifungal) active agent, and comprises a component that is adapted for bioadhesion to a vulvovaginal surface. The composition provides differential release of the active agents at such a surface, wherein the second active agent exhibits a... Agent: Harness, Dickey, & Pierce, P.l.c

20070154512 - Low temperature drying methods for forming drug-containing polymeric compositions: The present invention relates to a process for reducing solvent contents in drug-containing polymeric compositions. Specifically, the solvent contents in the drug-containing polymeric compositions are first reduced by one or more conventional drying methods, to a range from about 0.5 wt % to about 10 wt % of the total... Agent: Philip S. Johnson Johnson & Johnson

20070154513 - Medical devices having multiple charged layers: According to an aspect of the present invention, medical devices are provided, which are adapted for implantation or insertion into a subject and which include at least one multilayer region that contains multiple charged layers of alternating charge. The multiple charged layers, in turn, include the following: (i) at least... Agent: Mayer & Williams PC

20070154517 - Methods and devices for promoting endothelial morphogenesis: In one aspect the present invention provides methods for promoting endothelial morphogenesis. The methods of this aspect of the invention include the step of providing to one or more endothelial cells an amount of an osteoprotegerin sufficient to promote endothelial morphogenesis. The methods of this aspect of the invention can... Agent: Christensen, O'connor, Johnson, Kindness, PLLC

20070154511 - Retention of endothelial cells on vascular grafts: An implantable device including a surface containing a plurality of first zones and a plurality of second zones depressed relative to the first zones so as to provide valleys below a plane defined by the first zones, wherein a first zone to second zone width ratio is non-random throughout the... Agent: Ratnerprestia

20070154518 - Photoactive biocompatible coating composition: The present invention discloses a biocompatible coating composition that can be photo crosslinked when exposed to long wavelength ultraviolet light. The biocompatible coating composition comprises at least one biocompatible polymer having a photoactive moiety covalently attached thereto, and a biologically active molecule having a photoactive moiety covalently attached thereto. The... Agent: Philip S. Johnson Johnson & Johnson

20070154519 - Self-assembling cross-linking molecular nano film: The present invention is a molecular nano film formed on a surface of an implantable medical device to provide a barrier to tissue attachment. The film comprises self-assembling cross-linking molecules.... Agent: Medtronic, Inc.

20070154520 - Pharmaceutical compositions: having an ethylene carbonate content of 70 to 100 Mol %, an intrinsic viscosity of 0.4 to 4.0 dl/g measured in chloroform at 20° C. at a concentration of 1 g/dl and a glass transition temperature of from 5 to 50° C., degradable by surface erosion which is governed by... Agent: Novartis Corporate Intellectual Property

20070154521 - Tri-branched biologically active copolymer: The present invention discloses a tri-branched copolymer comprising a hydrophobic domain, a hydrophilic domain, a biologically active moiety, and an alkyl core of 2 to 10 carbon atoms. The hydrophobic domain, the hydrophilic domain, and the biologically active moiety are separately linked to the alkyl core of 2 to 10... Agent: Philip S. Johnson Johnson & Johnson

20070154525 - Apparatus and method for preventing adhesions between an implant and surrounding tissues: An anti-adhesion membrane is placed onto an implant introduced into a surgical site of a patient to prevent post-surgical adhesions between the implant and surrounding tissue. The implant may comprise either biological material, such as a transplanted organ, or non-biological material such as a medical device. The membrane may be... Agent: Stout, Uxa, Buyan & Mullins LLP

20070154523 - Controlled pupil dilation for diagnostic and treatment of visual anomalies: Methods and compositions are disclosed for topically applying an ophthalmic solution to the eye to at least temporarily reduce the effects of various visual anomalies. The solution contains a therapeutically effective amount of one or more pupil dilating agents that generate a moderate amount of dilation in order to relieve... Agent: John P. O'banion O'banion & Ritchey LLP

20070154524 - Micronized device for the delivery of biologically active molecules and methods of use thereof: The invention provides micronized encapsulated cell therapy devices that are capable of delivering a biologically active molecule to the eye. Also provided are methods of using the same to deliver biologically active molecules to the eye and to treat ophthalmic disorders in patients suffering there from.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070154522 - Polymer having interconnected pores for drug delivery and method: A bicontinuous microemulsion of water, a monomer, and a surfactant copolymerizable with the monomer is polymerized to form a transparent and porous polymer defining interconnected pores. The pores may have a pore diameter in the range of 10 to 100 mm. The microemulsion may further include a drug such that,... Agent: Klarquist Sparkman, LLP

20070154526 - Ingestible carrier for medications and structure and method for making: The present invention is an ingestible carrier for a medication to be taken orally by an individual. The carrier includes a cavity into which one or more medications can be inserted and frictionally retained by the carrier. The carrier is formed of an easily ingestible material and is shaped in... Agent: Boyle Fredrickson Newholm Stein & Gratz, S.c.

20070154528 - Flexible wound dressing: The present invention relates to flexible wound dressings. More particularly, the present invention is directed to flexible wound dressings comprising ionomer resins. The invention involves treating the injured tissue with films comprising a special biocompatible crosslinked resin that optionally contains leachable healing and antibiotic agents.... Agent: Crowell & Moring LLP Intellectual Property Group

20070154527 - Topical film compositions for delivery of actives: The invention relates to the film products and methods of their preparation that demonstrate a non-self-aggregating uniform heterogeneity. Desirably, the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film. Desirably, the films contain a topical... Agent: Hoffmann & Baron, LLP

20070154529 - Uses of dna binding proteins: The invention relates to the use, especially in vitro, of one or more nucleic acids, the transcription product(s) thereof and/or the translation product(s) thereof for a process. Said process is selected from the group including angiogenesis, neovascularization, transmyocardial revascularization, wound healing, wound bed angiogenesis, epithelization and healing in of dental... Agent: Proskauer Rose LLP

20070154530 - Wound dressings comprising oxidized cellulose and human recombinant collagen: A wound dressing composition comprising a human recombinant collagen and an oxidized cellulose. For example, the composition may be in the form of a sponge formed by freeze drying an aqueous dispersion of human recombinant collagen and oxidized regenerated cellulose (ORC). The composition is especially suitable for the treatment of... Agent: Philip S. Johnson Johnson & Johnson

20070154531 - Anti-inflammatory analgesic preparation: An adhesive patch comprising a substrate and a pressure-sensitive adhesive base, wherein the pressure-sensitive adhesive base comprises a rubbery polymer having double bonds in the main chain and a nonsteroidal anti-inflammatory analgesic and contains a UVA screening agent and/or UVB screening agent as a stabilizer for the rubbery polymer. The... Agent: Licata & Tyrrell P.C.

20070154532 - Compositions comprising vitamins and/or derivatives thereof stablished with olea europea extract and/or ionene polymers: The present invention relates to compositions comprising vitamins, such as L-ascorbic acid and its derivatives, sta-bilised with Olea Europea and/or ionene polymers. Particularly, the invention concerns stable compositions with high concentration of vitamins, for example L-ascorbic acid, to be advantageously employed in the medial and cosmetic field, for example for... Agent: Casella & Hespos

20070154533 - Method of increasing testosterone and related steriod concentrations in women: The present invention relates to methods, kits, combinations, and compositions for treating, preventing or reducing the risk of developing a testosterone-deficient disorder, or the symptoms associated with, or related to a testosterone-deficient disorder in a subject in need thereof. The present invention also relates to a method of administering a... Agent: Mayer, Brown, Rowe & Maw LLP

20070154536 - Drug delivery method by enhanced topical application: Methods for enhancing penetration of compounds/drugs into an animal or human through their hair follicles are provided. The methods employ topical application of swellable compositions which can maintain a passage for desired drugs by either opening hair follicles and preventing them from collapsing or increasing the depth of inner lumen... Agent: Dr. Bolesh J. Skutnik Ceramoptec Industries, Inc

20070154535 - Tulobuterol adhesive patch: The present invention provides a tulobuterol adhesive patch comprising (a) a support, (b) an acrylic pressure-sensitive adhesive layer containing the percutaneously absorbing drug tulobuterol and if necessary a lipophilic oily plasticizer, and (c) a release liner, laminated in that order, wherein the acrylic pressure-sensitive adhesive is a copolymer obtained by... Agent: Ohlandt, Greeley, Ruggiero & Perle, LLP

20070154534 - Use of secretin in the treatment of schizophrenia: The treatment of schizophrenia by administration of secretin to a patient in need thereof is disclosed.... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20070154539 - Nanolipidic particles: Nanolipidic Particles (NLPs) having average mean diameters of 1 nm to 20 nm are made from a precursor solution. NLPs can be loaded with a desired passenger molecule. Assemblies of these particles, called NLP assemblies, result in a vehicle population of a desired size. Single application or multifunction NLP assemblies... Agent: Eugenia S. Hansen Hemingway & Hansen, LLP

20070154537 - Lipid-derivatized bisphosphonic acid: n

20070154538 - Removal of fat cells by pdt: A non-surgical, minimally invasive PhotoDynamic Therapy (PDT) method for destruction of undesirable fat cells in the body, which cause obesity, obesity related health problems, and undesirable body contours. In this method photosensitizing agents are formulated into a liposomal formulation or into other delivery means for administering the drug systemically, directly... Agent: Bolesh J. Skutnik Ceramoptec Industries, Inc.

20070154540 - Composition for treatment of osteoarthritis containing apigenin as chondroregenerative agent: Disclosed is a novel use of apigenin as a chondroregenerative agent, which has the effects of reducing elevated of cartilage destruction markers including total synovial fluid volume and proteoglycan, total proteins and prostaglandin in a synovial fluid, improving the condition of synovial cells, and regenerating cartilage. Also, the present invention... Agent: Fish & Richardson PC

20070154541 - Seamless capsule containing water-soluble active substance: A seamless capsule containing a water-soluble active substance in which the water-soluble active substance is protected from becoming unstable and a process for producing the same. The seamless capsule includes: content having a water-soluble active substance and an oily compound, a shell covering the content, and an intermediate layer, which... Agent: Darby & Darby P.C.

20070154542 - Oral pharmaceutical formulations containing non-steroidal anti-inflammatory drugs and acid inhibitors: The present disclosure provides enteric coated capsules and orally dissolving films comprising non-steroidal anti-inflammatory drugs and acid inhibitors, as well as methods of treating treatment humans for pain and/or inflammation while reducing gastrointestinal side effects.... Agent: Morgan, Lewis & Bockius, LLP

20070154545 - Dry formulations of aripiprazole: The invention encompasses dry compression pharmaceutical compositions of aripiprazole, methods of making tablets from the compositions, and tablets of the dry compression pharmaceutical composition.... Agent: Kenyon & Kenyon LLP

20070154543 - Solid preparation for oral use: Upon performing the clinical study of (S)-2-[3-[N-[4-(4-fluorophenoxy)benzyl]carbamoyl]-4-methoxybenz yl]butanoic acid (hereinafter abbreviated as KRP-101), of which improvement in the lipidmetabolism is expected in a microdose, no oral solid dosage form that allows KRP-101 to be administered quantitatively has been embodied. After mixing KRP-101 with additives (excipient, disintegrator and lubricant), the mixture... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070154544 - Wet formulations of aripiprazole: The invention encompasses wet granulation pharmaceutical compositions of aripiprazole, methods of making tablets from the compositions, and tablets of the wet granulation pharmaceutical composition.... Agent: Kenyon & Kenyon LLP

20070154547 - Gastric release pulse system for drug delivery: Disclosed are pharmaceutical products for providing pulses of at least one pharmaceutically active ingredient from a patient's stomach, or from a subsequent gastrointestinal site proximal thereto, for absorption thereof at a site(s) more distal in the gastrointestinal tract than the patient's stomach, or than the subsequent gastrointestinal site proximal thereto.... Agent: C/o Carella, Byrne, Bain, Gilfillan, Cecchi, Stewart & Olstein

20070154548 - Controlled release metformin formulations: Sustained release pharmaceutical formulations comprising an antihyperglycemic drug or a pharmaceutically acceptable salt thereof are disclosed. The formulations provide therapeutic plasma levels of the antihyperglycemic drug to a human patient over a 24 hour period after administration.... Agent: Davidson, Davidson & Kappel, LLC

20070154546 - Sustained release pharmaceutical compositions: The present invention relates to a pharmaceutical composition comprising a salt of quaternary ammonium of an acid drug in the form of a suspension or an emulsion, suitable for parenteral administration and providing a sustained release of the drug. In one preferred embodiment, the present invention is directed to a... Agent: Christie, Parker & Hale, LLP

20070154549 - Multiparticulate formulations for oral delivery: The present invention is directed to multiparticulate formulations for oral use, preferably comprising one or more therapeutically active agents. In particular, the present invention relates to fast melt formulations which are capable of masking the taste of the active agent, by virtue of one or more tastemasking measures, whilst retaining... Agent: Davidson, Davidson & Kappel, LLC

20070154551 - Coating method: The present invention concerns a method for coating granules comprising mesalazine, with a coating mixture comprising two polymers, polymer I and polymer II; said polymer I being selected to allow formation of a closing membrane around said granules in the absence of said polymer II, and said polymer II being... Agent: Foley And Lardner LLP Suite 500

20070154550 - Pharmaceutical composition comprising anticonvulsant with taste mask coating: A pharmaceutical composition in the form of coated core particles comprising an anticonvulsant drug, which can be sprinkled onto food, wherein said core particles are coated with a taste mask coating which is less than 7% by weight of the pharmaceutical composition.... Agent: Novartis Corporate Intellectual Property

20070154553 - Cucurbituril-containing gel and method of preparing the same: p

20070154552 - Biologically active native biomatrix composition: The present disclosure relates to a biologically active biomatrix composition. In one embodiment, the biomatrix composition is derived from human amnions. The biomatrix is termed HuBiogel™. The composition of HuBiogel™ closely mimics naturally occurring basement membrane compositions and is capable of supporting a wide variety of cell types in vitro... Agent: Bradley Arant Rose & White, LLP Intellectual Property Department-nwj

20070154555 - Augmentation of intraluminal microvessel formation to facilitate guide wire crossing in chronic total occlusions: Method of preparing a clogged animal vessel, e.g. chronic total occlusion of an artery so as to be capable of crossing by a guidewire of an intraluminal device, e.g., angioplasty balloon. The method includes delivering an angiogenic agent to the occlusion site to promote angiogenesis within the occlusion to increases... Agent: Torys LLP

20070154556 - Injectable gel-type bone-repairing material and preparing method thereof: The present invention provides an injectable gel-type bone-repairing bioactive material and its preparation method. Each unit dose of said material is composed of 1 ml of component A and 45 to 55 mg of component B, wherein each milliliter sterile saline of component A contains: 10 to 40 mg alginate,... Agent: Jacobson Holman PLLC

20070154554 - Polymeric compositions comprising therapeutic agents in crystalline phases, and methods of forming the same: The present invention relates to a drug-containing polymeric composition comprising at least one therapeutic agent encapsulated in at least one biocompatible polymer, wherein at least a portion of the therapeutic agent in this polymeric composition is crystalline. The at least one biocompatible polymer may form a substantially continuous polymeric matrix... Agent: Philip S. Johnson Johnson & Johnson

20070154558 - Gelled biopolymer based foam: Gelled biopolymer based foams are disclosed. The gelled foams comprise a cross-linked biopolymer, preferably alginate; optionally, a foaming agent such as hydroxy propyl methyl cellulose; and a plasticizer, preferably glycerin sorbitol, or a mixture thereof, that forms the predominant portion of the gelled foam. The foams are soft and pliable... Agent: Patent Administrator Fmc Corporation

20070154557 - Particulate comprising phytosterols and food compositions comprising said creamer: Particulate compositions comprising 10-95% wt of a matrix material and 5-90% wt of fatty matter, wherein said fatty matter comprises 5-100% of phytosterols (and wherein the compositions are preferably low in triglycerides of transunsaturated fatty acids), for use as for example a creamer and/or whitener. The invention also relates to... Agent: Unilever Intellectual Property Group

20070154562 - Inhalable biodegradable microparticles for target-specific drug delivery in tuberculosis and a process thereof: The present invention relates to a biodegradable microparticle composition useful for the target specific drug delivery to manage pulmonary tuberculosis, said composition comprising two anti-tuberculosis drugs, and a biodegradable polymer for drug delivery in a ratio of about 1:2 to 2: 1, wherein the anti-tubercular drugs are in the ratio... Agent: Sughrue Mion, PLLC

20070154561 - Metal oxide particle and its uses: An object of the present invention is to provide a metal oxide particle which exercises more excellent ultraviolet absorbency as a matter of course and combines therewith merits of, for example, either being shifted in ultraviolet absorption edge toward the longer wavelength side and being excellent also in the absorption... Agent: Robert J Jacobson Pa

20070154559 - Nanoparticle compositions of water-soluble drugs for oral administration and preparation methods thereof: The present invention relates to an orally administrable composition containing nanoparticles with the particle size of 500 nm or less, comprising 0.1˜30 weight % of a complex of a water-soluble drug and a counter-ion substance in which the charged water-soluble drug is bonded with the counter-ion substance, 0.5˜80 weight %... Agent: Birch Stewart Kolasch & Birch

20070154560 - Process for producing microsphere and apparatus for producing the same: A process and apparatus for producing microspheres containing an active component as to be releasable, the process comprising: preparing polymer solution or dispersion having at least active agent, solvent or dispersant, and polymer; drop-wise spitting the polymer solution or dispersion into a flowing fluid, at a predetermined temperature, as to... Agent: Jordan And Hamburg LLP

20070154563 - Bone matrix compositions and methods: The present invention provides methods of improving the osteogenic and/or chondrogenic activity of a bone matrix, e.g., a dermineralized bone matrix (DBM), by exposing the bone matrix to one or more treatments or conditions. In preferred embodiments the bone matrix is derived from human bone. The treatment or condition may... Agent: Choate Hall & Stewart

20070154564 - Oxides for wound healing and body repair: The invention provides a homogeneous composition comprising a hemostatically effective amount of a charged oxide, wherein the composition has an isoelectric point, as measured in calcium chloride, below 7.3 or above 7.4. Typically, the charged oxide is selected from the group consisting of silaceous oxides, titanium oxides, aluminum oxides, calcium... Agent: Bozicevic, Field & Francis LLP

20070154565 - Method for control of insects on plants and plant tissue: This invention is directed to a method for control of insects, nematodes, fungi as well as other pathogens on plant tissue which includes applying a solution that includes hydrogen peroxide generating substance alone or in combination with chemicals such as hydrogen peroxide to the plant tissue. Some forms of the... Agent: Bio Intellectual Property Services (bio Ips) LLC

20070154566 - Method for preparing therapeutic agent for cancer: A method for the production of a material for cancer treatment, which comprises preparing a first aqueous acidic to neutral solution containing a metal to be insoluble in an alkaline solution and a carboxylic acid amide, and a second aqueous solution containing an enzyme catalyzing hydrolysis of the carboxylic acid... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070154567 - Use of mercury to treat cancer: The invention relates to the use of inorganic mercury (II) in an ionized or ionizable state to treat a variety of solid tumors and lymphoma and leukemia. The present invention also relates to pharmaceutical compositions useful for treating cancer, such as solid tumor and lymphoma, which comprises inorganic mercury (II).... Agent: Yelena G. Sheptovitsky

20070154568 - Clay purification method: The invention relates to a method for the purification of a clay that is intended for therapeutic use.... Agent: Hunton & Williams LLP Intellectual Property Department

20070154570 - Use of nitric oxide in the treatment and disinfection of biofilms: The administration of gaseous nitric oxide as a biocidal moiety is proffered as a de novo treatment in the control and eradication of biofilms. The present invention relates to the use or methods of application of exogenous nitric oxide gas (gNO) as a stand alone biocidal agent or in cohort... Agent: Carissa A. Tener Sidley Austin LLP

20070154569 - Use of nitrite salts for the treatment of cardiovascular conditions: It has been surprisingly discovered that administration of nitrite to subjects causes a reduction in blood pressure and an increase in blood flow to tissues. The effect is particularly beneficial, for example, to tissues in regions of low oxygen tension. This discovery provides useful treatments to regulate a subject's blood... Agent: Klarquist Sparkman, LLP

20070154573 - Method of preparing and using a cold extract from the leaves of nerium oleander: A method of preparing and using a sterile non-toxic pyrogen-free cold extract from the leaves of Nerium oleander as a supplementary medication to cancer chemo-, hormon and/or radiotherapy to restore and/or ameliorate the immune system of the patient and/or to decrease side effects and increase the antitumor effects of radiotherapy... Agent: Renner Otto Boisselle & Sklar, LLP

20070154572 - Compositions derived from portulaca oleracea l. and methods of using same for modulating blood glucose levels: Compositions including anti hyperglycemic agents from Portulaca oleracea L. are provided. Also provided are methods of isolating such anti hyperglycemic agents and methods of using same.... Agent: Martin D Moynihan Prtsi Inc

20070154571 - Extraction method and the apparatus thereof: The invention discloses an extraction method and the apparatus thereof. The method according to the invention comprises the following steps: crushing and soaking the raw material, and then extracting, wherein the extracting step is carried out under a 18˜33 kHz nonlinear vibration, using water as solvent, under 25˜35 MPa pressure... Agent: Merchant & Gould PC

20070154574 - Fungicides compositions comprising the extract of chloranthus henryi and a novel sesquiterpene compound isolated from them: The present invention relates to a fungicidal composition for agricultural use, comprising Chloranthus henryi extract or a novel sesquiterpene compound separated from Chloranthus henryi extract as an active ingredient, and in particular it relates to a fungicidal composition supported by the findings that Chloranthus henryi extracts or a novel sesquiterpene... Agent: Merchant & Gould PC

20070154575 - Anti-inflammatory agent: This invention provides an anti-inflammatory agent or the like which is safer and less adverse and has the great effectiveness to prevent and treat arthritis, or the like. An anti-inflammatory agent or the like in this invention is characterized by comprising anthocyanidin and gingerol as an active substance. Also, the... Agent: Clark & Brody

20070154576 - Protein kinase modulation by hops and acacia products: Botanical compounds to modulate kinase activity are disclosed. The compounds and methods disclosed also inhibit expression of COX-2, inhibit synthesis of prostaglandins selectively in target cells, and inhibit inflammatory response selectively. The compositions contain at least one fraction isolated or derived from hops or Acacia.... Agent: Mcdermott Will & Emery LLP

20070154577 - Herbal compositions inhibiting free radicals: An herbal composition. The herbal composition capable of inhibition of free radicals includes one of Polygonum cuspidatum and Viola yedoensis in an effective amount. The herbal composition is suitable for mammalian subjects. The Polygonum cuspidatum is selected from fresh Polygonum cuspidatum herbage, and the Viola yedoensis is selected from fresh... Agent: Birch Stewart Kolasch & Birch

20070154581 - Composition and method for enhancing or stimulating the immune system: The present invention relates to a composition and method for stimulating or enhancing the immune system in a human being. The composition comprises a mixture of Manapol, beta-1,3-D-glucan, arabinogalactin, elderberry extract standardized to about 30% anthocyanins, zinc gluconate and allicin. This composition, taken as a food supplement, is particularly useful... Agent: Birch Stewart Kolasch & Birch

20070154580 - Antiviral morinda citrifolia l. based formulations and methods of administration: The present invention relates to methods and formulations directed to the management of Cathepsin G, Cathepsin S, Cathepsin B, Cathepsin L, Butyryl Cholinesterase, Peptidase HIV-1, and NF-kB enzymes comprising the administration of processed Morinda citrifolia based formulations.... Agent: Kirton And Mcconkie

20070154578 - Athermal process for the concentration of garcinia extract: The present invention relates to an athermal process of obtaining concentrated Garcinia extract by using osmotic membrane distillation (OMD).... Agent: Ladas & Parry

20070154579 - Morinda citrifolia based formulation and methods for weight management: The present invention relates to weight management utilizing processed Morinda citrifolia products. Research supporting this invention indicates that processed Morinda citrifolia products may be used in weight management. The present invention is supported by research findings that suggest that oral administration of Morinda citrifolia can increase metabolic rate. An increased... Agent: Kirton & Mcconkie Attorneys At Law

20070154582 - Preventative and treatment effects of morinda citrifolia as an aromatase inhibitor: The present invention is directed to methods of inhibiting Aromatase or Aromatase enzymes that function to convert androgens to estrogens, inhibiting receptors from binding with estrogen, and reducing and/or regulating estrogen production, as well as reducing the amount of estrogen produced within the body and regulating such production. The present... Agent: Kirton And Mcconkie

20070154583 - Treatment of inflammatory bowel disease: The present invention relates to compositions (including medicaments and nutritional products) for use in the prevention or treatment of Inflammatory Bowel Disease. Such compositions comprise a therapeutically effective amount of a soluble fibre derivable from fruit of the Musa spp. The soluble fibre may in particular be derived from plantains... Agent: Davis Wright Tremaine LLP